US20100213057A1 - Self-Powered Analyte Sensor - Google Patents
Self-Powered Analyte Sensor Download PDFInfo
- Publication number
- US20100213057A1 US20100213057A1 US12/393,921 US39392109A US2010213057A1 US 20100213057 A1 US20100213057 A1 US 20100213057A1 US 39392109 A US39392109 A US 39392109A US 2010213057 A1 US2010213057 A1 US 2010213057A1
- Authority
- US
- United States
- Prior art keywords
- analyte
- analyte sensor
- sensor assembly
- sensor
- powered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1486—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using enzyme electrodes, e.g. with immobilised oxidase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0002—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network
- A61B5/0004—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network characterised by the type of physiological signal transmitted
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
- A61B5/6846—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive
- A61B5/6847—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive mounted on an invasive device
- A61B5/6848—Needles
- A61B5/6849—Needles in combination with a needle set
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
- A61B90/90—Identification means for patients or instruments, e.g. tags
- A61B90/98—Identification means for patients or instruments, e.g. tags using electromagnetic means, e.g. transponders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/001—Enzyme electrodes
- C12Q1/005—Enzyme electrodes involving specific analytes or enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/001—Enzyme electrodes
- C12Q1/005—Enzyme electrodes involving specific analytes or enzymes
- C12Q1/006—Enzyme electrodes involving specific analytes or enzymes for glucose
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
- G01N27/28—Electrolytic cell components
- G01N27/30—Electrodes, e.g. test electrodes; Half-cells
- G01N27/327—Biochemical electrodes, e.g. electrical or mechanical details for in vitro measurements
- G01N27/3271—Amperometric enzyme electrodes for analytes in body fluids, e.g. glucose in blood
- G01N27/3273—Devices therefor, e.g. test element readers, circuitry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
- G01N27/28—Electrolytic cell components
- G01N27/30—Electrodes, e.g. test electrodes; Half-cells
- G01N27/327—Biochemical electrodes, e.g. electrical or mechanical details for in vitro measurements
- G01N27/3271—Amperometric enzyme electrodes for analytes in body fluids, e.g. glucose in blood
- G01N27/3274—Corrective measures, e.g. error detection, compensation for temperature or hematocrit, calibration
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
- G01N27/403—Cells and electrode assemblies
- G01N27/4035—Combination of a single ion-sensing electrode and a single reference electrode
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
- Y02E60/00—Enabling technologies; Technologies with a potential or indirect contribution to GHG emissions mitigation
- Y02E60/30—Hydrogen technology
- Y02E60/50—Fuel cells
Definitions
- these systems are powered externally by batteries.
- the smallest batteries are, however, much larger than the implantable sensors and their associated signal amplifier circuits.
- the size of autonomous packages that include a sensor, an amplifier-transmitter, and a power source are generally defined by the battery. Batteries cannot be made as small as the sensors or amplifiers because the batteries require cases and seals, the miniaturization of which is difficult and prohibitively expensive.
- Known fuel cells are also much larger than available sensors because they require a case and a seal, and usually also a membrane, which is difficult to miniaturize and seal.
- Biological fuel cells also known as biofuel cells, have been described in the past fifty years. However, only a few of these biofuel cells could be operated under physiological conditions. Physiological conditions include, for instance, a pH of about 7.2 to 7.4, a temperature of near 37° C., and a chloride concentration of about 0.14 M.
- known biofuel cells having higher power densities require ion-conducting separation membranes.
- FIG. 1 is a schematic illustration of electron transfer in the electrocatalytic oxidation of glucose and in the electrocatalytic reduction of oxygen that occurs in a self-powered analyte sensor according to an embodiment of the invention.
- FIG. 2 is a schematic illustration of an application of a self-powered analyte sensor according to an embodiment of the invention for use in transcutaneous sensing of an analyte level.
- Panel A shows an embodiment in which a self-powered analyte sensor is implanted transcutaneously and a hand-held display is contacted directly to sensor leads as desired to measure the current flow and calculate the analyte level.
- Panel B shows an embodiment in which a self-powered analyte sensor is implanted transcutaneously, where the self-powered analyte sensor is further coupled to a radio-frequency (RF) powered measurement circuit. The RF powered measurement circuit is then remotely queried at regular intervals by an RF-power equipped hand-held display in order to provide continuous analyte level measurements.
- RF radio-frequency
- FIG. 3 is a schematic illustration of a fully implanted self-powered analyte sensor coupled to a radio-frequency (RF)-powered measurement circuit that may be intermittently RF-powered with an external RF-power source when an analyte measurement is desired.
- RF radio-frequency
- the RF-power source may be moved away from the site of implantation of the self-powered analyte sensor at any time and no re-equilibration period is required when it is brought back into RF communication with the site of implantation.
- FIG. 4 shows a block diagram of an embodiment of a data monitoring and management system according to embodiments of the invention.
- FIG. 5 shows a block diagram of an embodiment of the transmitter unit of the data monitoring and management system of FIG. 4 .
- FIG. 6 shows a block diagram of an embodiment of the receiver/monitor unit of the data monitoring and management system of FIG. 4 .
- FIG. 7 shows a schematic diagram of an embodiment of an exemplary analyte sensor.
- FIGS. 8A and 8B show a perspective view and a cross sectional view, respectively of another exemplary analyte sensor.
- FIG. 9 is a graph showing sensor calibration comparison for three sensors having a wired glucose oxidase (GOX) working electrode: a potentiostat powered analyte sensor control; a self-powered analyte sensor having a platinum-carbon (Pt—C) counter electrode; and a self-powered analyte sensor having a redox polymer counter electrode.
- GOX wired glucose oxidase
- FIG. 10 is a graph showing calibration curves for three sensors having a wired glucose oxidase (GOX) working electrode: a potentiostat powered analyte sensor control (circles); a self-powered analyte sensor having a platinum-carbon (Pt—C) counter electrode (squares); and a self-powered analyte sensor having a redox polymer counter electrode (triangles).
- GOX wired glucose oxidase
- FIG. 11 is a graph showing the equilibration time required for a standard potentiostat powered analyte sensor and a self-powered analyte sensor following disconnection and connection of powered measurement electronics.
- FIG. 12 is a graph showing the calibration curves for three sensors. Data for a potentiostat powered analyte sensor control are represented with crosses, data for a self-powered analyte sensor having a platinum (Pt) counter electrode are represented with diamonds, and data for a self-powered analyte sensor having a redox polymer and bilirubin oxidase (BOD) counter electrode are represented with squares.
- Pt platinum
- BOD bilirubin oxidase
- FIG. 13 is a graph showing shows sensor calibration comparison for three sensors having FADGDH based working electrodes.
- Data for a potentiostat powered analyte sensor control are represented with diamonds
- data for a self-powered analyte sensor having a platinum-carbon (Pt—C) counter electrode are represented with squares
- data for a self-powered analyte sensor having bilirubin oxidase (BOD) counter electrode are represented with triangles.
- FIG. 14 is a graph showing the effect of R value of the resistance on sensor current.
- FIG. 15 is a graph showing correlation between an in vivo self powered glucose sensor signal and reference glucose values.
- embodiments of the invention relate to self-powered analyte determining devices (e.g., electrochemical analyte monitoring systems) that include a working electrode, a counter electrode, and an optional resistance value, where the working electrode includes analyte sensing components and the self-powered analyte determining device spontaneously passes a current directly proportional to analyte concentration in the absence of an external power source.
- self-powered analyte determining devices e.g., electrochemical analyte monitoring systems
- the working electrode includes analyte sensing components
- the self-powered analyte determining device spontaneously passes a current directly proportional to analyte concentration in the absence of an external power source.
- systems and methods of using the, for example electrochemical, analyte sensors in analyte monitoring are also provided.
- the self-powered analyte sensor uses compounds available in a variety of biological systems to provide a low level of power and also detect a level of an analyte.
- the self-powered analyte sensor described herein spontaneously passes a current proportional to an analyte concentration, such as glucose, in the absence of an external power supply, such as a battery.
- an analyte concentration such as glucose
- a self-powered analyte sensor that is partially implanted under the skin of a subject or fully implanted under the skin of a subject can be coupled to a radio-frequency powered measurement circuit to remotely provide analyte levels.
- Non-self-powered continuous analyte sensors have fairly long equilibration times, and therefore need to be continuously powered after inserting a portion thereof under the skin of a subject. That is, if the power supply of a continuous analyte sensor is removed and it is turned “off”, then a fairly long wait time of approximately 10 to 15 minutes must pass before a reliable analyte level reading is detected following reconnection of the power supply.
- a self-powered analyte sensor as described herein, has the advantage of providing a low level of continuous power in the absence of an external power supply while also detecting an analyte level thereby requiring little to no equilibration time between analyte measurement intervals.
- the primary reactant e.g., reductant
- the secondary reactant e.g., oxidant
- the redox polymer 102 disposed on the working electrode passes electrons, or a current, between the primary reactant and the working electrode, while the electrocatalyst layer 101 disposed on the counter electrode, such as redox polymer, redox polymer with enzyme, or platinum, passes electrons, or a current to the counter electrode.
- the electrical power is generated from the overall oxidation or reduction of the working electrode primary reactant, such as a reductant or oxidant, by the counter electrode secondary reactant, such as oxidant or reductant.
- the electrical power can be generated by the overall oxidation of glucose, lactate, or pyruvate by dissolved oxygen, delivered as, for example, hemoglobin-bound oxygen (HbO 2 ), which is in rapid equilibrium with dissolved oxygen passing through the oxygen-permeable membranes of red blood cells.
- HbO 2 hemoglobin-bound oxygen
- the self-powered analyte sensor facilitates this oxidation reaction, and uses the resulting flow of electrons to produce an electrical current that provides a low-level of power.
- the electrocatalyst layer of the working electrode is involved in generating the low-level of power and also functions as the sensing layer that is involved in analyte-level detection, thereby providing the dual-function of power generation and analyte level detection.
- an enzyme used for the electrooxidation of glucose can be GOx disposed on the working electrode with redox polymer and cross-linker, and the electrocatalyst for the electroreduction of oxygen can be redox polymer, redox polymer with enzyme, or platinum-carbon cloth disposed on the counter electrode.
- the electrocatalyst for the electroreduction of oxygen can be redox polymer, redox polymer with enzyme, or platinum-carbon cloth disposed on the counter electrode.
- FIG. 1 illustrates the electron transfer involved in the electrocatalytic oxidation of glucose and the electron transfer involved in the electrocatalytic reduction of oxygen.
- the working electrode and the counter electrode reside in the same solution or same compartment.
- electrons are first transmitted from a glucose molecule to an enzyme, such as GOx merely by way of illustration.
- Glucose is therefore electrooxidized to form a gluconolactone molecule, and enzyme is reduced. Protons are generally released into the biological system via this reaction (see Eq.
- the captured electrons are transmitted to the working electrode through a redox polymer, such as an osmium(Os)-complex-based redox polymer, disposed on the working electrode.
- the electrons then travel from the working electrode to an electrical circuit to provide a low level of power.
- the electrons eventually make their way to the counter electrode via an optional resistor having an R value, where they are transmitted through an electrocatalyst layer, such as an Os-complex-based redox polymer merely by way of illustration, disposed on the counter electrode.
- the electrons are then passed on to an oxygen molecule in the biological system, which captures both the transmitted electrons and protons from the biological system to form a water molecule.
- a working electrode of the self-powered analyte sensor effectuates the electrooxidation of the reductant, such as the electrooxidation of glucose to gluconolactone as schematically illustrated in FIG. 1 .
- the reductant such as glucose to gluconolactone
- enzymes examples of which are oxidases and dehydrogenases, disposed on the working electrode catalyze this electrooxidation of the reductant, such as glucose.
- These enzymes are wired to the working electrode via a redox polymer disposed proximate to the enzyme and the working electrode.
- An example of a redox polymer is a polymer derived from the copolymer of poly(acrylamide) and poly(4-vinyl pyridine) and including an Os complex.
- a redox polymer is a redox polymer derived from poly(N-vinyl imidazole) and including an Os complex.
- the Os(II) and Os(III) centers of the redox polymers and the enzymes are immobilized in electron-conducting films on the surfaces of the working electrode.
- a counter electrode of the self-powered analyte sensor effectuates the four-electron electroreduction of O 2 to water under physiological conditions as schematically illustrated in FIG. 1 .
- the counter electrode can also, for example catalyze the two electrode reduction of O 2 to hydrogen peroxide.
- This electroreduction reaction is catalyzed by the electrocatalyst 101 layer disposed on the counter electrode.
- the electrocatalyst 101 includes platinum wire, platinum black, platinum ink, or platinum impregnated carbon disposed on the counter electrode.
- the electrocatalyst 101 is a redox polymer disposed on the counter electrode.
- An example of a redox polymer of a electrocatalyst layer 101 disposed on a counter electrode is a polymer derived from the copolymer of poly(acrylamide) and poly(4-vinyl pyridine) and including an Os complex.
- Another example of a redox polymer is a redox polymer derived from poly(N-vinyl imidazole) and including an Os complex.
- the Os(II) and Os(III) centers of the redox polymers are immobilized in electron-conducting films disposed on the surfaces of the counter electrode.
- enzymes such as BOD, Laccase, and the like, are complexed to the redox polymer disposed on the counter electrode. Both working and counter electrode may be overlaid by a flux-reducing biocompatible membrane, as described in the examples, below.
- the physical dimensions of the self-powered analyte sensor, as well as its operational parameters (e.g., output power and voltage) are, at least in part, a function of the components that form the sensor.
- the voltage drop across the resistance, R, of the self-powered analyte sensor can range from about 0 volts to about 1.2 volts, and typically, from about 0 volts to about 0.3 volts.
- the self-powered analyte sensor further includes an optional resistance disposed between the working electrode and the counter electrode and having an R value that is chosen from within a range of R values for which an electrochemical analyte sensor current output at an analyte concentration at the top of the physically relevant range of the analyte is independent of R.
- R value can be calculated, as exemplified in FIG. 14 , by determining the current output at a selected analyte concentration at the top of the physically relevant range of the analyte for a variety of selected R values.
- the R value is then determined to be the series of R values that correspond to a steady state current output from the electrochemical sensor, i.e., the rate at which the current output is stable and does not change over the varying R values.
- the current output (solid line with diamonds) for the sensor is independent of the R value from 0 M ⁇ to 10 M ⁇ tilde over ( ⁇ ) ⁇ .
- the R value is a whole integer and in other embodiments the R value is a fraction of a whole integer.
- the self-powered analyte sensor is usually assembled without the case, the seal, and the compartment-separating membrane required by conventional batteries.
- the self-powered analyte sensor can be manufactured with a footprint smaller than about 3 mm 2 , including smaller than about 1 mm 2 , such as smaller than about 0.3 mm 2 .
- the self-powered analyte sensor with dimensions on the millimeter to sub-millimeter level, can power sensor components, as further described herein. Further, the self-powered analyte sensor can be constructed so that none of its components, including its catalytic components, will be dissolved or leached while residing in the body.
- FIG. 2 is a schematic illustration of an application of a self-powered analyte sensor according to an embodiment of the invention for use in transcutaneous sensing of an analyte level.
- Panel A shows an embodiment in which a self-powered analyte sensor is implanted transcutaneously and a hand-held display and primary receiver unit is contacted directly to sensor leads as desired to measure the current flow and calculate the analyte level.
- Panel B shows an embodiment in which a self-powered analyte sensor is implanted transcutaneously, where the self-powered analyte sensor is further coupled to a radio-frequency (RF) powered measurement circuit.
- RF radio-frequency
- the RF powered measurement circuit and data processing unit is then remotely queried at regular intervals by an RF-power equipped hand-held display and primary receiver unit in order to provide analyte level measurements.
- the RF-powered equipped hand-held display and primary receiver unit is brought into close proximity to the transcutaneously implanted sensor at regular intervals.
- the radio-frequency powered current measuring circuit and data processing unit is intermittently powered.
- the sensor is coupled to an inductively powered current measuring circuit and data processing unit. In certain embodiments, the inductively powered current measuring circuit and data processing unit is intermittently powered.
- FIG. 3 is a schematic illustration of a fully implanted self-powered analyte sensor coupled to a radio-frequency (RF)-powered potentiostat measurement circuit and data processing unit that may be intermittently RF-powered with an external RF-power source when an analyte measurement is desired.
- the RF-powered potentiostat measurement circuit and data processing unit is brought into close proximity to the implanted sensor at regular intervals.
- the RF-power source may be moved away from the site of implantation of the self-powered analyte sensor at any time and no re-equilibration period is required when it is brought back into RF communication with the site of implantation.
- the radio-frequency powered current measuring circuit and data processing unit is intermittently powered.
- the sensor is coupled to an inductively powered current measuring circuit and data processing unit. In certain embodiments, the inductively powered current measuring circuit and data processing unit is intermittently powered.
- a self-powered analyte sensor may be an in vivo sensor or an in vitro sensor (i.e., a discrete monitoring test strip).
- a sensor can be formed on a substrate, e.g., a substantially planar substrate.
- a sensor is a wire, e.g., a working electrode wire inner portion with one or more other electrodes associated (e.g., on, including wrapped around) therewith.
- the sensor also includes at least one counter electrode.
- analyte sensors such as glucose sensors
- glucose sensors that are capable of in vivo detection of an analyte for about one hour or more, e.g., about a few hours or more, e.g., about a few days or more, e.g., about three or more days, e.g., about five days or more, e.g., about seven days or more, e.g., about several weeks or at least one month or more.
- Future analyte levels may be predicted based on information obtained, e.g., the current analyte level at time t 0 , the rate of change of the analyte, etc.
- Predictive alarms may notify the user of a predicted analyte levels that may be of concern in advance of the user's analyte level reaching the future level. This provides the user an opportunity to take corrective action.
- Analytes that may be monitored include, but are not limited to, acetyl choline, amylase, bilirubin, cholesterol, chorionic gonadotropin, creatine kinase (e.g., CK-MB), creatine, creatinine, DNA, fructosamine, glucose, glutamine, growth hormones, hormones, ketone bodies, lactate, peroxide, prostate-specific antigen, prothrombin, RNA, thyroid stimulating hormone, and troponin.
- concentration of drugs such as, for example, antibiotics (e.g., gentamicin, vancomycin, and the like), digitoxin, digoxin, drugs of abuse, theophylline, and warfarin, may also be monitored. In those embodiments that monitor more than one analyte, the analytes may be monitored at the same or different times.
- the analyte monitoring system 400 includes a sensor 401 , a data processing unit 402 connectable to the sensor 401 , and a primary receiver unit 404 which is configured to communicate with the data processing unit 402 via a communication link 403 .
- the primary receiver unit 104 may be further configured to transmit data to a data processing terminal 405 to evaluate or otherwise process or format data received by the primary receiver unit 404 .
- the data processing terminal 405 may be configured to receive data directly from the data processing unit 402 via a communication link which may optionally be configured for bi-directional communication.
- the data processing unit 402 may include a transmitter or a transceiver to transmit and/or receive data to and/or from the primary receiver unit 404 and/or the data processing terminal 405 and/or optionally the secondary receiver unit 406 .
- an optional secondary receiver unit 406 which is operatively coupled to the communication link and configured to receive data transmitted from the data processing unit 402 .
- the secondary receiver unit 406 may be configured to communicate with the primary receiver unit 404 , as well as the data processing terminal 405 .
- the secondary receiver unit 406 may be configured for bi-directional wireless communication with each of the primary receiver unit 404 and the data processing terminal 405 .
- the secondary receiver unit 406 may be a de-featured receiver as compared to the primary receiver, i.e., the secondary receiver may include a limited or minimal number of functions and features as compared with the primary receiver unit 404 .
- the secondary receiver unit 406 may include a smaller (in one or more, including all, dimensions), compact housing or embodied in a device including a wrist watch, arm band, PDA, etc., for example.
- the secondary receiver unit 406 may be configured with the same or substantially similar functions and features as the primary receiver unit 404 .
- the secondary receiver unit 406 may include a docking portion to be mated with a docking cradle unit for placement by, e.g., the bedside for night time monitoring, and/or a bi-directional communication device.
- a docking cradle may recharge a powers supply.
- the analyte monitoring system 400 may be a continuous monitoring system, or semi-continuous, or a discrete monitoring system.
- each component may be configured to be uniquely identified by one or more of the other components in the system so that communication conflict may be readily resolved between the various components within the analyte monitoring system 400 .
- unique IDs, communication channels, and the like may be used.
- the senor 401 is physically positioned in or on the body of a user whose analyte level is being monitored.
- the sensor 401 may be configured to at least periodically sample the analyte level of the user and convert the sampled analyte level into a corresponding signal for transmission by the data processing unit 402 .
- the data processing unit 402 is coupleable to the self-powered sensor 401 so that both devices are positioned in or on the user's body, with at least a portion of the self-powered analyte sensor 401 positioned transcutaneously.
- the data processing unit may include a fixation element such as adhesive or the like to secure it to the user's body.
- the primary receiver unit 404 in certain embodiments is configured to synchronize with the data processing unit 402 to uniquely identify the data processing unit 402 , based on, for example, an identification information of the data processing unit 402 , and thereafter, to periodically receive signals transmitted from the data processing unit 402 associated with the monitored analyte levels detected by the sensor 401 .
- the data processing terminal 405 may include a personal computer, a portable computer including a laptop or a handheld device (e.g., personal digital assistants (PDAs), telephone including a cellular phone (e.g., a multimedia and Internet-enabled mobile phone including an iPhoneTM, iPODTM or similar phone), mp3 player, pager, and the like), drug delivery device, each of which may be configured for data communication with the receiver via a wired or a wireless connection. Additionally, the data processing terminal 405 may further be connected to a data network (not shown) for storing, retrieving, updating, and/or analyzing data corresponding to the detected analyte level of the user.
- a data network not shown
- the data processing terminal 405 which may include an insulin pump, may be configured to receive the analyte signals from the data processing unit 402 , and thus, incorporate the functions of the primary receiver unit 404 including data processing for managing the patient's insulin therapy and analyte monitoring.
- the communication link 403 as well as one or more of the other communication interfaces shown in FIG. 4 may use one or more of: an RF communication protocol, an infrared communication protocol, a Bluetooth enabled communication protocol, an 802.11x wireless communication protocol, or an equivalent wireless communication protocol which would allow secure, wireless communication of several units (for example, per HIPPA requirements), while avoiding potential data collision and interference.
- the sensor unit 401 ( FIG. 4 ) includes three contacts, two of which are electrodes—working electrode (W) 510 , and counter electrode (C) 513 , each operatively coupled to the analog interface 501 of the data processing unit 402 .
- This embodiment also shows optional guard contact (G) 511 . Fewer or greater electrodes may be employed. For example, there may be more than one working electrode and/or counter electrode, etc.
- FIG. 6 is a block diagram of an embodiment of a receiver/monitor unit such as the primary receiver unit 404 of the data monitoring and management system shown in FIG. 4 .
- the primary receiver unit 404 includes one or more of: a blood glucose test strip interface 601 , an RF receiver 602 , an input 603 , a temperature detection section 604 , and a clock 605 , each of which is operatively coupled to a processing and storage section 607 .
- the primary receiver unit 404 also includes a power supply 606 operatively coupled to a power conversion and monitoring section 608 . Further, the power conversion and monitoring section 608 is also coupled to the receiver processor 607 .
- a receiver serial communication section 609 and an output 610 , each operatively coupled to the processing and storage unit 607 .
- the receiver may include user input and/or interface components or may be free of user input and/or interface components.
- Glucose information obtained by the in vitro glucose testing device may be used for a variety of purposes, computations, etc.
- the information may be used to calibrate sensor 401 , confirm results of the sensor 401 to increase the confidence thereof (e.g., in instances in which information obtained by sensor 401 is employed in therapy related decisions), etc.
- the data processing unit 402 and/or the primary receiver unit 404 and/or the secondary receiver unit 405 , and/or the data processing terminal/infusion section 405 may be configured to receive the blood glucose value wirelessly over a communication link from, for example, a blood glucose meter.
- a user manipulating or using the analyte monitoring system 400 may manually input the blood glucose value using, for example, a user interface (for example, a keyboard, keypad, voice commands, and the like) incorporated in the one or more of the data processing unit 402 , the primary receiver unit 404 , secondary receiver unit 405 , or the data processing terminal/infusion section 405 .
- FIG. 7 schematically shows an embodiment of an analyte sensor in accordance with the embodiments of the invention.
- This sensor embodiment includes electrodes 701 and 703 on a base 704 .
- Electrodes (and/or other features) may be applied or otherwise processed using any suitable technology, e.g., chemical vapor deposition (CVD), physical vapor deposition, sputtering, reactive sputtering, printing, coating, ablating (e.g., laser ablation), painting, dip coating, etching, and the like.
- CVD chemical vapor deposition
- sputtering e.g., reactive sputtering
- printing e.g., coating
- ablating e.g., laser ablation
- Materials include, but are not limited to, any one or more of aluminum, carbon (including graphite), cobalt, copper, gallium, gold, indium, iridium, iron, lead, magnesium, mercury (as an amalgam), nickel, niobium, osmium, palladium, platinum, rhenium, rhodium, selenium, silicon (e.g., doped polycrystalline silicon), silver, tantalum, tin, titanium, tungsten, uranium, vanadium, zinc, zirconium, mixtures thereof, and alloys, oxides, or metallic compounds of these elements.
- the sensor may be wholly implantable in a user or may be configured so that only a portion is positioned within (internal) a user and another portion outside (external) a user.
- the sensor 700 may include a portion positionable above a surface of the skin 710 , and a portion positioned below the skin.
- the external portion may include contacts (connected to respective electrodes of the second portion by traces) to connect to another device also external to the user such as a transmitter unit. While the embodiment of FIG.
- FIG. 7 shows two electrodes side-by-side on the same surface of base 704 , other configurations are contemplated, e.g., greater electrodes, some or all electrodes on different surfaces of the base or present on another base, some or all electrodes stacked together, electrodes of differing materials and dimensions, etc.
- FIG. 8A shows a perspective view of an embodiment of an electrochemical analyte sensor 800 having a first portion (which in this embodiment may be characterized as a major portion) positionable above a surface of the skin 810 , and a second portion (which in this embodiment may be characterized as a minor portion) that includes an insertion tip 830 positionable below the skin, e.g., penetrating through the skin and into, e.g., the subcutaneous space 820 , in contact with the user's biofluid such as interstitial fluid.
- Contact portions of a working electrode 801 and a counter electrode 803 are positioned on the portion of the sensor 800 situated above the skin surface 810 .
- Working electrode 801 and a counter electrode 803 are shown at the second section and particularly at the insertion tip 830 . Traces may be provided from the electrode at the tip to the contact, as shown in FIG. 8A . It is to be understood that greater or fewer electrodes may be provided on a sensor. For example, a sensor may include more than one working electrodes.
- FIG. 8B shows a cross sectional view of a portion of the sensor 800 of FIG. 8A .
- the electrodes 801 and 803 of the sensor 800 as well as the substrate and the dielectric layers are provided in a layered configuration or construction.
- the sensor 800 (such as the sensor unit 401 FIG. 4 ), includes a substrate layer 804 , and a first conducting layer 801 such as carbon, gold, etc., disposed on at least a portion of the substrate layer 804 , and which may provide the working electrode. Also shown disposed on at least a portion of the first conducting layer 801 is a sensing layer 808 .
- a first insulation layer such as a first dielectric layer 805 is disposed or layered on at least a portion of the first conducting layer 801 .
- a second conducting layer 803 may provide the counter electrode 803 . It may be disposed on at least a portion of the first insulation layer 805 .
- a second insulation layer may be disposed or layered on at least a portion of the second conducting layer 803 .
- the sensor 800 may be layered such that at least a portion of each of the conducting layers is separated by a respective insulation layer (for example, a dielectric layer).
- the embodiment of FIGS. 8A and 8B show the layers having different lengths. Some or all of the layers may have the same or different lengths and/or widths.
- some or all of the electrodes 801 , 803 may be provided on the same side of the substrate 804 in the layered construction as described above, or alternatively, may be provided in a co-planar manner such that two or more electrodes may be positioned on the same plane (e.g., side-by side (e.g., parallel) or angled relative to each other) on the substrate 804 .
- co-planar electrodes may include a suitable spacing there between and/or include dielectric material or insulation material disposed between the conducting layers/electrodes.
- one or more of the electrodes 801 , 803 may be disposed on opposing sides of the substrate 804 . In such embodiments, contact pads may be one the same or different sides of the substrate.
- an electrode may be on a first side and its respective contact may be on a second side, e.g., a trace connecting the electrode and the contact may traverse through the substrate.
- analyte sensors may include an analyte-responsive enzyme to provide a sensing component or sensing layer.
- Some analytes such as oxygen, can be directly electrooxidized or electroreduced on a sensor, and more specifically at least on a working electrode of a sensor.
- Other analytes such as glucose and lactate, require the presence of at least one electron transfer agent and/or at least one catalyst to facilitate the electrooxidation or electroreduction of the analyte.
- each working electrode includes a sensing layer (see for example sensing layer 808 of FIG. 8B ) proximate to or on a surface of a working electrode.
- a sensing layer is formed near or on only a small portion of at least a working electrode.
- the sensing layer includes one or more components constructed to facilitate the electrochemical oxidation or reduction of the analyte.
- the sensing layer may include, for example, a catalyst to catalyze a reaction of the analyte and produce a response at the working electrode, an electron transfer agent to transfer electrons between the analyte and the working electrode (or other component), or both.
- the sensing layer and the working electrode also function as the anode of the power generating component of the self-powered analyte sensor, thereby providing the dual-function of power generation and analyte level detection.
- the sensing layer is deposited on the conductive material of a working electrode.
- the sensing layer may extend beyond the conductive material of the working electrode. In some cases, the sensing layer may also extend over other electrodes.
- a sensing layer that is in direct contact with the working electrode may contain an electron transfer agent to transfer electrons directly or indirectly between the analyte and the working electrode, and/or a catalyst to facilitate a reaction of the analyte.
- a glucose, lactate, or oxygen electrode may be formed having a sensing layer which contains a catalyst, including glucose oxidase, glucose dehydrogenase, lactate oxidase, or laccase, respectively, and an electron transfer agent that facilitates the electrooxidation of the glucose, lactate, or oxygen, respectively.
- the sensing layer is not deposited directly on the working electrode.
- the sensing layer 808 may be spaced apart from the working electrode, and separated from the working electrode, e.g., by a separation layer.
- a separation layer may include one or more membranes or films or a physical distance.
- the separation layer may also act as a mass transport limiting layer and/or an interferent eliminating layer and/or a biocompatible layer.
- one or more of the working electrodes may not have a corresponding sensing layer, or may have a sensing layer which does not contain one or more components (e.g., an electron transfer agent and/or catalyst) needed to electrolyze the analyte.
- the signal at this working electrode may correspond to background signal which may be removed from the analyte signal obtained from one or more other working electrodes that are associated with fully-functional sensing layers by, for example, subtracting the signal.
- the sensing layer includes one or more electron transfer agents.
- Electron transfer agents that may be employed are electroreducible and electrooxidizable ions or molecules having redox potentials that are a few hundred millivolts above or below the redox potential of the standard calomel electrode (SCE).
- the electron transfer agent may be organic, organometallic, or inorganic. Examples of organic redox species are quinones and species that in their oxidized state have quinoid structures, such as Nile blue and indophenol. Examples of organometallic redox species are metallocenes including ferrocene. Examples of inorganic redox species are hexacyanoferrate (III), ruthenium hexamine etc. Additional examples include those described in U.S. Pat. No. 6,736,957 and U.S. Patent Publication Nos. 2004/0079653 and 2006/0201805, the disclosures of which are incorporated herein by reference in their entirety.
- electron transfer agents have structures or charges which prevent or substantially reduce the diffusional loss of the electron transfer agent during the period of time that the sample is being analyzed.
- electron transfer agents include but are not limited to a redox species, e.g., bound to a polymer which can in turn be disposed on or near the working electrode.
- the bond between the redox species and the polymer may be covalent, coordinative, or ionic.
- the redox species is a transition metal compound or complex, e.g., osmium, ruthenium, iron, and cobalt compounds or complexes. It will be recognized that many redox species described for use with a polymeric component may also be used, without a polymeric component.
- polymeric electron transfer agent contains a redox species covalently bound in a polymeric composition.
- An example of this type of mediator is poly(vinylferrocene).
- Another type of electron transfer agent contains an ionically-bound redox species.
- This type of mediator may include a charged polymer coupled to an oppositely charged redox species.
- Examples of this type of mediator include a negatively charged polymer coupled to a positively charged redox species such as an osmium or ruthenium polypyridyl cation.
- Suitable electron transfer agents are osmium transition metal complexes with one or more ligands, each ligand having a nitrogen-containing heterocycle such as 2,2′-bipyridine, 1,10-phenanthroline, 1-methyl, 2-pyridyl biimidazole, or derivatives thereof.
- the electron transfer agents may also have one or more ligands covalently bound in a polymer, each ligand having at least one nitrogen-containing heterocycle, such as pyridine, imidazole, or derivatives thereof.
- an electron transfer agent includes (a) a polymer or copolymer having pyridine or imidazole functional groups and (b) osmium cations complexed with two ligands, each ligand containing 2,2′-bipyridine, 1,10-phenanthroline, or derivatives thereof, the two ligands not necessarily being the same.
- Some derivatives of 2,2′-bipyridine for complexation with the osmium cation include but are not limited to 4,4′-dimethyl-2,2′-bipyridine and mono-, di-, and polyalkoxy-2,2′-bipyridines, including 4,4′-dimethoxy-2,2′-bipyridine.
- 1,10-phenanthroline for complexation with the osmium cation include but are not limited to 4,7-dimethyl-1,10-phenanthroline and mono, di-, and polyalkoxy-1,10-phenanthrolines, such as 4,7-dimethoxy-1,10-phenanthroline.
- Polymers for complexation with the osmium cation include but are not limited to polymers and copolymers of poly(1-vinyl imidazole) (referred to as “PVI”) and poly(4-vinyl pyridine) (referred to as “PVP”).
- Embodiments may employ electron transfer agents having a redox potential ranging from about ⁇ 200 mV to about +200 mV versus the standard calomel electrode (SCE).
- the sensing layer may also include a catalyst which is capable of catalyzing a reaction of the analyte.
- the catalyst may also, in some embodiments, act as an electron transfer agent.
- One example of a suitable catalyst is an enzyme which catalyzes a reaction of the analyte.
- a catalyst including a glucose oxidase, glucose dehydrogenase (e.g., pyrroloquinoline quinone (PQQ), dependent glucose dehydrogenase, flavine adenine dinucleotide (FAD) dependent glucose dehydrogenase, or nicotinamide adenine dinucleotide (NAD) dependent glucose dehydrogenase), may be used when the analyte of interest is glucose.
- PQQ pyrroloquinoline quinone
- FAD flavine adenine dinucleotide
- NAD nicotinamide adenine dinucleotide dependent glucose dehydrogenase
- a lactate oxidase or lactate dehydrogenase may be used when the analyte of interest is lactate.
- Laccase may be used when the analyte of interest is oxygen or when oxygen is generated or consumed in response to a reaction of the analyte.
- a catalyst including a glucose oxidase, glucose dehydrogenase (e.g., pyrroloquinoline quinone (PQQ), dependent glucose dehydrogenase or oligosaccharide dehydrogenase, flavine adenine dinucleotide (FAD) dependent glucose dehydrogenase, nicotinamide adenine dinucleotide (NAD) dependent glucose dehydrogenase), may be used when the analyte of interest is glucose.
- a lactate oxidase or lactate dehydrogenase may be used when the analyte of interest is lactate.
- Laccase may be used when the analyte of interest is oxygen or when oxygen is generated or consumed in response to a reaction of the analyte.
- a catalyst may be attached to a polymer, cross linking the catalyst with another electron transfer agent, which, as described above, may be polymeric.
- a second catalyst may also be used in certain embodiments. This second catalyst may be used to catalyze a reaction of a product compound resulting from the catalyzed reaction of the analyte. The second catalyst may operate with an electron transfer agent to electrolyze the product compound to generate a signal at the working electrode.
- a second catalyst may be provided in an interferent-eliminating layer to catalyze reactions that remove interferents.
- Embodiments also include membranes that are made of a polyurethane, or polyether urethane, or chemically related material, or membranes that are made of silicone, and the like.
- a membrane may be formed by crosslinking in situ a polymer, modified with a zwitterionic moiety, a non-pyridine copolymer component, and optionally another moiety that is either hydrophilic or hydrophobic, and/or has other desirable properties, in an alcohol-buffer solution.
- the membrane formulation further includes a plasticizer.
- the modified polymer may be made from a precursor polymer containing heterocyclic nitrogen groups.
- a precursor polymer may be polyvinylpyridine or polyvinylimidazole.
- hydrophilic or hydrophobic modifiers may be used to “fine-tune” the permeability of the resulting membrane to an analyte of interest.
- hydrophilic modifiers such as poly(ethylene glycol), hydroxyl or polyhydroxyl modifiers, may be used to enhance the biocompatibility of the polymer or the resulting membrane.
- a membrane may be formed in situ by applying an alcohol-buffer solution of a crosslinker and a modified polymer over an enzyme-containing sensing layer and allowing the solution to cure for about one to two days or other appropriate time period.
- the crosslinker-polymer solution may be applied to the sensing layer by placing a droplet or droplets of the solution on the sensor, by dipping the sensor into the solution, or the like.
- the thickness of the membrane is controlled by the concentration of the solution, by the number of droplets of the solution applied, by the number of times the sensor is dipped in the solution, or by any combination of these factors.
- a membrane applied in this manner may have any combination of the following functions: (1) mass transport limitation, i.e., reduction of the flux of analyte that can reach the sensing layer, (2) biocompatibility enhancement, or (3) interferent reduction.
- the substrate may be formed using a variety of non-conducting materials, including, for example, polymeric or plastic materials and ceramic materials. Suitable materials for a particular sensor may be determined, at least in part, based on the desired use of the sensor and properties of the materials.
- the substrate is flexible.
- the sensor may be made flexible (although rigid sensors may also be used for implantable sensors) to reduce pain to the patient and damage to the tissue caused by the implantation of and/or the wearing of the sensor.
- a flexible substrate often increases the patient's comfort and allows a wider range of activities.
- Suitable materials for a flexible substrate include, for example, non-conducting plastic or polymeric materials and other non-conducting, flexible, deformable materials.
- the sensors are made using a relatively rigid substrate to, for example, provide structural support against bending or breaking.
- rigid materials that may be used as the substrate include poorly conducting ceramics, such as aluminum oxide and silicon dioxide.
- One advantage of an implantable sensor having a rigid substrate is that the sensor may have a sharp point and/or a sharp edge to aid in implantation of a sensor without an additional insertion device.
- implantable sensors should have a substrate which is physiologically harmless, for example, a substrate approved by a regulatory agency or private institution for in vivo use.
- the sensor may include optional features to facilitate insertion of an implantable sensor.
- the sensor may be pointed at the tip to ease insertion.
- the sensor may include a barb which assists in anchoring the sensor within the tissue of the patient during operation of the sensor.
- the barb is typically small enough so that little damage is caused to the subcutaneous tissue when the sensor is removed for replacement.
- An implantable sensor may also, optionally, have an anticlotting agent disposed on a portion of the substrate which is implanted into a patient.
- This anticlotting agent may reduce or eliminate the clotting of blood or other body fluid around the sensor, particularly after insertion of the sensor. Blood clots may foul the sensor or irreproducibly reduce the amount of analyte which diffuses into the sensor.
- useful anticlotting agents include heparin and tissue plasminogen activator (TPA), as well as other known anticlotting agents.
- the anticlotting agent may be applied to at least a portion of that part of the sensor that is to be implanted.
- the anticlotting agent may be applied, for example, by bath, spraying, brushing, or dipping.
- the anticlotting agent is allowed to dry on the sensor.
- the anticlotting agent may be immobilized on the surface of the sensor or it may be allowed to diffuse away from the sensor surface.
- the quantities of anticlotting agent disposed on the sensor are far below the amounts typically used for treatment of medical conditions involving blood clots and, therefore, have only a limited, localized effect.
- An insertion device can be used to subcutaneously insert the self-powered analyte sensor into the patient.
- the insertion device is typically formed using structurally rigid materials, such as metal or rigid plastic. Exemplary materials include stainless steel and ABS (acrylonitrile-butadiene-styrene) plastic.
- the insertion device is pointed and/or sharp at the tip to facilitate penetration of the skin of the patient. A sharp, thin insertion device may reduce pain felt by the patient upon insertion of the self-powered analyte sensor.
- the tip of the insertion device has other shapes, including a blunt or flat shape. These embodiments may be particularly useful when the insertion device does not penetrate the skin but rather serves as a structural support for the sensor as the sensor is pushed into the skin.
- the sensor control unit can be integrated in the sensor, part or all of which is subcutaneously implanted or it can be configured to be placed on the skin of a patient.
- the sensor control unit is optionally formed in a shape that is comfortable to the patient and which may permit concealment, for example, under a patient's clothing.
- the thigh, leg, upper arm, shoulder, or abdomen are convenient parts of the patient's body for placement of the sensor control unit to maintain concealment.
- the sensor control unit may be positioned on other portions of the patient's body.
- One embodiment of the sensor control unit has a thin, oval shape to enhance concealment. However, other shapes and sizes may be used.
- the particular profile, as well as the height, width, length, weight, and volume of the sensor control unit may vary and depends, at least in part, on the components and associated functions included in the sensor control unit.
- the sensor control unit includes a housing typically formed as a single integral unit that rests on the skin of the patient.
- the housing typically contains most or all of the electronic components of the sensor control unit.
- the housing of the sensor control unit may be formed using a variety of materials, including, for example, plastic and polymeric materials, particularly rigid thermoplastics and engineering thermoplastics. Suitable materials include, for example, polyvinyl chloride, polyethylene, polypropylene, polystyrene, ABS polymers, and copolymers thereof.
- the housing of the sensor control unit may be formed using a variety of techniques including, for example, injection molding, compression molding, casting, and other molding methods. Hollow or recessed regions may be formed in the housing of the sensor control unit.
- the electronic components of the sensor control unit and/or other items, including a battery or a speaker for an audible alarm, may be placed in the hollow or recessed areas.
- the sensor control unit is typically attached to the skin of the patient, for example, by adhering the sensor control unit directly to the skin of the patient with an adhesive provided on at least a portion of the housing of the sensor control unit which contacts the skin or by suturing the sensor control unit to the skin through suture openings in the sensor control unit.
- the senor and the electronic components within the sensor control unit are coupled via conductive contacts.
- the one or more working electrodes, counter electrode, and optional temperature probe are attached to individual conductive contacts.
- the conductive contacts are provided on the interior of the sensor control unit.
- Other embodiments of the sensor control unit have the conductive contacts disposed on the exterior of the housing. The placement of the conductive contacts is such that they are in contact with the contact pads on the sensor when the sensor is properly positioned within the sensor control unit.
- the sensor control unit also typically includes at least a portion of the electronic components that measure the sensor current and the analyte monitoring device system.
- the electronic components of the sensor control unit typically include a power supply for operating the sensor control unit, a sensor circuit for obtaining signals from the sensor, a measurement circuit that converts sensor signals to a desired format, and a processing circuit that, at minimum, obtains signals from the sensor circuit and/or measurement circuit and provides the signals to an optional transmitter.
- the processing circuit may also partially or completely evaluate the signals from the sensor and convey the resulting data to the optional transmitter and/or activate an optional alarm system if the analyte level exceeds a threshold.
- the processing circuit often includes digital logic circuitry.
- the sensor control unit may optionally contain a transmitter for transmitting the sensor signals or processed data from the processing circuit to a receiver/display unit; a data storage unit for temporarily or permanently storing data from the processing circuit; a temperature probe circuit for receiving signals from and operating a temperature probe; a reference voltage generator for providing a reference voltage for comparison with sensor-generated signals; and/or a watchdog circuit that monitors the operation of the electronic components in the sensor control unit.
- the sensor control unit may also include digital and/or analog components utilizing semiconductor devices, including transistors.
- the sensor control unit may include other components including, for example, a bias control generator to correctly bias analog and digital semiconductor devices, an oscillator to provide a clock signal, and a digital logic and timing component to provide timing signals and logic operations for the digital components of the circuit.
- the sensor circuit and the optional temperature probe circuit provide raw signals from the sensor to the measurement circuit.
- the measurement circuit converts the raw signals to a desired format, using for example, a current-to-voltage converter, current-to-frequency converter, and/or a binary counter or other indicator that produces a signal proportional to the absolute value of the raw signal. This may be used, for example, to convert the raw signal to a format that can be used by digital logic circuits.
- the processing circuit may then, optionally, evaluate the data and provide commands to operate the electronics.
- Sensors may be configured to require no system calibration or no user calibration.
- a sensor may be factory calibrated and need not require further calibrating.
- calibration may be required, but may be done without user intervention, i.e., may be automatic.
- the calibration may be according to a predetermined schedule or may be dynamic, i.e., the time for which may be determined by the system on a real-time basis according to various factors, including, but not limited to, glucose concentration and/or temperature and/or rate of change of glucose, etc.
- an optional receiver may be included in the sensor control unit.
- the transmitter is a transceiver, operating as both a transmitter and a receiver.
- the receiver may be used to receive calibration data for the sensor.
- the calibration data may be used by the processing circuit to correct signals from the sensor.
- This calibration data may be transmitted by the receiver/display unit or from some other source such as a control unit in a doctor's office.
- the optional receiver may be used to receive a signal from the receiver/display units to direct the transmitter, for example, to change frequencies or frequency bands, to activate or deactivate the optional alarm system and/or to direct the transmitter to transmit at a higher rate.
- Calibration data may be obtained in a variety of ways.
- the calibration data may simply be factory-determined calibration measurements which can be input into the sensor control unit using the receiver or may alternatively be stored in a calibration data storage unit within the sensor control unit itself (in which case a receiver may not be needed).
- the calibration data storage unit may be, for example, a readable or readable/writeable memory circuit.
- Calibration may be accomplished using an in vitro test strip (or other reference), e.g., a small sample test strip such as a test strip that requires less than about 1 microliter of sample (for example FreeStyle® blood glucose monitoring test strips from Abbott Diabetes Care). For example, test strips that require less than about 1 nanoliter of sample may be used.
- a sensor may be calibrated using only one sample of body fluid per calibration event. For example, a user need only lance a body part one time to obtain sample for a calibration event (e.g., for a test strip), or may lance more than one time within a short period of time if an insufficient volume of sample is firstly obtained.
- Embodiments include obtaining and using multiple samples of body fluid for a given calibration event, where glucose values of each sample are substantially similar. Data obtained from a given calibration event may be used independently to calibrate or combined with data obtained from previous calibration events, e.g., averaged including weighted averaged, etc., to calibrate. In certain embodiments, a system need only be calibrated once by a user, where recalibration of the system is not required.
- Alternative or additional calibration data may be provided based on tests performed by a doctor or some other professional or by the patient. For example, it is common for diabetic individuals to determine their own blood glucose concentration using commercially available testing kits. The results of this test is input into the sensor control unit either directly, if an appropriate input device (e.g., a keypad, an optical signal receiver, or a port for connection to a keypad or computer) is incorporated in the sensor control unit, or indirectly by inputting the calibration data into the receiver/display unit and transmitting the calibration data to the sensor control unit.
- an appropriate input device e.g., a keypad, an optical signal receiver, or a port for connection to a keypad or computer
- calibration data may also be used to obtain calibration data.
- This type of calibration data may supplant or supplement factory-determined calibration values.
- calibration data may be required at periodic intervals, for example, every eight hours, once a day, or once a week, to confirm that accurate analyte levels are being reported. Calibration may also be required each time a new sensor is implanted or if the sensor exceeds a threshold minimum or maximum value or if the rate of change in the sensor signal exceeds a threshold value. In some cases, it may be necessary to wait a period of time after the implantation of the sensor before calibrating to allow the sensor to achieve equilibrium. In some embodiments, the sensor is calibrated only after it has been inserted. In other embodiments, no calibration of the sensor is needed.
- An alarm may also be activated if the sensor readings indicate a value that is beyond a measurement range of the sensor.
- the physiologically relevant measurement range is typically about 30 to 500 mg/dL, including about 40-300 mg/dL and about 50-250 mg/dL, of glucose in the interstitial fluid.
- the alarm system may also, or alternatively, be activated when the rate of change or acceleration of the rate of change in analyte level increase or decrease reaches or exceeds a threshold rate or acceleration.
- a threshold rate or acceleration For example, in the case of a subcutaneous glucose monitor, the alarm system might be activated if the rate of change in glucose concentration exceeds a threshold value which might indicate that a hyperglycemic or hypoglycemic condition is likely to occur.
- a system may also include system alarms that notify a user of system information such as battery condition, calibration, sensor dislodgment, sensor malfunction, etc.
- Alarms may be, for example, auditory and/or visual.
- Other sensory-stimulating alarm systems may be used including alarm systems which heat, cool, vibrate, or produce a mild electrical shock when activated.
- the subject invention also includes sensors used in sensor-based drug delivery systems.
- the system may provide a drug to counteract the high or low level of the analyte in response to the signals from one or more sensors. Alternatively, the system may monitor the drug concentration to ensure that the drug remains within a desired therapeutic range.
- the drug delivery system may include one or more (e.g., two or more) sensors, a processing unit such as a transmitter, a receiver/display unit, and a drug administration system. In some cases, some or all components may be integrated in a single unit.
- a sensor-based drug delivery system may use data from the one or more sensors to provide necessary input for a control algorithm/mechanism to adjust the administration of drugs, e.g., automatically or semi-automatically.
- a glucose sensor may be used to control and adjust the administration of insulin from an external or implanted insulin pump.
- a self-powered glucose sensor was constructed using either a redox polymer or platinum-carbon cloth (Pt—C) as an oxygen reducing species on the counter electrode and glucose oxidase (GOx) as glucose oxidizing species on the working electrode, which also acts as the analyte responsive enzyme of the glucose sensor. Fabrication of the self-powered analyte sensors is described below.
- Working electrode glucose oxidizing anode: 30 nL of a solution including 8.2 mg/mL GOx, 6.8 mg/mL redox polymer (a poly(vinylpyridine) derivative containing covalently bound Os complexes), and 5 mg/mL PEG 400 crosslinker, all dissolved in 10 mM HEPES, was deposited on the working electrode of a continuous glucose monitor sensor, such as a Navigator® electrode, to form an active area of about 0.1 mm 2 . This electrode was overlaid with the flux-limiting membrane, approximately 50 micron thick coating of the membrane polymer (a poly(vinylpyridine) derivative) crosslinked with tri-glycidyl glycerol.
- a continuous glucose monitor sensor such as a Navigator® electrode
- Counter electrode oxygen reducing cathode: 150 nL of a solution including 5.2 mg/mL redox polymer dissolved in PBS, was deposited on the entirety of the working electrode of a continuous glucose monitor sensor, such as a Navigator® electrode, to form an active area of about 0.9 mm 2 .
- This electrode was overlaid with a flux-limiting membrane, an approximately 50 micron thick coating of the membrane polymer (a poly(vinylpyridine) derivative), crosslinked with tri-glycidyl glycerol.
- Glucose aliquots were added to produce concentrations of 4, 12, 20, and 28 mM, as evident from the humps in FIG. 9 .
- concentrations of 4, 12, 20, and 28 mM as evident from the humps in FIG. 9 .
- FIG. 9 it was observed that the self-powered glucose sensor with a Pt—C counter electrode provided an identical result to a three electrode potentiostat-powered sensor, while the self-powered glucose sensor fabricated with a redox polymer based counter electrode gave a somewhat reduced current response.
- FIG. 10 Calibration curves from the data shown in FIG. 9 are provided in FIG. 10 .
- the Pt—C counter electrode based self-powered sensor provided equivalent data to the three electrode potentiostat-powered sensor, while the self-powered glucose sensor fabricated with a redox polymer based counter electrode gave a somewhat reduced current response.
- FIG. 11 shows a comparison of intermittently powering the current generation of a standard continuous glucose sensor (P-stat powered) and self-powered sensor having a Pt—C counter electrode as described in Example 1 (Self-powered, Pt—C as CTR).
- the oxygen reducing counter electrode of a self-powered sensor can also be constructed of an oxygen reducing enzyme, in addition to the other materials previously discussed, such as Pt, Pt black, and redox polymer.
- the enzyme in this case bilirubin oxidase (BOD) can accept electrons directly from oxygen, then transmit them to the counter electrode through a cross-linked redox polymer. Fabrication of the self-powered analyte sensors is described below.
- Counter electrode oxygen reducing cathode: 150 nL of a solution including 12.6 mg/mL BOD, 5.2 mg/mL redox polymer, and 5.4 mg/mL PEG 400 cross-linker, all dissolved in PBS, was deposited on the entirety of the working electrode of a second continuous glucose sensor, such as a Navigator® sensor, to form an active area of about 0.9 mm 2 .
- This electrode was overlaid with a flux-limiting membrane, an approximately 50 micron thick coating of the membrane polymer (a poly(vinylpyridine) derivative) cross-linked with tri-glycidyl glycerol.
- a self-powered glucose sensor was constructed using either a redox polymer or platinum (Pt) as an oxygen reducing species on the counter electrode and glucose dehydrogenase complexed with flavin adenine dinucleotide (FADGDH) on the working electrode, which also acts the analyte responsive enzyme for the sensor. Fabrication of the self-powered analyte sensors is described below.
- Working electrode 30 nL of a solution including 8.2 mg/mL FADGDH, 6.8 mg/mL redox polymer (a poly(vinylpyridine) derivative containing covalently bound Os complexes), and 5 mg/mL PEG 400 crosslinker, all dissolved in 10 mM HEPES, was deposited on the working electrode of a continuous glucose monitor sensor, such as a Navigator® electrode, to form an active area of about 0.1 mm 2 .
- This electrode was overlaid with the flux-limiting membrane, an approximately 50 micron thick coating of the membrane polymer (a poly(vinylpyridine) derivative) crosslinked with tri-glycidyl glycerol.
- Counter electrode (cathode) 150 nL of a solution including 12.6 mg/mL BOD, 5.2 mg/mL redox polymer, and 5.4 mg/mL PEG 400 cross-linker, all dissolved in PBS, was deposited on the entirety of the working electrode of a second continuous glucose sensor, such as a Navigator® sensor, to form an active area of about 0.9 mm 2 .
- This electrode was overlaid with a flux-limiting membrane, an approximately 50 micron thick coating of the membrane polymer (a poly(vinylpyridine) derivative) cross-linked with tri-glycidyl glycerol.
- Glucose aliquots were added to produce concentrations of 4, 12, 20, and 28 mM. Calibration curves from the three sensors are shown in FIG. 13 . As shown in FIG. 13 , the Pt—C based counter electrode based self-powered sensor as well as the BOD based counter electrode based self-powered sensor provided equivalent data to the three electrode potentiostat-powered sensor.
- the current is essentially independent of resistance for resistance values of 10 M ⁇ or less, then falls off gradually at higher potentials, as the potential drop becomes a substantial fraction of the open circuit potential. Therefore, to correctly configure the sensor, a value of R should be selected that does not reduce the current output from its maximum value, as illustrated by the plateau in the graph of FIG. 14 .
- the range of R values from 0 to 10 M ⁇ is the range of R values for which the sensor output, at an analyte concentration at the top of its physically relevant range, is independent of R. Therefore, an R value of 0 to 10 M ⁇ should be selected.
- the open circuit potential (shown) is 474 mV.
- the potential drop across the resistor is, for example, less than 75% of the open circuit potential, such as less than 50% of the open circuit potential, and less than 25% of the open circuit potential in certain embodiments.
- An in vivo self-powered glucose sensor used for subcutaneous implantation was constructed using the two carbon electrodes on a continuous glucose monitoring electrode of a Navigator® sensor: the working electrode, the counter electrode, and a resistor disposed in between the working electrode and the counter electrode and having an R value of 4.85 Mohm.
- the working electrode was constructed to include redox polymer, glucose oxidase, and cross-linker sensing layer.
- the counter electrode was constructed to include a layer of platinum catalyst formed by depositing 50 nL 20 mg/ml platinum-carbon black (HiSPEC 8000, Alfa Aesar) suspension in 80% ethanol-20% water. The sensor was then dip-coated with a flux-limiting polymer membrane. After sterilization, the sensor was subcutaneously implanted with an insertion device. The data was collected with a transmitter that sent via radio-frequency, the self-powered sensor current signal to a standard receiver. Reference glucose values were obtained through frequent measurement with FreeStyle® glucose strips. The results in FIG. 15 show good correlation between the in vivo self powered glucose sensor signal and the reference glucose values.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Pathology (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Surgery (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- General Physics & Mathematics (AREA)
- Electrochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Optics & Photonics (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Emergency Medicine (AREA)
- Physiology (AREA)
- Computer Networks & Wireless Communication (AREA)
- Electromagnetism (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
Abstract
Generally, embodiments of the invention relate to self-powered analyte determining devices (e.g., electrochemical analyte monitoring systems) that include a working electrode, a counter electrode, and an optional resistance value, where the working electrode includes analyte sensing components and the self-powered analyte determining device spontaneously passes a current directly proportional to analyte concentration in the absence of an external power source. Also provided are systems and methods of using the, for example electrochemical, analyte sensors in analyte monitoring.
Description
- Electronic and electromechanical systems that are implanted in the body of animals, such as sensors and their associated electronic circuits that function to amplify the sensor signals and transmit them to a nearby receiver, require a power source. Currently, these systems are powered externally by batteries. The smallest batteries are, however, much larger than the implantable sensors and their associated signal amplifier circuits. For this reason, the size of autonomous packages that include a sensor, an amplifier-transmitter, and a power source are generally defined by the battery. Batteries cannot be made as small as the sensors or amplifiers because the batteries require cases and seals, the miniaturization of which is difficult and prohibitively expensive.
- Known fuel cells are also much larger than available sensors because they require a case and a seal, and usually also a membrane, which is difficult to miniaturize and seal. Biological fuel cells, also known as biofuel cells, have been described in the past fifty years. However, only a few of these biofuel cells could be operated under physiological conditions. Physiological conditions include, for instance, a pH of about 7.2 to 7.4, a temperature of near 37° C., and a chloride concentration of about 0.14 M. Furthermore, known biofuel cells having higher power densities require ion-conducting separation membranes.
- Accordingly, there still exists a need for the development of a system having millimeter to sub-millimeter dimensions that can function under physiological conditions to provide power to a sensor.
- Generally, embodiments of the invention relate to self-powered analyte determining devices (e.g., electrochemical analyte monitoring systems) that include a working electrode, a counter electrode, and an optional resistance value, where the working electrode includes analyte sensing components and the self-powered analyte determining device spontaneously passes a current directly proportional to analyte concentration in the absence of an external power source. Also provided are systems and methods of using the, for example electrochemical, analyte sensors in analyte monitoring.
- These and other objects, advantages, and features of the invention will become apparent to those persons skilled in the art upon reading the details of the invention as more fully described below.
- The invention is best understood from the following detailed description when read in conjunction with the accompanying drawings. It is emphasized that, according to common practice, the various features of the drawings are not to-scale. On the contrary, the dimensions of the various features are arbitrarily expanded or reduced for clarity. Included in the drawings are the following figures:
-
FIG. 1 is a schematic illustration of electron transfer in the electrocatalytic oxidation of glucose and in the electrocatalytic reduction of oxygen that occurs in a self-powered analyte sensor according to an embodiment of the invention. -
FIG. 2 is a schematic illustration of an application of a self-powered analyte sensor according to an embodiment of the invention for use in transcutaneous sensing of an analyte level. Panel A shows an embodiment in which a self-powered analyte sensor is implanted transcutaneously and a hand-held display is contacted directly to sensor leads as desired to measure the current flow and calculate the analyte level. Panel B shows an embodiment in which a self-powered analyte sensor is implanted transcutaneously, where the self-powered analyte sensor is further coupled to a radio-frequency (RF) powered measurement circuit. The RF powered measurement circuit is then remotely queried at regular intervals by an RF-power equipped hand-held display in order to provide continuous analyte level measurements. -
FIG. 3 is a schematic illustration of a fully implanted self-powered analyte sensor coupled to a radio-frequency (RF)-powered measurement circuit that may be intermittently RF-powered with an external RF-power source when an analyte measurement is desired. As a result, the RF-power source may be moved away from the site of implantation of the self-powered analyte sensor at any time and no re-equilibration period is required when it is brought back into RF communication with the site of implantation. -
FIG. 4 shows a block diagram of an embodiment of a data monitoring and management system according to embodiments of the invention. -
FIG. 5 shows a block diagram of an embodiment of the transmitter unit of the data monitoring and management system ofFIG. 4 . -
FIG. 6 shows a block diagram of an embodiment of the receiver/monitor unit of the data monitoring and management system ofFIG. 4 . -
FIG. 7 shows a schematic diagram of an embodiment of an exemplary analyte sensor. -
FIGS. 8A and 8B show a perspective view and a cross sectional view, respectively of another exemplary analyte sensor. -
FIG. 9 is a graph showing sensor calibration comparison for three sensors having a wired glucose oxidase (GOX) working electrode: a potentiostat powered analyte sensor control; a self-powered analyte sensor having a platinum-carbon (Pt—C) counter electrode; and a self-powered analyte sensor having a redox polymer counter electrode. -
FIG. 10 is a graph showing calibration curves for three sensors having a wired glucose oxidase (GOX) working electrode: a potentiostat powered analyte sensor control (circles); a self-powered analyte sensor having a platinum-carbon (Pt—C) counter electrode (squares); and a self-powered analyte sensor having a redox polymer counter electrode (triangles). -
FIG. 11 is a graph showing the equilibration time required for a standard potentiostat powered analyte sensor and a self-powered analyte sensor following disconnection and connection of powered measurement electronics. -
FIG. 12 is a graph showing the calibration curves for three sensors. Data for a potentiostat powered analyte sensor control are represented with crosses, data for a self-powered analyte sensor having a platinum (Pt) counter electrode are represented with diamonds, and data for a self-powered analyte sensor having a redox polymer and bilirubin oxidase (BOD) counter electrode are represented with squares. -
FIG. 13 is a graph showing shows sensor calibration comparison for three sensors having FADGDH based working electrodes. Data for a potentiostat powered analyte sensor control are represented with diamonds, data for a self-powered analyte sensor having a platinum-carbon (Pt—C) counter electrode are represented with squares, and data for a self-powered analyte sensor having bilirubin oxidase (BOD) counter electrode are represented with triangles. -
FIG. 14 is a graph showing the effect of R value of the resistance on sensor current. -
FIG. 15 is a graph showing correlation between an in vivo self powered glucose sensor signal and reference glucose values. - Before the present invention is described, it is to be understood that this invention is not limited to particular embodiments described, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present invention will be limited only by the appended claims.
- Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limits of that range is also specifically disclosed. Each smaller range between any stated value or intervening value in a stated range and any other stated or intervening value in that stated range is encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included or excluded in the range, and each range where either, neither or both limits are included in the smaller ranges is also encompassed within the invention, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the invention.
- Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, some potential and preferred methods and materials are now described. All publications mentioned herein are incorporated herein by reference to disclose and describe the methods and/or materials in connection with which the publications are cited. It is understood that the present disclosure supercedes any disclosure of an incorporated publication to the extent there is a contradiction.
- It must be noted that as used herein and in the appended claims, the singular forms “a”, “an”, and “the” include plural referents unless the context clearly dictates otherwise.
- The publications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention. Further, the dates of publication provided may be different from the actual publication dates which may need to be independently confirmed.
- Generally, embodiments of the invention relate to self-powered analyte determining devices (e.g., electrochemical analyte monitoring systems) that include a working electrode, a counter electrode, and an optional resistance value, where the working electrode includes analyte sensing components and the self-powered analyte determining device spontaneously passes a current directly proportional to analyte concentration in the absence of an external power source. Also provided are systems and methods of using the, for example electrochemical, analyte sensors in analyte monitoring.
- The self-powered analyte sensor uses compounds available in a variety of biological systems to provide a low level of power and also detect a level of an analyte. In general, the self-powered analyte sensor described herein spontaneously passes a current proportional to an analyte concentration, such as glucose, in the absence of an external power supply, such as a battery. As such, a self-powered analyte sensor that is partially implanted under the skin of a subject or fully implanted under the skin of a subject can be coupled to a radio-frequency powered measurement circuit to remotely provide analyte levels.
- Non-self-powered continuous analyte sensors have fairly long equilibration times, and therefore need to be continuously powered after inserting a portion thereof under the skin of a subject. That is, if the power supply of a continuous analyte sensor is removed and it is turned “off”, then a fairly long wait time of approximately 10 to 15 minutes must pass before a reliable analyte level reading is detected following reconnection of the power supply. In contrast, a self-powered analyte sensor, as described herein, has the advantage of providing a low level of continuous power in the absence of an external power supply while also detecting an analyte level thereby requiring little to no equilibration time between analyte measurement intervals.
- With reference to the schematic illustration of
FIG. 1 , during the operation of the self-powered analyte sensor, the primary reactant (e.g., reductant) is electrooxidized at the workingelectrode electrocatalyst layer electrode electrocatalyst layer 101. Theredox polymer 102 disposed on the working electrode passes electrons, or a current, between the primary reactant and the working electrode, while theelectrocatalyst layer 101 disposed on the counter electrode, such as redox polymer, redox polymer with enzyme, or platinum, passes electrons, or a current to the counter electrode. The electrical power is generated from the overall oxidation or reduction of the working electrode primary reactant, such as a reductant or oxidant, by the counter electrode secondary reactant, such as oxidant or reductant. In a biological system, for example, the electrical power can be generated by the overall oxidation of glucose, lactate, or pyruvate by dissolved oxygen, delivered as, for example, hemoglobin-bound oxygen (HbO2), which is in rapid equilibrium with dissolved oxygen passing through the oxygen-permeable membranes of red blood cells. The self-powered analyte sensor facilitates this oxidation reaction, and uses the resulting flow of electrons to produce an electrical current that provides a low-level of power. The electrocatalyst layer of the working electrode is involved in generating the low-level of power and also functions as the sensing layer that is involved in analyte-level detection, thereby providing the dual-function of power generation and analyte level detection. - In one embodiment of the invention, an enzyme used for the electrooxidation of glucose can be GOx disposed on the working electrode with redox polymer and cross-linker, and the electrocatalyst for the electroreduction of oxygen can be redox polymer, redox polymer with enzyme, or platinum-carbon cloth disposed on the counter electrode. In the operation of the cell, via its wiring, electrons are collected from glucose-reduced GOx at the working electrode, where glucose is electrooxidized to δ-gluconolactone (see Eq. 1 below), and electrons are delivered to the reox polymer, redox polymer with enzyme, or platinum-carbon cloth at the counter electrode, where oxygen is electroreduced to water (see Eq. 2 below). The overall reaction is that of Eq. 3 below.
-
D-glucose→δgluconolactone+2H++2e− (Eq. 1) -
O2+4H++4e−→2H2O (Eq. 2) -
2D-glucose+O2→2 δ-gluconolactone+2H2O (Eq. 3) - The reactions represented by Eqs. 1-3 above are now described in relation to the schematic illustration of
FIG. 1 .FIG. 1 illustrates the electron transfer involved in the electrocatalytic oxidation of glucose and the electron transfer involved in the electrocatalytic reduction of oxygen. In the self-powered analyte sensor, the working electrode and the counter electrode reside in the same solution or same compartment. As shown, electrons are first transmitted from a glucose molecule to an enzyme, such as GOx merely by way of illustration. Glucose is therefore electrooxidized to form a gluconolactone molecule, and enzyme is reduced. Protons are generally released into the biological system via this reaction (see Eq. 1), while the captured electrons are transmitted to the working electrode through a redox polymer, such as an osmium(Os)-complex-based redox polymer, disposed on the working electrode. The electrons then travel from the working electrode to an electrical circuit to provide a low level of power. The electrons eventually make their way to the counter electrode via an optional resistor having an R value, where they are transmitted through an electrocatalyst layer, such as an Os-complex-based redox polymer merely by way of illustration, disposed on the counter electrode. The electrons are then passed on to an oxygen molecule in the biological system, which captures both the transmitted electrons and protons from the biological system to form a water molecule. - A working electrode of the self-powered analyte sensor effectuates the electrooxidation of the reductant, such as the electrooxidation of glucose to gluconolactone as schematically illustrated in
FIG. 1 . As described previously, enzymes, examples of which are oxidases and dehydrogenases, disposed on the working electrode catalyze this electrooxidation of the reductant, such as glucose. These enzymes are wired to the working electrode via a redox polymer disposed proximate to the enzyme and the working electrode. An example of a redox polymer is a polymer derived from the copolymer of poly(acrylamide) and poly(4-vinyl pyridine) and including an Os complex. Another example of a redox polymer is a redox polymer derived from poly(N-vinyl imidazole) and including an Os complex. In these examples, the Os(II) and Os(III) centers of the redox polymers and the enzymes are immobilized in electron-conducting films on the surfaces of the working electrode. - A counter electrode of the self-powered analyte sensor effectuates the four-electron electroreduction of O2 to water under physiological conditions as schematically illustrated in
FIG. 1 . The counter electrode can also, for example catalyze the two electrode reduction of O2 to hydrogen peroxide. This electroreduction reaction is catalyzed by theelectrocatalyst 101 layer disposed on the counter electrode. In some embodiments, theelectrocatalyst 101 includes platinum wire, platinum black, platinum ink, or platinum impregnated carbon disposed on the counter electrode. In certain embodiments, theelectrocatalyst 101 is a redox polymer disposed on the counter electrode. An example of a redox polymer of aelectrocatalyst layer 101 disposed on a counter electrode is a polymer derived from the copolymer of poly(acrylamide) and poly(4-vinyl pyridine) and including an Os complex. Another example of a redox polymer is a redox polymer derived from poly(N-vinyl imidazole) and including an Os complex. In these examples, the Os(II) and Os(III) centers of the redox polymers are immobilized in electron-conducting films disposed on the surfaces of the counter electrode. In certain embodiments, enzymes such as BOD, Laccase, and the like, are complexed to the redox polymer disposed on the counter electrode. Both working and counter electrode may be overlaid by a flux-reducing biocompatible membrane, as described in the examples, below. - The physical dimensions of the self-powered analyte sensor, as well as its operational parameters (e.g., output power and voltage) are, at least in part, a function of the components that form the sensor. Merely by way of example, the voltage drop across the resistance, R, of the self-powered analyte sensor can range from about 0 volts to about 1.2 volts, and typically, from about 0 volts to about 0.3 volts.
- The output current of an implanted self-powered analyte sensor, can be limited by electrode kinetics, ohmic resistance, and/or mass transport. When the electrode kinetics is fast and the self-powered analyte sensor is small enough for the ohmic resistance of the electrolytic solution to be low, the output current is determined by the mass transport of the reactants to the electrodes. In particular, output current is generally determined by mass transport of a single limiting reactant, for example glucose. The mass-transport-limited current density increases upon raising the concentration of the reactants, particularly the limiting reactant, or upon increasing the permeability of any overlying membrane.
- The self-powered analyte sensor further includes an optional resistance disposed between the working electrode and the counter electrode and having an R value that is chosen from within a range of R values for which an electrochemical analyte sensor current output at an analyte concentration at the top of the physically relevant range of the analyte is independent of R. Such an R value can be calculated, as exemplified in
FIG. 14 , by determining the current output at a selected analyte concentration at the top of the physically relevant range of the analyte for a variety of selected R values. The R value is then determined to be the series of R values that correspond to a steady state current output from the electrochemical sensor, i.e., the rate at which the current output is stable and does not change over the varying R values. For example, inFIG. 14 , the current output (solid line with diamonds) for the sensor is independent of the R value from 0 MΩ to 10 M{tilde over (Ω)}. In some embodiments, the R value is a whole integer and in other embodiments the R value is a fraction of a whole integer. - In some embodiments, the R value is chosen such that the potential drop across the resistor, at an analyte concentration at the top of its physically relevant range, is less than 75% of the open circuit potential. In other embodiments, the R value is chosen such that the potential drop across the resistor, at an analyte concentration at the top of its physically relevant range, is less than 50% of the open circuit potential. In some embodiments, the R value is chosen such that the potential drop across the resistor, at an analyte concentration at the top of its physically relevant range, is less than 25% of the open circuit potential. In certain embodiments, the R value is less than about 40 MΩ, including less than about 20 MΩ, less than about 10 MΩ, and less than abou{tilde over (t)} 1 MΩ,
- Thus, in accordance with an embodiment of the invention, the self-powered analyte sensor is usually assembled without the case, the seal, and the compartment-separating membrane required by conventional batteries. As a result, the self-powered analyte sensor can be manufactured with a footprint smaller than about 3 mm2, including smaller than about 1 mm2, such as smaller than about 0.3 mm2. The self-powered analyte sensor, with dimensions on the millimeter to sub-millimeter level, can power sensor components, as further described herein. Further, the self-powered analyte sensor can be constructed so that none of its components, including its catalytic components, will be dissolved or leached while residing in the body.
-
FIG. 2 is a schematic illustration of an application of a self-powered analyte sensor according to an embodiment of the invention for use in transcutaneous sensing of an analyte level. Panel A shows an embodiment in which a self-powered analyte sensor is implanted transcutaneously and a hand-held display and primary receiver unit is contacted directly to sensor leads as desired to measure the current flow and calculate the analyte level. Panel B shows an embodiment in which a self-powered analyte sensor is implanted transcutaneously, where the self-powered analyte sensor is further coupled to a radio-frequency (RF) powered measurement circuit. The RF powered measurement circuit and data processing unit is then remotely queried at regular intervals by an RF-power equipped hand-held display and primary receiver unit in order to provide analyte level measurements. In such embodiments, the RF-powered equipped hand-held display and primary receiver unit is brought into close proximity to the transcutaneously implanted sensor at regular intervals. In some embodiments, the radio-frequency powered current measuring circuit and data processing unit is intermittently powered. In some embodiments, the sensor is coupled to an inductively powered current measuring circuit and data processing unit. In certain embodiments, the inductively powered current measuring circuit and data processing unit is intermittently powered. -
FIG. 3 is a schematic illustration of a fully implanted self-powered analyte sensor coupled to a radio-frequency (RF)-powered potentiostat measurement circuit and data processing unit that may be intermittently RF-powered with an external RF-power source when an analyte measurement is desired. In such embodiments, the RF-powered potentiostat measurement circuit and data processing unit is brought into close proximity to the implanted sensor at regular intervals. As a result, the RF-power source may be moved away from the site of implantation of the self-powered analyte sensor at any time and no re-equilibration period is required when it is brought back into RF communication with the site of implantation. In some embodiments, the radio-frequency powered current measuring circuit and data processing unit is intermittently powered. In some embodiments, the sensor is coupled to an inductively powered current measuring circuit and data processing unit. In certain embodiments, the inductively powered current measuring circuit and data processing unit is intermittently powered. - Embodiments of the invention relate to methods and devices for detecting at least one analyte, including glucose, in body fluid. Embodiments relate to the continuous and/or automatic in vivo monitoring of the level of one or more analytes using a continuous analyte monitoring system that includes an analyte sensor at least a portion of which is to be positioned beneath a skin surface of a user for a period of time and/or the discrete monitoring of one or more analytes using an in vitro blood glucose (“BG”) meter and an analyte test strip. Embodiments include combined or combinable devices, systems and methods and/or transferring data between an in vivo continuous system and an in vivo system. In some embodiments, the systems, or at least a portion of the systems, are integrated into a single unit.
- A self-powered analyte sensor may be an in vivo sensor or an in vitro sensor (i.e., a discrete monitoring test strip). Such a sensor can be formed on a substrate, e.g., a substantially planar substrate. In certain embodiments, such a sensor is a wire, e.g., a working electrode wire inner portion with one or more other electrodes associated (e.g., on, including wrapped around) therewith. The sensor also includes at least one counter electrode.
- Accordingly, embodiments include self-powered analyte monitoring devices and systems that include an analyte sensor at least a portion of which is positionable beneath the skin of the user for the in vivo detection, of an analyte, including glucose, lactate, and the like, in a body fluid. Embodiments include wholly implantable self-powered analyte sensors and analyte sensors in which only a portion of the sensor is positioned under the skin and a portion of the sensor resides above the skin, e.g., for contact to a sensor control unit (which may include a transmitter), a receiver/display unit, transceiver, processor, etc. The sensor may be, for example, subcutaneously positionable in a patient for the continuous or periodic monitoring of a level of an analyte in a patient's interstitial fluid. For the purposes of this description, continuous monitoring and periodic monitoring will be used interchangeably, unless noted otherwise. The sensor response may be correlated and/or converted to analyte levels in blood or other fluids. In certain embodiments, an analyte sensor may be positioned in contact with interstitial fluid to detect the level of glucose, which detected glucose may be used to infer the glucose level in the patient's bloodstream. Self-powered analyte sensors may be insertable into a vein, artery, or other portion of the body containing fluid. Embodiments of the analyte sensors of the subject invention having a plasticizer may be configured for monitoring the level of the analyte over a time period which may range from seconds, minutes, hours, days, weeks, to months, or longer.
- Of interest are self-powered analyte sensors, such as glucose sensors, that are capable of in vivo detection of an analyte for about one hour or more, e.g., about a few hours or more, e.g., about a few days or more, e.g., about three or more days, e.g., about five days or more, e.g., about seven days or more, e.g., about several weeks or at least one month or more. Future analyte levels may be predicted based on information obtained, e.g., the current analyte level at time t0, the rate of change of the analyte, etc. Predictive alarms may notify the user of a predicted analyte levels that may be of concern in advance of the user's analyte level reaching the future level. This provides the user an opportunity to take corrective action.
-
FIG. 4 shows a data monitoring and management system such as, for example, an analyte (e.g., glucose)monitoring system 400 in accordance with certain embodiments. Embodiments of the subject invention are further described primarily with respect to glucose monitoring devices and systems, and methods of glucose detection, for convenience only and such description is in no way intended to limit the scope of the invention. It is to be understood that the self-powered analyte monitoring system may be configured to monitor a variety of analytes at the same time or at different times. - Analytes that may be monitored include, but are not limited to, acetyl choline, amylase, bilirubin, cholesterol, chorionic gonadotropin, creatine kinase (e.g., CK-MB), creatine, creatinine, DNA, fructosamine, glucose, glutamine, growth hormones, hormones, ketone bodies, lactate, peroxide, prostate-specific antigen, prothrombin, RNA, thyroid stimulating hormone, and troponin. The concentration of drugs, such as, for example, antibiotics (e.g., gentamicin, vancomycin, and the like), digitoxin, digoxin, drugs of abuse, theophylline, and warfarin, may also be monitored. In those embodiments that monitor more than one analyte, the analytes may be monitored at the same or different times.
- The
analyte monitoring system 400 includes asensor 401, adata processing unit 402 connectable to thesensor 401, and aprimary receiver unit 404 which is configured to communicate with thedata processing unit 402 via acommunication link 403. In certain embodiments, the primary receiver unit 104 may be further configured to transmit data to adata processing terminal 405 to evaluate or otherwise process or format data received by theprimary receiver unit 404. Thedata processing terminal 405 may be configured to receive data directly from thedata processing unit 402 via a communication link which may optionally be configured for bi-directional communication. Further, thedata processing unit 402 may include a transmitter or a transceiver to transmit and/or receive data to and/or from theprimary receiver unit 404 and/or thedata processing terminal 405 and/or optionally thesecondary receiver unit 406. - Also shown in
FIG. 4 is an optionalsecondary receiver unit 406 which is operatively coupled to the communication link and configured to receive data transmitted from thedata processing unit 402. Thesecondary receiver unit 406 may be configured to communicate with theprimary receiver unit 404, as well as thedata processing terminal 405. Thesecondary receiver unit 406 may be configured for bi-directional wireless communication with each of theprimary receiver unit 404 and thedata processing terminal 405. As discussed in further detail below, in certain embodiments thesecondary receiver unit 406 may be a de-featured receiver as compared to the primary receiver, i.e., the secondary receiver may include a limited or minimal number of functions and features as compared with theprimary receiver unit 404. As such, thesecondary receiver unit 406 may include a smaller (in one or more, including all, dimensions), compact housing or embodied in a device including a wrist watch, arm band, PDA, etc., for example. Alternatively, thesecondary receiver unit 406 may be configured with the same or substantially similar functions and features as theprimary receiver unit 404. Thesecondary receiver unit 406 may include a docking portion to be mated with a docking cradle unit for placement by, e.g., the bedside for night time monitoring, and/or a bi-directional communication device. A docking cradle may recharge a powers supply. - Only one self-powered
sensor 401,data processing unit 402 anddata processing terminal 405 are shown in the embodiment of theanalyte monitoring system 400 illustrated inFIG. 4 . However, it will be appreciated by one of ordinary skill in the art that theanalyte monitoring system 400 may include more than onesensor 401 and/or more than onedata processing unit 402, and/or more than onedata processing terminal 405. Multiple self-powered sensors may be positioned in a patient for analyte monitoring at the same or different times. In certain embodiments, analyte information obtained by a first positioned sensor may be employed as a comparison to analyte information obtained by a second sensor. This may be useful to confirm or validate analyte information obtained from one or both of the sensors. Such redundancy may be useful if analyte information is contemplated in critical therapy-related decisions. In certain embodiments, a first sensor may be used to calibrate a second sensor. - The
analyte monitoring system 400 may be a continuous monitoring system, or semi-continuous, or a discrete monitoring system. In a multi-component environment, each component may be configured to be uniquely identified by one or more of the other components in the system so that communication conflict may be readily resolved between the various components within theanalyte monitoring system 400. For example, unique IDs, communication channels, and the like, may be used. - In certain embodiments, the
sensor 401 is physically positioned in or on the body of a user whose analyte level is being monitored. Thesensor 401 may be configured to at least periodically sample the analyte level of the user and convert the sampled analyte level into a corresponding signal for transmission by thedata processing unit 402. Thedata processing unit 402 is coupleable to the self-poweredsensor 401 so that both devices are positioned in or on the user's body, with at least a portion of the self-poweredanalyte sensor 401 positioned transcutaneously. The data processing unit may include a fixation element such as adhesive or the like to secure it to the user's body. An optional mount (not shown) attachable to the user and mateable with theunit 402 may be used. For example, a mount may include an adhesive surface. Thedata processing unit 402 performs data processing functions, where such functions may include but are not limited to, filtering and encoding of data signals, each of which corresponds to a sampled analyte level of the user, for transmission to theprimary receiver unit 404 via thecommunication link 403. In one embodiment, the self-poweredsensor 401 or thedata processing unit 402 or a combined self-powered sensor/data processing unit may be wholly implantable under the skin layer of the user. - In certain embodiments, the
primary receiver unit 404 may include an analog interface section including and RF receiver and an antenna that is configured to communicate with thedata processing unit 402 via thecommunication link 403, and a data processing section for processing the received data from thedata processing unit 402 including data decoding, error detection and correction, data clock generation, data bit recovery, etc., or any combination thereof. - In operation, the
primary receiver unit 404 in certain embodiments is configured to synchronize with thedata processing unit 402 to uniquely identify thedata processing unit 402, based on, for example, an identification information of thedata processing unit 402, and thereafter, to periodically receive signals transmitted from thedata processing unit 402 associated with the monitored analyte levels detected by thesensor 401. - Referring again to
FIG. 4 , thedata processing terminal 405 may include a personal computer, a portable computer including a laptop or a handheld device (e.g., personal digital assistants (PDAs), telephone including a cellular phone (e.g., a multimedia and Internet-enabled mobile phone including an iPhone™, iPOD™ or similar phone), mp3 player, pager, and the like), drug delivery device, each of which may be configured for data communication with the receiver via a wired or a wireless connection. Additionally, thedata processing terminal 405 may further be connected to a data network (not shown) for storing, retrieving, updating, and/or analyzing data corresponding to the detected analyte level of the user. - The
data processing terminal 405 may include an infusion device such as an insulin infusion pump or the like, which may be configured to administer insulin to patients, and which may be configured to communicate with theprimary receiver unit 404 for receiving, among others, the measured analyte level. Alternatively, theprimary receiver unit 404 may be configured to integrate an infusion device therein so that theprimary receiver unit 404 is configured to administer insulin (or other appropriate drug) therapy to patients, for example, for administering and modifying basal profiles, as well as for determining appropriate boluses for administration based on, among others, the detected analyte levels received from thedata processing unit 402. An infusion device may be an external device or an internal device (wholly implantable in a user). - In certain embodiments, the
data processing terminal 405, which may include an insulin pump, may be configured to receive the analyte signals from thedata processing unit 402, and thus, incorporate the functions of theprimary receiver unit 404 including data processing for managing the patient's insulin therapy and analyte monitoring. In certain embodiments, thecommunication link 403 as well as one or more of the other communication interfaces shown inFIG. 4 , may use one or more of: an RF communication protocol, an infrared communication protocol, a Bluetooth enabled communication protocol, an 802.11x wireless communication protocol, or an equivalent wireless communication protocol which would allow secure, wireless communication of several units (for example, per HIPPA requirements), while avoiding potential data collision and interference. -
FIG. 5 shows a block diagram of an embodiment of a data processing unit of the data monitoring and detection system shown inFIG. 4 . User input and/or interface components may optionally be included or a data processing unit may be free of user input and/or interface components. In certain embodiments, one or more application-specific integrated circuits (ASIC) may be used to implement one or more functions or routins associated with the operations of the data processing unit (and/or receiver unit) using for example one or more state machines and buffers. - As can be seen in the embodiment of
FIG. 5 , the sensor unit 401 (FIG. 4 ) includes three contacts, two of which are electrodes—working electrode (W) 510, and counter electrode (C) 513, each operatively coupled to theanalog interface 501 of thedata processing unit 402. This embodiment also shows optional guard contact (G) 511. Fewer or greater electrodes may be employed. For example, there may be more than one working electrode and/or counter electrode, etc. -
FIG. 6 is a block diagram of an embodiment of a receiver/monitor unit such as theprimary receiver unit 404 of the data monitoring and management system shown inFIG. 4 . Theprimary receiver unit 404 includes one or more of: a blood glucosetest strip interface 601, anRF receiver 602, aninput 603, atemperature detection section 604, and aclock 605, each of which is operatively coupled to a processing andstorage section 607. Theprimary receiver unit 404 also includes apower supply 606 operatively coupled to a power conversion andmonitoring section 608. Further, the power conversion andmonitoring section 608 is also coupled to thereceiver processor 607. Moreover, also shown are a receiverserial communication section 609, and anoutput 610, each operatively coupled to the processing andstorage unit 607. The receiver may include user input and/or interface components or may be free of user input and/or interface components. - In certain embodiments, the
test strip interface 601 includes a glucose level testing portion to receive a blood (or other body fluid sample) glucose test or information related thereto. For example, the interface may include a test strip port to receive a glucose test strip. The device may determine the glucose level of the test strip, and optionally display (or otherwise notice) the glucose level on theoutput 610 of theprimary receiver unit 404. Any suitable test strip may be employed, e.g., test strips that only require a very small amount (e.g., one microliter or less, e.g., 0.5 microliter or less, e.g., 0.1 microliter or less), of applied sample to the strip in order to obtain accurate glucose information, e.g. FreeStyle® blood glucose test strips from Abbott Diabetes Care, Inc. Glucose information obtained by the in vitro glucose testing device may be used for a variety of purposes, computations, etc. For example, the information may be used to calibratesensor 401, confirm results of thesensor 401 to increase the confidence thereof (e.g., in instances in which information obtained bysensor 401 is employed in therapy related decisions), etc. - In further embodiments, the
data processing unit 402 and/or theprimary receiver unit 404 and/or thesecondary receiver unit 405, and/or the data processing terminal/infusion section 405 may be configured to receive the blood glucose value wirelessly over a communication link from, for example, a blood glucose meter. In further embodiments, a user manipulating or using the analyte monitoring system 400 (FIG. 4 ) may manually input the blood glucose value using, for example, a user interface (for example, a keyboard, keypad, voice commands, and the like) incorporated in the one or more of thedata processing unit 402, theprimary receiver unit 404,secondary receiver unit 405, or the data processing terminal/infusion section 405. - Additional detailed descriptions are provided in U.S. Pat. Nos. 5,262,035; 5,264,104; 5,262,305; 5,320,715; 5,593,852; 6,175,752; 6,650,471; 6,746,582, and in application Ser. No. 10/745,878 filed Dec. 26, 2003 entitled “Continuous Glucose Monitoring System and Methods of Use”, each of which is incorporated herein by reference.
-
FIG. 7 schematically shows an embodiment of an analyte sensor in accordance with the embodiments of the invention. This sensor embodiment includeselectrodes base 704. Electrodes (and/or other features) may be applied or otherwise processed using any suitable technology, e.g., chemical vapor deposition (CVD), physical vapor deposition, sputtering, reactive sputtering, printing, coating, ablating (e.g., laser ablation), painting, dip coating, etching, and the like. Materials include, but are not limited to, any one or more of aluminum, carbon (including graphite), cobalt, copper, gallium, gold, indium, iridium, iron, lead, magnesium, mercury (as an amalgam), nickel, niobium, osmium, palladium, platinum, rhenium, rhodium, selenium, silicon (e.g., doped polycrystalline silicon), silver, tantalum, tin, titanium, tungsten, uranium, vanadium, zinc, zirconium, mixtures thereof, and alloys, oxides, or metallic compounds of these elements. - The sensor may be wholly implantable in a user or may be configured so that only a portion is positioned within (internal) a user and another portion outside (external) a user. For example, the
sensor 700 may include a portion positionable above a surface of theskin 710, and a portion positioned below the skin. In such embodiments, the external portion may include contacts (connected to respective electrodes of the second portion by traces) to connect to another device also external to the user such as a transmitter unit. While the embodiment ofFIG. 7 shows two electrodes side-by-side on the same surface ofbase 704, other configurations are contemplated, e.g., greater electrodes, some or all electrodes on different surfaces of the base or present on another base, some or all electrodes stacked together, electrodes of differing materials and dimensions, etc. -
FIG. 8A shows a perspective view of an embodiment of anelectrochemical analyte sensor 800 having a first portion (which in this embodiment may be characterized as a major portion) positionable above a surface of theskin 810, and a second portion (which in this embodiment may be characterized as a minor portion) that includes aninsertion tip 830 positionable below the skin, e.g., penetrating through the skin and into, e.g., the subcutaneous space 820, in contact with the user's biofluid such as interstitial fluid. Contact portions of a workingelectrode 801 and acounter electrode 803 are positioned on the portion of thesensor 800 situated above theskin surface 810. Working electrode 801and acounter electrode 803 are shown at the second section and particularly at theinsertion tip 830. Traces may be provided from the electrode at the tip to the contact, as shown inFIG. 8A . It is to be understood that greater or fewer electrodes may be provided on a sensor. For example, a sensor may include more than one working electrodes. -
FIG. 8B shows a cross sectional view of a portion of thesensor 800 ofFIG. 8A . Theelectrodes sensor 800 as well as the substrate and the dielectric layers are provided in a layered configuration or construction. For example, as shown inFIG. 8B , in one aspect, the sensor 800 (such as thesensor unit 401FIG. 4 ), includes asubstrate layer 804, and afirst conducting layer 801 such as carbon, gold, etc., disposed on at least a portion of thesubstrate layer 804, and which may provide the working electrode. Also shown disposed on at least a portion of thefirst conducting layer 801 is asensing layer 808. - A first insulation layer such as a first
dielectric layer 805 is disposed or layered on at least a portion of thefirst conducting layer 801. Asecond conducting layer 803 may provide thecounter electrode 803. It may be disposed on at least a portion of thefirst insulation layer 805. Finally, a second insulation layer may be disposed or layered on at least a portion of thesecond conducting layer 803. In this manner, thesensor 800 may be layered such that at least a portion of each of the conducting layers is separated by a respective insulation layer (for example, a dielectric layer). The embodiment ofFIGS. 8A and 8B show the layers having different lengths. Some or all of the layers may have the same or different lengths and/or widths. - In certain embodiments, some or all of the
electrodes substrate 804 in the layered construction as described above, or alternatively, may be provided in a co-planar manner such that two or more electrodes may be positioned on the same plane (e.g., side-by side (e.g., parallel) or angled relative to each other) on thesubstrate 804. For example, co-planar electrodes may include a suitable spacing there between and/or include dielectric material or insulation material disposed between the conducting layers/electrodes. Furthermore, in certain embodiments one or more of theelectrodes substrate 804. In such embodiments, contact pads may be one the same or different sides of the substrate. - For example, an electrode may be on a first side and its respective contact may be on a second side, e.g., a trace connecting the electrode and the contact may traverse through the substrate.
- As noted above, analyte sensors may include an analyte-responsive enzyme to provide a sensing component or sensing layer. Some analytes, such as oxygen, can be directly electrooxidized or electroreduced on a sensor, and more specifically at least on a working electrode of a sensor. Other analytes, such as glucose and lactate, require the presence of at least one electron transfer agent and/or at least one catalyst to facilitate the electrooxidation or electroreduction of the analyte.
- Catalysts may also be used for those analytes, such as oxygen, that can be directly electrooxidized or electroreduced on the working electrode. For these analytes, each working electrode includes a sensing layer (see for
example sensing layer 808 ofFIG. 8B ) proximate to or on a surface of a working electrode. In many embodiments, a sensing layer is formed near or on only a small portion of at least a working electrode. - The sensing layer includes one or more components constructed to facilitate the electrochemical oxidation or reduction of the analyte. The sensing layer may include, for example, a catalyst to catalyze a reaction of the analyte and produce a response at the working electrode, an electron transfer agent to transfer electrons between the analyte and the working electrode (or other component), or both. The sensing layer and the working electrode also function as the anode of the power generating component of the self-powered analyte sensor, thereby providing the dual-function of power generation and analyte level detection.
- A variety of different sensing layer configurations may be used. In certain embodiments, the sensing layer is deposited on the conductive material of a working electrode. The sensing layer may extend beyond the conductive material of the working electrode. In some cases, the sensing layer may also extend over other electrodes.
- A sensing layer that is in direct contact with the working electrode may contain an electron transfer agent to transfer electrons directly or indirectly between the analyte and the working electrode, and/or a catalyst to facilitate a reaction of the analyte. For example, a glucose, lactate, or oxygen electrode may be formed having a sensing layer which contains a catalyst, including glucose oxidase, glucose dehydrogenase, lactate oxidase, or laccase, respectively, and an electron transfer agent that facilitates the electrooxidation of the glucose, lactate, or oxygen, respectively.
- In other embodiments the sensing layer is not deposited directly on the working electrode. Instead, the
sensing layer 808 may be spaced apart from the working electrode, and separated from the working electrode, e.g., by a separation layer. A separation layer may include one or more membranes or films or a physical distance. In addition to separating the working electrode from the sensing layer the separation layer may also act as a mass transport limiting layer and/or an interferent eliminating layer and/or a biocompatible layer. - In certain embodiments which include more than one working electrode, one or more of the working electrodes may not have a corresponding sensing layer, or may have a sensing layer which does not contain one or more components (e.g., an electron transfer agent and/or catalyst) needed to electrolyze the analyte. Thus, the signal at this working electrode may correspond to background signal which may be removed from the analyte signal obtained from one or more other working electrodes that are associated with fully-functional sensing layers by, for example, subtracting the signal.
- In certain embodiments, the sensing layer includes one or more electron transfer agents. Electron transfer agents that may be employed are electroreducible and electrooxidizable ions or molecules having redox potentials that are a few hundred millivolts above or below the redox potential of the standard calomel electrode (SCE). The electron transfer agent may be organic, organometallic, or inorganic. Examples of organic redox species are quinones and species that in their oxidized state have quinoid structures, such as Nile blue and indophenol. Examples of organometallic redox species are metallocenes including ferrocene. Examples of inorganic redox species are hexacyanoferrate (III), ruthenium hexamine etc. Additional examples include those described in U.S. Pat. No. 6,736,957 and U.S. Patent Publication Nos. 2004/0079653 and 2006/0201805, the disclosures of which are incorporated herein by reference in their entirety.
- In certain embodiments, electron transfer agents have structures or charges which prevent or substantially reduce the diffusional loss of the electron transfer agent during the period of time that the sample is being analyzed. For example, electron transfer agents include but are not limited to a redox species, e.g., bound to a polymer which can in turn be disposed on or near the working electrode. The bond between the redox species and the polymer may be covalent, coordinative, or ionic. Although any organic, organometallic or inorganic redox species may be bound to a polymer and used as an electron transfer agent, in certain embodiments the redox species is a transition metal compound or complex, e.g., osmium, ruthenium, iron, and cobalt compounds or complexes. It will be recognized that many redox species described for use with a polymeric component may also be used, without a polymeric component.
- One type of polymeric electron transfer agent contains a redox species covalently bound in a polymeric composition. An example of this type of mediator is poly(vinylferrocene). Another type of electron transfer agent contains an ionically-bound redox species. This type of mediator may include a charged polymer coupled to an oppositely charged redox species. Examples of this type of mediator include a negatively charged polymer coupled to a positively charged redox species such as an osmium or ruthenium polypyridyl cation. Another example of an ionically-bound mediator is a positively charged polymer including quaternized poly(4-vinyl pyridine) or poly(l-vinyl imidazole) coupled to a negatively charged redox species such as ferricyanide or ferrocyanide. In other embodiments, electron transfer agents include a redox species coordinatively bound to a polymer. For example, the mediator may be formed by coordination of an osmium or cobalt 2,2′-bipyridyl complex to poly(l-vinyl imidazole) or poly(4-vinyl pyridine).
- Suitable electron transfer agents are osmium transition metal complexes with one or more ligands, each ligand having a nitrogen-containing heterocycle such as 2,2′-bipyridine, 1,10-phenanthroline, 1-methyl, 2-pyridyl biimidazole, or derivatives thereof. The electron transfer agents may also have one or more ligands covalently bound in a polymer, each ligand having at least one nitrogen-containing heterocycle, such as pyridine, imidazole, or derivatives thereof. One example of an electron transfer agent includes (a) a polymer or copolymer having pyridine or imidazole functional groups and (b) osmium cations complexed with two ligands, each ligand containing 2,2′-bipyridine, 1,10-phenanthroline, or derivatives thereof, the two ligands not necessarily being the same. Some derivatives of 2,2′-bipyridine for complexation with the osmium cation include but are not limited to 4,4′-dimethyl-2,2′-bipyridine and mono-, di-, and polyalkoxy-2,2′-bipyridines, including 4,4′-dimethoxy-2,2′-bipyridine. Derivatives of 1,10-phenanthroline for complexation with the osmium cation include but are not limited to 4,7-dimethyl-1,10-phenanthroline and mono, di-, and polyalkoxy-1,10-phenanthrolines, such as 4,7-dimethoxy-1,10-phenanthroline. Polymers for complexation with the osmium cation include but are not limited to polymers and copolymers of poly(1-vinyl imidazole) (referred to as “PVI”) and poly(4-vinyl pyridine) (referred to as “PVP”). Suitable copolymer substituents of poly(l-vinyl imidazole) include acrylonitrile, acrylamide, and substituted or quaternized N-vinyl imidazole, e.g., electron transfer agents with osmium complexed to a polymer or copolymer of poly(1-vinyl imidazole).
- Embodiments may employ electron transfer agents having a redox potential ranging from about −200 mV to about +200 mV versus the standard calomel electrode (SCE). The sensing layer may also include a catalyst which is capable of catalyzing a reaction of the analyte. The catalyst may also, in some embodiments, act as an electron transfer agent. One example of a suitable catalyst is an enzyme which catalyzes a reaction of the analyte. For example, a catalyst, including a glucose oxidase, glucose dehydrogenase (e.g., pyrroloquinoline quinone (PQQ), dependent glucose dehydrogenase, flavine adenine dinucleotide (FAD) dependent glucose dehydrogenase, or nicotinamide adenine dinucleotide (NAD) dependent glucose dehydrogenase), may be used when the analyte of interest is glucose. A lactate oxidase or lactate dehydrogenase may be used when the analyte of interest is lactate. Laccase may be used when the analyte of interest is oxygen or when oxygen is generated or consumed in response to a reaction of the analyte.
- The sensing layer may also include a catalyst which is capable of catalyzing a reaction of the analyte. The catalyst may also, in some embodiments, act as an electron transfer agent. One example of a suitable catalyst is an enzyme which catalyzes a reaction of the analyte. For example, a catalyst, including a glucose oxidase, glucose dehydrogenase (e.g., pyrroloquinoline quinone (PQQ), dependent glucose dehydrogenase or oligosaccharide dehydrogenase, flavine adenine dinucleotide (FAD) dependent glucose dehydrogenase, nicotinamide adenine dinucleotide (NAD) dependent glucose dehydrogenase), may be used when the analyte of interest is glucose. A lactate oxidase or lactate dehydrogenase may be used when the analyte of interest is lactate. Laccase may be used when the analyte of interest is oxygen or when oxygen is generated or consumed in response to a reaction of the analyte.
- In certain embodiments, a catalyst may be attached to a polymer, cross linking the catalyst with another electron transfer agent, which, as described above, may be polymeric. A second catalyst may also be used in certain embodiments. This second catalyst may be used to catalyze a reaction of a product compound resulting from the catalyzed reaction of the analyte. The second catalyst may operate with an electron transfer agent to electrolyze the product compound to generate a signal at the working electrode. Alternatively, a second catalyst may be provided in an interferent-eliminating layer to catalyze reactions that remove interferents.
- In certain embodiments, the sensing layer functions at a gentle oxidizing potential, e.g., a potential of about +40 mV vs. Ag/AgCl. This sensing layer uses, for example, an osmium (Os)-based mediator constructed for low potential operation and includes a plasticizer. Accordingly, in certain embodiments the sensing element is a redox active component that includes (1) Osmium-based mediator molecules that include (bidente) ligands, and (2) glucose oxidase enzyme molecules. These two constituents are combined together with a cross-linker.
- A mass transport limiting layer (not shown), e.g., an analyte flux modulating layer, may be included with the sensor to act as a diffusion-limiting barrier to reduce the rate of mass transport of the analyte, for example, glucose or lactate, into the region around the working electrodes. The mass transport limiting layers are useful in limiting the flux of an analyte to a working electrode in an electrochemical sensor so that the sensor is linearly responsive over a large range of analyte concentrations and is easily calibrated. Mass transport limiting layers may include polymers and may be biocompatible. A mass transport limiting layer may provide many functions, e.g., biocompatibility and/or interferent-eliminating, etc.
- In certain embodiments, a mass transport limiting layer is a membrane composed of crosslinked polymers containing heterocyclic nitrogen groups, such as polymers of polyvinylpyridine and polyvinylimidazole. In some embodiments, a plasticizer is combined with the mass transport limiting layer or membrane.
- Embodiments also include membranes that are made of a polyurethane, or polyether urethane, or chemically related material, or membranes that are made of silicone, and the like.
- A membrane may be formed by crosslinking in situ a polymer, modified with a zwitterionic moiety, a non-pyridine copolymer component, and optionally another moiety that is either hydrophilic or hydrophobic, and/or has other desirable properties, in an alcohol-buffer solution. In certain embodiments, the membrane formulation further includes a plasticizer. The modified polymer may be made from a precursor polymer containing heterocyclic nitrogen groups. For example, a precursor polymer may be polyvinylpyridine or polyvinylimidazole. Optionally, hydrophilic or hydrophobic modifiers may be used to “fine-tune” the permeability of the resulting membrane to an analyte of interest. Optional hydrophilic modifiers, such as poly(ethylene glycol), hydroxyl or polyhydroxyl modifiers, may be used to enhance the biocompatibility of the polymer or the resulting membrane.
- A membrane may be formed in situ by applying an alcohol-buffer solution of a crosslinker and a modified polymer over an enzyme-containing sensing layer and allowing the solution to cure for about one to two days or other appropriate time period. The crosslinker-polymer solution may be applied to the sensing layer by placing a droplet or droplets of the solution on the sensor, by dipping the sensor into the solution, or the like. Generally, the thickness of the membrane is controlled by the concentration of the solution, by the number of droplets of the solution applied, by the number of times the sensor is dipped in the solution, or by any combination of these factors. A membrane applied in this manner may have any combination of the following functions: (1) mass transport limitation, i.e., reduction of the flux of analyte that can reach the sensing layer, (2) biocompatibility enhancement, or (3) interferent reduction.
- The substrate may be formed using a variety of non-conducting materials, including, for example, polymeric or plastic materials and ceramic materials. Suitable materials for a particular sensor may be determined, at least in part, based on the desired use of the sensor and properties of the materials.
- In some embodiments, the substrate is flexible. For example, if the sensor is configured for implantation into a patient, then the sensor may be made flexible (although rigid sensors may also be used for implantable sensors) to reduce pain to the patient and damage to the tissue caused by the implantation of and/or the wearing of the sensor. A flexible substrate often increases the patient's comfort and allows a wider range of activities. Suitable materials for a flexible substrate include, for example, non-conducting plastic or polymeric materials and other non-conducting, flexible, deformable materials. Examples of useful plastic or polymeric materials include thermoplastics such as polycarbonates, polyesters (e.g., Mylar™ and polyethylene terephthalate (PET)), polyvinyl chloride (PVC), polyurethanes, polyethers, polyamides, polyimides, or copolymers of these thermoplastics, such as PETG (glycol-modified polyethylene terephthalate).
- In other embodiments, the sensors are made using a relatively rigid substrate to, for example, provide structural support against bending or breaking. Examples of rigid materials that may be used as the substrate include poorly conducting ceramics, such as aluminum oxide and silicon dioxide. One advantage of an implantable sensor having a rigid substrate is that the sensor may have a sharp point and/or a sharp edge to aid in implantation of a sensor without an additional insertion device.
- It will be appreciated that for many sensors and sensor applications, both rigid and flexible sensors will operate adequately. The flexibility of the sensor may also be controlled and varied along a continuum by changing, for example, the composition and/or thickness of the substrate.
- In addition to considerations regarding flexibility, it is often desirable that implantable sensors should have a substrate which is physiologically harmless, for example, a substrate approved by a regulatory agency or private institution for in vivo use.
- The sensor may include optional features to facilitate insertion of an implantable sensor. For example, the sensor may be pointed at the tip to ease insertion. In addition, the sensor may include a barb which assists in anchoring the sensor within the tissue of the patient during operation of the sensor. However, the barb is typically small enough so that little damage is caused to the subcutaneous tissue when the sensor is removed for replacement.
- An implantable sensor may also, optionally, have an anticlotting agent disposed on a portion of the substrate which is implanted into a patient. This anticlotting agent may reduce or eliminate the clotting of blood or other body fluid around the sensor, particularly after insertion of the sensor. Blood clots may foul the sensor or irreproducibly reduce the amount of analyte which diffuses into the sensor. Examples of useful anticlotting agents include heparin and tissue plasminogen activator (TPA), as well as other known anticlotting agents.
- The anticlotting agent may be applied to at least a portion of that part of the sensor that is to be implanted. The anticlotting agent may be applied, for example, by bath, spraying, brushing, or dipping. The anticlotting agent is allowed to dry on the sensor. The anticlotting agent may be immobilized on the surface of the sensor or it may be allowed to diffuse away from the sensor surface. Typically, the quantities of anticlotting agent disposed on the sensor are far below the amounts typically used for treatment of medical conditions involving blood clots and, therefore, have only a limited, localized effect.
- An insertion device can be used to subcutaneously insert the self-powered analyte sensor into the patient. The insertion device is typically formed using structurally rigid materials, such as metal or rigid plastic. Exemplary materials include stainless steel and ABS (acrylonitrile-butadiene-styrene) plastic. In some embodiments, the insertion device is pointed and/or sharp at the tip to facilitate penetration of the skin of the patient. A sharp, thin insertion device may reduce pain felt by the patient upon insertion of the self-powered analyte sensor. In other embodiments, the tip of the insertion device has other shapes, including a blunt or flat shape. These embodiments may be particularly useful when the insertion device does not penetrate the skin but rather serves as a structural support for the sensor as the sensor is pushed into the skin.
- The sensor control unit can be integrated in the sensor, part or all of which is subcutaneously implanted or it can be configured to be placed on the skin of a patient. The sensor control unit is optionally formed in a shape that is comfortable to the patient and which may permit concealment, for example, under a patient's clothing. The thigh, leg, upper arm, shoulder, or abdomen are convenient parts of the patient's body for placement of the sensor control unit to maintain concealment. However, the sensor control unit may be positioned on other portions of the patient's body. One embodiment of the sensor control unit has a thin, oval shape to enhance concealment. However, other shapes and sizes may be used.
- The particular profile, as well as the height, width, length, weight, and volume of the sensor control unit may vary and depends, at least in part, on the components and associated functions included in the sensor control unit. In general, the sensor control unit includes a housing typically formed as a single integral unit that rests on the skin of the patient. The housing typically contains most or all of the electronic components of the sensor control unit.
- The housing of the sensor control unit may be formed using a variety of materials, including, for example, plastic and polymeric materials, particularly rigid thermoplastics and engineering thermoplastics. Suitable materials include, for example, polyvinyl chloride, polyethylene, polypropylene, polystyrene, ABS polymers, and copolymers thereof. The housing of the sensor control unit may be formed using a variety of techniques including, for example, injection molding, compression molding, casting, and other molding methods. Hollow or recessed regions may be formed in the housing of the sensor control unit. The electronic components of the sensor control unit and/or other items, including a battery or a speaker for an audible alarm, may be placed in the hollow or recessed areas.
- The sensor control unit is typically attached to the skin of the patient, for example, by adhering the sensor control unit directly to the skin of the patient with an adhesive provided on at least a portion of the housing of the sensor control unit which contacts the skin or by suturing the sensor control unit to the skin through suture openings in the sensor control unit.
- When positioned on the skin of a patient, the sensor and the electronic components within the sensor control unit are coupled via conductive contacts. The one or more working electrodes, counter electrode, and optional temperature probe are attached to individual conductive contacts. For example, the conductive contacts are provided on the interior of the sensor control unit. Other embodiments of the sensor control unit have the conductive contacts disposed on the exterior of the housing. The placement of the conductive contacts is such that they are in contact with the contact pads on the sensor when the sensor is properly positioned within the sensor control unit.
- The sensor control unit also typically includes at least a portion of the electronic components that measure the sensor current and the analyte monitoring device system. The electronic components of the sensor control unit typically include a power supply for operating the sensor control unit, a sensor circuit for obtaining signals from the sensor, a measurement circuit that converts sensor signals to a desired format, and a processing circuit that, at minimum, obtains signals from the sensor circuit and/or measurement circuit and provides the signals to an optional transmitter. In some embodiments, the processing circuit may also partially or completely evaluate the signals from the sensor and convey the resulting data to the optional transmitter and/or activate an optional alarm system if the analyte level exceeds a threshold. The processing circuit often includes digital logic circuitry.
- The sensor control unit may optionally contain a transmitter for transmitting the sensor signals or processed data from the processing circuit to a receiver/display unit; a data storage unit for temporarily or permanently storing data from the processing circuit; a temperature probe circuit for receiving signals from and operating a temperature probe; a reference voltage generator for providing a reference voltage for comparison with sensor-generated signals; and/or a watchdog circuit that monitors the operation of the electronic components in the sensor control unit.
- Moreover, the sensor control unit may also include digital and/or analog components utilizing semiconductor devices, including transistors. To operate these semiconductor devices, the sensor control unit may include other components including, for example, a bias control generator to correctly bias analog and digital semiconductor devices, an oscillator to provide a clock signal, and a digital logic and timing component to provide timing signals and logic operations for the digital components of the circuit.
- As an example of the operation of these components, the sensor circuit and the optional temperature probe circuit provide raw signals from the sensor to the measurement circuit. The measurement circuit converts the raw signals to a desired format, using for example, a current-to-voltage converter, current-to-frequency converter, and/or a binary counter or other indicator that produces a signal proportional to the absolute value of the raw signal. This may be used, for example, to convert the raw signal to a format that can be used by digital logic circuits. The processing circuit may then, optionally, evaluate the data and provide commands to operate the electronics.
- Sensors may be configured to require no system calibration or no user calibration. For example, a sensor may be factory calibrated and need not require further calibrating. In certain embodiments, calibration may be required, but may be done without user intervention, i.e., may be automatic. In those embodiments in which calibration by the user is required, the calibration may be according to a predetermined schedule or may be dynamic, i.e., the time for which may be determined by the system on a real-time basis according to various factors, including, but not limited to, glucose concentration and/or temperature and/or rate of change of glucose, etc.
- In addition to a transmitter, an optional receiver may be included in the sensor control unit. In some cases, the transmitter is a transceiver, operating as both a transmitter and a receiver. The receiver may be used to receive calibration data for the sensor. The calibration data may be used by the processing circuit to correct signals from the sensor. This calibration data may be transmitted by the receiver/display unit or from some other source such as a control unit in a doctor's office. In addition, the optional receiver may be used to receive a signal from the receiver/display units to direct the transmitter, for example, to change frequencies or frequency bands, to activate or deactivate the optional alarm system and/or to direct the transmitter to transmit at a higher rate.
- Calibration data may be obtained in a variety of ways. For instance, the calibration data may simply be factory-determined calibration measurements which can be input into the sensor control unit using the receiver or may alternatively be stored in a calibration data storage unit within the sensor control unit itself (in which case a receiver may not be needed). The calibration data storage unit may be, for example, a readable or readable/writeable memory circuit.
- Calibration may be accomplished using an in vitro test strip (or other reference), e.g., a small sample test strip such as a test strip that requires less than about 1 microliter of sample (for example FreeStyle® blood glucose monitoring test strips from Abbott Diabetes Care). For example, test strips that require less than about 1 nanoliter of sample may be used. In certain embodiments, a sensor may be calibrated using only one sample of body fluid per calibration event. For example, a user need only lance a body part one time to obtain sample for a calibration event (e.g., for a test strip), or may lance more than one time within a short period of time if an insufficient volume of sample is firstly obtained.
- Embodiments include obtaining and using multiple samples of body fluid for a given calibration event, where glucose values of each sample are substantially similar. Data obtained from a given calibration event may be used independently to calibrate or combined with data obtained from previous calibration events, e.g., averaged including weighted averaged, etc., to calibrate. In certain embodiments, a system need only be calibrated once by a user, where recalibration of the system is not required.
- Alternative or additional calibration data may be provided based on tests performed by a doctor or some other professional or by the patient. For example, it is common for diabetic individuals to determine their own blood glucose concentration using commercially available testing kits. The results of this test is input into the sensor control unit either directly, if an appropriate input device (e.g., a keypad, an optical signal receiver, or a port for connection to a keypad or computer) is incorporated in the sensor control unit, or indirectly by inputting the calibration data into the receiver/display unit and transmitting the calibration data to the sensor control unit.
- Other methods of independently determining analyte levels may also be used to obtain calibration data. This type of calibration data may supplant or supplement factory-determined calibration values.
- In some embodiments of the invention, calibration data may be required at periodic intervals, for example, every eight hours, once a day, or once a week, to confirm that accurate analyte levels are being reported. Calibration may also be required each time a new sensor is implanted or if the sensor exceeds a threshold minimum or maximum value or if the rate of change in the sensor signal exceeds a threshold value. In some cases, it may be necessary to wait a period of time after the implantation of the sensor before calibrating to allow the sensor to achieve equilibrium. In some embodiments, the sensor is calibrated only after it has been inserted. In other embodiments, no calibration of the sensor is needed.
- In some embodiments of the invention, the analyte monitoring device includes a sensor control unit and a self-powered analyte sensor. In some embodiments, the processing circuit of the sensor control unit is able to determine a level of the analyte and activate an alarm system if the analyte level exceeds a threshold. The sensor control unit, in these embodiments, has an alarm system and may also include a display, such as an LCD or LED display.
- A threshold value is exceeded if the datapoint has a value that is beyond the threshold value in a direction indicating a particular condition. For example, a datapoint which correlates to a glucose level of 200 mg/dL exceeds a threshold value for hyperglycemia of 180 mg/dL, because the datapoint indicates that the patient has entered a hyperglycemic state. As another example, a datapoint which correlates to a glucose level of 65 mg/dL exceeds a threshold value for hypoglycemia of 70 mg/dL because the datapoint indicates that the patient is hypoglycemic as defined by the threshold value. However, a datapoint which correlates to a glucose level of 75 mg/dL would not exceed the same threshold value for hypoglycemia because the datapoint does not indicate that particular condition as defined by the chosen threshold value.
- An alarm may also be activated if the sensor readings indicate a value that is beyond a measurement range of the sensor. For glucose, the physiologically relevant measurement range is typically about 30 to 500 mg/dL, including about 40-300 mg/dL and about 50-250 mg/dL, of glucose in the interstitial fluid.
- The alarm system may also, or alternatively, be activated when the rate of change or acceleration of the rate of change in analyte level increase or decrease reaches or exceeds a threshold rate or acceleration. For example, in the case of a subcutaneous glucose monitor, the alarm system might be activated if the rate of change in glucose concentration exceeds a threshold value which might indicate that a hyperglycemic or hypoglycemic condition is likely to occur.
- A system may also include system alarms that notify a user of system information such as battery condition, calibration, sensor dislodgment, sensor malfunction, etc. Alarms may be, for example, auditory and/or visual. Other sensory-stimulating alarm systems may be used including alarm systems which heat, cool, vibrate, or produce a mild electrical shock when activated.
- The subject invention also includes sensors used in sensor-based drug delivery systems. The system may provide a drug to counteract the high or low level of the analyte in response to the signals from one or more sensors. Alternatively, the system may monitor the drug concentration to ensure that the drug remains within a desired therapeutic range. The drug delivery system may include one or more (e.g., two or more) sensors, a processing unit such as a transmitter, a receiver/display unit, and a drug administration system. In some cases, some or all components may be integrated in a single unit. A sensor-based drug delivery system may use data from the one or more sensors to provide necessary input for a control algorithm/mechanism to adjust the administration of drugs, e.g., automatically or semi-automatically. As an example, a glucose sensor may be used to control and adjust the administration of insulin from an external or implanted insulin pump.
- Each of the various references, presentations, publications, provisional and/or non-provisional U.S. Patent Applications, U.S. patents, non-U.S. Patent applications, and/or non-U.S. patents that have been identified herein, is incorporated herein in its entirety by this reference.
- Other aspects, advantages, and modifications within the scope of the invention will be apparent to those skilled in the art to which the invention pertains. Various modifications, processes, as well as numerous structures to which the embodiments of the invention may be applicable will be readily apparent to those of skill in the art to which the invention is directed upon review of the specification. Various aspects and features of the invention may have been explained or described in relation to understandings, beliefs, theories, underlying assumptions, and/or working or prophetic examples, although it will be understood that the invention is not bound to any particular understanding, belief, theory, underlying assumption, and/or working or prophetic example. Although various aspects and features of the invention may have been described largely with respect to applications, or more specifically, medical applications, involving diabetic humans, it will be understood that such aspects and features also relate to any of a variety of applications involving non-diabetic humans and any and all other animals. Further, although various aspects and features of the invention may have been described largely with respect to applications involving partially implanted sensors, such as transcutaneous or subcutaneous sensors, it will be understood that such aspects and features also relate to any of a variety of sensors that are suitable for use in connection with the body of an animal or a human, such as those suitable for use as fully implanted in the body of an animal or a human. Finally, although the various aspects and features of the invention have been described with respect to various embodiments and specific examples herein, all of which may be made or carried out conventionally, it will be understood that the invention is entitled to protection within the full scope of the appended claims.
- The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to make and use the present invention, and are not intended to limit the scope of what the inventors regard as their invention nor are they intended to represent that the experiments below are all or the only experiments performed. Efforts have been made to ensure accuracy with respect to numbers used (e.g. amounts, temperature, etc.) but some experimental errors and deviations should be accounted for. Unless indicated otherwise, parts are parts by weight, molecular weight is weight average molecular weight, temperature is in degrees Centigrade, and pressure is at or near atmospheric.
- A self-powered glucose sensor was constructed using either a redox polymer or platinum-carbon cloth (Pt—C) as an oxygen reducing species on the counter electrode and glucose oxidase (GOx) as glucose oxidizing species on the working electrode, which also acts as the analyte responsive enzyme of the glucose sensor. Fabrication of the self-powered analyte sensors is described below.
- Working electrode (glucose oxidizing anode): 30 nL of a solution including 8.2 mg/mL GOx, 6.8 mg/mL redox polymer (a poly(vinylpyridine) derivative containing covalently bound Os complexes), and 5 mg/
mL PEG 400 crosslinker, all dissolved in 10 mM HEPES, was deposited on the working electrode of a continuous glucose monitor sensor, such as a Navigator® electrode, to form an active area of about 0.1 mm2. This electrode was overlaid with the flux-limiting membrane, approximately 50 micron thick coating of the membrane polymer (a poly(vinylpyridine) derivative) crosslinked with tri-glycidyl glycerol. - Counter electrode (oxygen reducing cathode): 150 nL of a solution including 5.2 mg/mL redox polymer dissolved in PBS, was deposited on the entirety of the working electrode of a continuous glucose monitor sensor, such as a Navigator® electrode, to form an active area of about 0.9 mm2. This electrode was overlaid with a flux-limiting membrane, an approximately 50 micron thick coating of the membrane polymer (a poly(vinylpyridine) derivative), crosslinked with tri-glycidyl glycerol.
- A 4.67 Mohm resistor was placed between these two electrodes, and the resulting spontaneous current was measured, as the sensor pair was exposed to varying glucose concentrations and at varying time points. The output of this circuit was compared to that from the identical working electrode in 3-electrode mode (paired through a potentiostat with an Ag/AgCl reference and a carbon counter electrode), as well as to the same working electrode paired in self-powered mode with a Pt/carbon counter electrode. The results are shown in
FIG. 9 andFIG. 10 . - Glucose aliquots were added to produce concentrations of 4, 12, 20, and 28 mM, as evident from the humps in
FIG. 9 . As shown inFIG. 9 , it was observed that the self-powered glucose sensor with a Pt—C counter electrode provided an identical result to a three electrode potentiostat-powered sensor, while the self-powered glucose sensor fabricated with a redox polymer based counter electrode gave a somewhat reduced current response. - Calibration curves from the data shown in
FIG. 9 are provided inFIG. 10 . As shown inFIG. 10 , the Pt—C counter electrode based self-powered sensor provided equivalent data to the three electrode potentiostat-powered sensor, while the self-powered glucose sensor fabricated with a redox polymer based counter electrode gave a somewhat reduced current response. - For many applications, it is desirable to intermittently address or query a sensor for current values, while leaving the sensor unpowered in the intervening intervals, since this can result in enormous savings in power consumption, and therefore overall size of the analyte sensor. Unfortunately, it is not feasible to intermittently power the current generation of a standard continuous glucose sensors since they have a relatively long response time. This is illustrated in
FIG. 11 , which shows a comparison of intermittently powering the current generation of a standard continuous glucose sensor (P-stat powered) and self-powered sensor having a Pt—C counter electrode as described in Example 1 (Self-powered, Pt—C as CTR). - As shown in
FIG. 11 , when a potentiostat powered standard continuous glucose sensor is turned off for 10 minutes, it requires at least 6 minutes to equilibrate when it is turned back on. In addition, when the potentiostat powered standard continuous glucose sensor is turned off for an hour, it requires at least 15 minutes to equilibrate when it is turned back on. However, the self-powered sensor having a Pt—C counter electrode is always “on” even in the absence of any power expenditure. Therefore, as shown inFIG. 11 , there is no equilibration time required after the self-powered sensor is reconnected to a current or voltage measuring circuit. - The oxygen reducing counter electrode of a self-powered sensor can also be constructed of an oxygen reducing enzyme, in addition to the other materials previously discussed, such as Pt, Pt black, and redox polymer. The enzyme, in this case bilirubin oxidase (BOD) can accept electrons directly from oxygen, then transmit them to the counter electrode through a cross-linked redox polymer. Fabrication of the self-powered analyte sensors is described below.
- Working electrode (glucose oxidizing anode): 30 nL of a solution including 8.2 mg/mL GOx, 6.8 mg/mL redox polymer (a poly(vinylpyridine) derivative containing covalently bound Os complexes), and 5 mg/
mL PEG 400 cross-linker, all dissolved in 10 mM HEPES, was deposited on the working electrode of a continuous glucose sensor, such as a Navigator® sensor, to form an active area of about 0.1 mm2. This electrode was overlaid with a flux-limiting membrane, an approximately 50 micron thick coating of the membrane polymer (a poly(vinylpyridine) derivative)cross-linked with tri-glycidyl glycerol. - Counter electrode (oxygen reducing cathode): 150 nL of a solution including 12.6 mg/mL BOD, 5.2 mg/mL redox polymer, and 5.4 mg/
mL PEG 400 cross-linker, all dissolved in PBS, was deposited on the entirety of the working electrode of a second continuous glucose sensor, such as a Navigator® sensor, to form an active area of about 0.9 mm2. This electrode was overlaid with a flux-limiting membrane, an approximately 50 micron thick coating of the membrane polymer (a poly(vinylpyridine) derivative) cross-linked with tri-glycidyl glycerol. - A 4.67 Mohm resistor was placed between these two electrodes, and the resulting spontaneous current was measured, as the sensor pair was exposed to varying glucose concentrations. The output of this circuit was compared to that from the identical working electrode in 3-electrode mode (paired through a potentiostat with an Ag/AgCl reference and a carbon counter electrode), as well as to the same working electrode paired in self-powered mode with a Pt/carbon cloth counter electrode. The results are shown in
FIG. 12 . Note that the currents in all three modes are essentially identical, indicating the redox polymer/BOD counter electrode functions efficiently as an oxygen reducing counter electrode. - A self-powered glucose sensor was constructed using either a redox polymer or platinum (Pt) as an oxygen reducing species on the counter electrode and glucose dehydrogenase complexed with flavin adenine dinucleotide (FADGDH) on the working electrode, which also acts the analyte responsive enzyme for the sensor. Fabrication of the self-powered analyte sensors is described below.
- Working electrode (anode): 30 nL of a solution including 8.2 mg/mL FADGDH, 6.8 mg/mL redox polymer (a poly(vinylpyridine) derivative containing covalently bound Os complexes), and 5 mg/
mL PEG 400 crosslinker, all dissolved in 10 mM HEPES, was deposited on the working electrode of a continuous glucose monitor sensor, such as a Navigator® electrode, to form an active area of about 0.1 mm2. This electrode was overlaid with the flux-limiting membrane, an approximately 50 micron thick coating of the membrane polymer (a poly(vinylpyridine) derivative) crosslinked with tri-glycidyl glycerol. Counter electrode (cathode): 150 nL of a solution including 12.6 mg/mL BOD, 5.2 mg/mL redox polymer, and 5.4 mg/mL PEG 400 cross-linker, all dissolved in PBS, was deposited on the entirety of the working electrode of a second continuous glucose sensor, such as a Navigator® sensor, to form an active area of about 0.9 mm2. This electrode was overlaid with a flux-limiting membrane, an approximately 50 micron thick coating of the membrane polymer (a poly(vinylpyridine) derivative) cross-linked with tri-glycidyl glycerol. - A 4.67 Mohm resistor was placed between these two electrodes, and the resulting spontaneous current was measured, as the sensor pair was exposed to varying glucose concentrations and at varying time points. The output of this circuit was compared to that from the identical working electrode in 3-electrode mode (paired through a potentiostat with an Ag/AgCl reference and a carbon counter electrode), as well as to the same working electrode paired in self-powered mode with a Pt/carbon counter electrode. The results are shown in
FIG. 13 . - Glucose aliquots were added to produce concentrations of 4, 12, 20, and 28 mM. Calibration curves from the three sensors are shown in
FIG. 13 . As shown inFIG. 13 , the Pt—C based counter electrode based self-powered sensor as well as the BOD based counter electrode based self-powered sensor provided equivalent data to the three electrode potentiostat-powered sensor. - In order to have a linear response over the concentration range of analytical interest, the correct value of R must be chosen for the resistor which couples together the working electrode and the counter electrode. This is illustrated by the following experiment. A self powered sensor was made from a GOx and redox polymer working electrode, and a Pt-carbon cloth counter electrode, coupled together with a variety of resistors, ranging in resistance from 0 MΩ to 100 MΩ. This sensor was then immersed in 30 mM (540 mg/dL) glucose (the top of the analytical range of interest) in PBS buffer at 37° C., and the resulting spontaneous steady state current was measured for sensors configured with different R values. The results are shown in
FIG. 14 , with resistance plotted on a logarithmic scale. Note that the current is essentially independent of resistance for resistance values of 10 MΩ or less, then falls off gradually at higher potentials, as the potential drop becomes a substantial fraction of the open circuit potential. Therefore, to correctly configure the sensor, a value of R should be selected that does not reduce the current output from its maximum value, as illustrated by the plateau in the graph ofFIG. 14 . In this example, the range of R values from 0 to 10 MΩ is the range of R values for which the sensor output, at an analyte concentration at the top of its physically relevant range, is independent of R. Therefore, an R value of 0 to 10 MΩ should be selected. - Another way to elucidate the correct range for R is in terms of the potential across the resistor. In the sensor described by the graph above, the open circuit potential (shown) is 474 mV. When the potential drop across the resistor is more than half of the open circuit potential, the output of the sensor begins to decline. The potential drop across the resistor is, for example, less than 75% of the open circuit potential, such as less than 50% of the open circuit potential, and less than 25% of the open circuit potential in certain embodiments.
- An in vivo self-powered glucose sensor used for subcutaneous implantation was constructed using the two carbon electrodes on a continuous glucose monitoring electrode of a Navigator® sensor: the working electrode, the counter electrode, and a resistor disposed in between the working electrode and the counter electrode and having an R value of 4.85 Mohm.
- The working electrode was constructed to include redox polymer, glucose oxidase, and cross-linker sensing layer. The counter electrode was constructed to include a layer of platinum catalyst formed by depositing 50
nL 20 mg/ml platinum-carbon black (HiSPEC 8000, Alfa Aesar) suspension in 80% ethanol-20% water. The sensor was then dip-coated with a flux-limiting polymer membrane. After sterilization, the sensor was subcutaneously implanted with an insertion device. The data was collected with a transmitter that sent via radio-frequency, the self-powered sensor current signal to a standard receiver. Reference glucose values were obtained through frequent measurement with FreeStyle® glucose strips. The results inFIG. 15 show good correlation between the in vivo self powered glucose sensor signal and the reference glucose values. - The preceding merely illustrates the principles of the invention. It will be appreciated that those skilled in the art will be able to devise various arrangements which, although not explicitly described or shown herein, embody the principles of the invention and are included within its spirit and scope. Furthermore, all examples and conditional language recited herein are principally intended to aid the reader in understanding the principles of the invention and the concepts contributed by the inventors to furthering the art, and are to be construed as being without limitation to such specifically recited examples and conditions. Moreover, all statements herein reciting principles, aspects, and embodiments of the invention as well as specific examples thereof, are intended to encompass both structural and functional equivalents thereof. Additionally, it is intended that such equivalents include both currently known equivalents and equivalents developed in the future, i.e., any elements developed that perform the same function, regardless of structure. The scope of the present invention, therefore, is not intended to be limited to the exemplary embodiments shown and described herein. Rather, the scope and spirit of present invention is embodied by the appended claims.
Claims (51)
1.-46. (canceled)
47. An analyte sensor assembly, comprising:
a self-powered electrochemical analyte sensor comprising:
a working electrode comprising an analyte-responsive enzyme disposed on the working electrode, wherein the working electrode is configured and arranged for electrooxidizing or electroreducing a primary reactant in the presence of the analyte-responsive enzyme;
a counter electrode capable of electroreducing or electrooxidizing a secondary reactant,
wherein the self-powered electrochemical analyte sensor spontaneously passes a current directly proportional to analyte concentration in the absence of an external power source; and
a transmitter unit operatively coupled to the electrochemical analyte sensor and configured to receive one or more signals from the electrochemical analyte sensor corresponding to an analyte level of a subject.
48. The analyte sensor assembly of claim 47 , wherein the working electrode is configured and arranged for electrooxidizing a primary reactant in the presence of the enzyme and the counter electrode is configured for electroreducing a secondary reactant.
49. The analyte sensor assembly of claim 47 , wherein the working electrode is configured and arranged for electroreducing a primary reactant in the presence of the enzyme and the counter electrode is configured for electrooxidizing a secondary reactant.
50. The analyte sensor assembly of claim 47 , wherein the electrochemical analyte sensor comprises resistance having an R value, wherein the R value is chosen from within a range of R values for which an electrochemical analyte sensor current output at an analyte concentration at the top of the physically relevant range of the analyte is independent of R.
51. The analyte sensor assembly of claim 50 , wherein the R value is chosen such that the potential drop across the resistor, at an analyte concentration at the top of its physically relevant range, is less than 75% of the open circuit potential.
52. The analyte sensor assembly of claim 50 , wherein the R value is chosen such that the potential drop across the resistor, at an analyte concentration at the top of its physically relevant range, is less than 50% of the open circuit potential.
53. The analyte sensor assembly of claim 50 , wherein the R value is chosen such that the potential drop across the resistor, at an analyte concentration at the top of its physically relevant range, is less than 25% of the open circuit potential.
54. The analyte sensor assembly of claim 50 , wherein the R value is less than 40 MΩ.
55. The analyte sensor assembly of claim 50 , wherein the R value is less than 20 MΩ.
56. The analyte sensor assembly of claim 50 , wherein the R value is less than 10 MΩ.
57. The analyte sensor assembly of claim 50 , wherein the R value is less than 1 MΩ.
58. The analyte sensor assembly of claim 47 , wherein the primary reactant is glucose.
59. The analyte sensor assembly of claim 47 , wherein the secondary reactant is oxygen.
60. The analyte sensor assembly of claim 47 , wherein the counter electrode comprises redox polymer disposed on the counter electrode.
61. The analyte sensor assembly of claim 60 , wherein the counter electrode comprises enzyme disposed proximate to the redox polymer.
62. The analyte sensor assembly of claim 47 , wherein the counter electrode comprises platinum.
63. The analyte sensor assembly of claim 47 , wherein the counter electrode comprises platinum wire, platinum black, platinum ink, or platinum impregnated carbon.
64. The analyte sensor assembly of claim 47 , wherein the working electrode comprises redox polymer disposed proximate to the analyte-responsive enzyme.
65. The analyte sensor assembly of claim 47 , wherein the analyte-responsive enzyme is a glucose-responsive enzyme.
66. The analyte sensor assembly of claim 65 , wherein the glucose-responsive enzyme is glucose oxidase or glucose dehydrogenase.
67. The analyte sensor assembly of claim 66 , wherein the glucose dehydrogenase is associated with a co-factor.
68. The analyte sensor assembly of claim 67 , wherein the co-factor is flavin adenine dinucleotide (FAD), nicotinamide adenine dinucleotide (NAD), or pyrroloquinoline quinone (PQQ).
69. The analyte sensor assembly of claim 47 , wherein the enzyme comprises a complex of glucose dehydrogenase (GDH) and flavin adenine dinucleotide (FAD).
70. The analyte sensor assembly of claim 47 , wherein the working electrode further comprising a flux limiting membrane layer disposed proximate to the enzyme.
71. The analyte sensor assembly of claim 64 , wherein the redox polymer comprises a redox mediator.
72. The analyte sensor assembly of claim 71 , wherein the redox mediator comprises ferricyanide, phenanthroline quinone, or ferrocene.
73. The analyte sensor assembly of claim 71 , wherein the redox mediator comprises a transition metal complex.
74. The analyte sensor assembly of claim 73 , wherein the transition metal complex comprises a ruthenium-containing complex or an osmium-containing complex.
75. The analyte sensor assembly of claim 64 , wherein the redox polymer comprises a heterocyclic nitrogen constituent selected from a group consisting of pyridine, imidazole, oxazole, thiazole, pyrazole, and any derivative thereof.
76. The analyte sensor assembly of claim 64 , wherein the redox polymer comprises a heterocyclic nitrogen constituent selected from a group consisting of 2-vinylpyridine, 3-vinylpyridine, 4-vinylpyridine, 1-vinylimidazole, 2-vinylimidazole, and 4-vinylimidazole.
77. The analyte sensor assembly of claim 47 , wherein the sensor is a glucose sensor.
78. The analyte sensor assembly of claim 47 , wherein the sensor is an in vivo sensor.
79. The analyte sensor assembly of claim 48 , wherein at least a portion of the analyte sensor assembly is adapted to be subcutaneously positioned in a subject.
80. The analyte sensor assembly of claim 79 , wherein the sensor is configured for intermittent interrogation by a detectable current measuring device.
81. The analyte sensor assembly of claim 79 , wherein the sensor is coupled to a radio-frequency powered current measuring circuit.
82. The analyte sensor assembly of claim 81 , wherein the radio-frequency powered current measuring circuit is intermittently powered.
83. The analyte sensor assembly of claim 79 , wherein the sensor is coupled to an inductively powered current measuring circuit.
84. The analyte sensor assembly of claim 83 , wherein the inductively powered current measuring circuit is intermittently powered.
85. The analyte sensor assembly of claim 47 , wherein the analyte sensor assembly is adapted to be fully positioned subcutaneously in a subject.
86. The analyte sensor assembly of claim 85 , wherein the sensor is coupled to a radio-frequency powered current measuring circuit.
87. The analyte sensor assembly of claim 86 , wherein the radio-frequency powered current measuring circuit is intermittently powered.
88. The analyte sensor assembly of claim 85 , wherein the sensor is coupled to an inductively powered current measuring circuit.
89. The analyte sensor assembly of claim 88 , wherein the inductively powered current measuring circuit is intermittently powered.
90. The analyte sensor assembly of claim 47 , wherein sensor output stabilizes is less than about 5 minutes after application of a powered measuring circuit to the sensor.
91. The analyte sensor assembly of claim 47 , wherein sensor output stabilizes is less than about 1 minute after application of a powered measuring circuit to the sensor.
92. The analyte sensor assembly of claim 47 , wherein sensor output stabilizes is less than about 10 seconds after application of a powered measuring circuit to the sensor.
93. The analyte sensor assembly of claim 47 , further comprising a current measuring device in electrical communication with the resistance.
94. The analyte sensor assembly of claim 93 , wherein the current measuring device is connected to the resistance in series.
95. The analyte sensor assembly of claim 47 , wherein the resistance is an adjustable resistance.
96-128. (canceled)
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/393,921 US20100213057A1 (en) | 2009-02-26 | 2009-02-26 | Self-Powered Analyte Sensor |
EP22208507.8A EP4219733A1 (en) | 2009-02-26 | 2010-02-25 | Self-powered analyte sensor |
PCT/US2010/025436 WO2010099335A1 (en) | 2009-02-26 | 2010-02-25 | Self-powered analyte sensor |
EP17183254.6A EP3255154B1 (en) | 2009-02-26 | 2010-02-25 | Method for operating a self-powered analyte sensor |
EP10746844.9A EP2401390B1 (en) | 2009-02-26 | 2010-02-25 | Self-powered analyte sensor |
US12/717,634 US9668684B2 (en) | 2009-02-26 | 2010-03-04 | Self-powered analyte sensor |
US13/087,190 US8965477B2 (en) | 2009-02-26 | 2011-04-14 | Analyte monitoring device and methods |
US13/877,543 US9339229B2 (en) | 2009-02-26 | 2011-12-13 | Analyte monitoring devices and methods |
US14/629,171 US9724029B2 (en) | 2009-02-26 | 2015-02-23 | Analyte monitoring device and methods |
US15/155,680 US9526453B2 (en) | 2009-02-26 | 2016-05-16 | Analyte monitoring devices and methods |
US15/351,177 US10022077B2 (en) | 2009-02-26 | 2016-11-14 | Analyte monitoring devices and methods |
US15/351,162 US10004441B2 (en) | 2009-02-26 | 2016-11-14 | Self-powered analyte sensor |
US16/015,882 US10631768B2 (en) | 2009-02-26 | 2018-06-22 | Self-powered analyte sensor |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/393,921 US20100213057A1 (en) | 2009-02-26 | 2009-02-26 | Self-Powered Analyte Sensor |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/717,634 Division US9668684B2 (en) | 2009-02-26 | 2010-03-04 | Self-powered analyte sensor |
US12/717,634 Continuation US9668684B2 (en) | 2009-02-26 | 2010-03-04 | Self-powered analyte sensor |
Publications (1)
Publication Number | Publication Date |
---|---|
US20100213057A1 true US20100213057A1 (en) | 2010-08-26 |
Family
ID=42630004
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/393,921 Abandoned US20100213057A1 (en) | 2009-02-26 | 2009-02-26 | Self-Powered Analyte Sensor |
US12/717,634 Active 2031-12-04 US9668684B2 (en) | 2009-02-26 | 2010-03-04 | Self-powered analyte sensor |
US15/351,162 Active US10004441B2 (en) | 2009-02-26 | 2016-11-14 | Self-powered analyte sensor |
US16/015,882 Active US10631768B2 (en) | 2009-02-26 | 2018-06-22 | Self-powered analyte sensor |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/717,634 Active 2031-12-04 US9668684B2 (en) | 2009-02-26 | 2010-03-04 | Self-powered analyte sensor |
US15/351,162 Active US10004441B2 (en) | 2009-02-26 | 2016-11-14 | Self-powered analyte sensor |
US16/015,882 Active US10631768B2 (en) | 2009-02-26 | 2018-06-22 | Self-powered analyte sensor |
Country Status (3)
Country | Link |
---|---|
US (4) | US20100213057A1 (en) |
EP (3) | EP3255154B1 (en) |
WO (1) | WO2010099335A1 (en) |
Cited By (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100064800A1 (en) * | 2008-07-17 | 2010-03-18 | Abbott Diabetes Care Inc. | Strip connectors for measurement devices |
WO2010091028A1 (en) | 2009-02-03 | 2010-08-12 | Abbott Diabetes Care Inc. | Compact on-body physiological monitoring devices and methods thereof |
US20110184264A1 (en) * | 2010-01-28 | 2011-07-28 | Abbott Diabetes Care Inc. | Universal Test Strip Port |
WO2011119896A1 (en) | 2010-03-24 | 2011-09-29 | Abbott Diabetes Care Inc. | Medical device inserters and processes of inserting and using medical devices |
WO2012048168A2 (en) | 2010-10-07 | 2012-04-12 | Abbott Diabetes Care Inc. | Analyte monitoring devices and methods |
WO2012058237A1 (en) | 2010-10-26 | 2012-05-03 | Abbott Diabetes Care Inc. | Analyte measurement devices and systems, and components and methods related thereto |
WO2012068393A1 (en) * | 2010-11-18 | 2012-05-24 | Abbott Diabetes Care Inc. | Adaptor for on-body analyte monitoring system |
WO2012078908A1 (en) | 2010-12-09 | 2012-06-14 | Abbott Diabetes Care Inc. | Analyte sensors with a sensing surface having small sensing spots |
CN102781308A (en) * | 2010-03-11 | 2012-11-14 | 霍夫曼-拉罗奇有限公司 | Method for the electrochemical measurement of an analyte concentration in vivo, and fuel cell for this purpose |
WO2013040079A1 (en) * | 2011-09-13 | 2013-03-21 | Dose Medical Corporation | Intraocular physiological sensor |
WO2013039455A1 (en) * | 2011-09-13 | 2013-03-21 | Nanyang Technological University | Amperometric sensor |
USD680454S1 (en) | 2011-10-25 | 2013-04-23 | Abbott Diabetes Care Inc. | Analyte meter and strip port |
WO2013163342A1 (en) | 2012-04-24 | 2013-10-31 | Abbott Diabetes Care Inc. | Methods of lag-compensation for analyte measurements, and devices related thereto |
US8702928B2 (en) | 2010-11-22 | 2014-04-22 | Abbott Diabetes Care Inc. | Modular analyte measurement system with extendable strip port |
WO2014085602A1 (en) | 2012-11-29 | 2014-06-05 | Abbott Diabetes Care Inc. | Methods, devices, and systems related to analyte monitoring |
US8965477B2 (en) | 2009-02-26 | 2015-02-24 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods |
US9069536B2 (en) | 2011-10-31 | 2015-06-30 | Abbott Diabetes Care Inc. | Electronic devices having integrated reset systems and methods thereof |
WO2015102745A1 (en) | 2013-12-31 | 2015-07-09 | Abbott Diabetes Care Inc. | Self-powered analyte sensor and devices using the same |
US9320432B2 (en) | 2010-04-16 | 2016-04-26 | Abbott Diabetes Care Inc. | Analyte meter communication module |
US9326707B2 (en) | 2008-11-10 | 2016-05-03 | Abbott Diabetes Care Inc. | Alarm characterization for analyte monitoring devices and systems |
US9339229B2 (en) | 2009-02-26 | 2016-05-17 | Abbott Diabetes Care Inc. | Analyte monitoring devices and methods |
US9380965B2 (en) | 2011-05-20 | 2016-07-05 | Abbott Diabetes Care Inc. | Analyte sensors having a membrane with low temperature sensitivity |
US9474475B1 (en) | 2013-03-15 | 2016-10-25 | Abbott Diabetes Care Inc. | Multi-rate analyte sensor data collection with sample rate configurable signal processing |
US9501272B2 (en) | 2010-05-24 | 2016-11-22 | Abbott Diabetes Care Inc. | Systems and methods for updating a medical device |
WO2016205378A1 (en) | 2015-06-15 | 2016-12-22 | Abbott Diabetes Care Inc. | Stabilized lactate responsive enzymes, electrodes and sensors, and methods for making and using the same |
US9532737B2 (en) | 2011-02-28 | 2017-01-03 | Abbott Diabetes Care Inc. | Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same |
US9541556B2 (en) | 2008-05-30 | 2017-01-10 | Abbott Diabetes Care Inc. | Method and apparatus for providing glycemic control |
US9572534B2 (en) | 2010-06-29 | 2017-02-21 | Abbott Diabetes Care Inc. | Devices, systems and methods for on-skin or on-body mounting of medical devices |
US9622691B2 (en) | 2011-10-31 | 2017-04-18 | Abbott Diabetes Care Inc. | Model based variable risk false glucose threshold alarm prevention mechanism |
US9625410B1 (en) * | 2010-09-17 | 2017-04-18 | Hrl Laboratories, Llc | Substance detection device and method |
US9675290B2 (en) | 2012-10-30 | 2017-06-13 | Abbott Diabetes Care Inc. | Sensitivity calibration of in vivo sensors used to measure analyte concentration |
US20170188915A1 (en) * | 2014-05-30 | 2017-07-06 | I-Sens, Inc. | Measurement error correction device of bio-measurer |
JP2017125914A (en) * | 2016-01-13 | 2017-07-20 | 国立研究開発法人科学技術振興機構 | Transmission circuit, biological molecule detection device, detection data collection method, and detection data collection system |
US9713440B2 (en) | 2010-12-08 | 2017-07-25 | Abbott Diabetes Care Inc. | Modular analyte measurement systems, modular components thereof and related methods |
US9730638B2 (en) | 2013-03-13 | 2017-08-15 | Glaukos Corporation | Intraocular physiological sensor |
WO2017151952A1 (en) | 2016-03-04 | 2017-09-08 | Abbott Diabetes Care Inc. | Nad(p)-dependent responsive enzymes, electrodes and sensors, and methods for making and using the same |
US9760679B2 (en) | 2011-02-11 | 2017-09-12 | Abbott Diabetes Care Inc. | Data synchronization between two or more analyte detecting devices in a database |
US9775549B2 (en) | 2014-08-15 | 2017-10-03 | Abbott Diabetes Care Inc. | Temperature insensitive in vivo analyte devices, methods and systems |
US9795326B2 (en) | 2009-07-23 | 2017-10-24 | Abbott Diabetes Care Inc. | Continuous analyte measurement systems and systems and methods for implanting them |
US9882660B2 (en) | 2006-10-26 | 2018-01-30 | Abbott Diabetes Care Inc. | Method, system and computer program product for real-time detection of sensitivity decline in analyte sensors |
US9907492B2 (en) | 2012-09-26 | 2018-03-06 | Abbott Diabetes Care Inc. | Method and apparatus for improving lag correction during in vivo measurement of analyte concentration with analyte concentration variability and range data |
US9913600B2 (en) | 2007-06-29 | 2018-03-13 | Abbott Diabetes Care Inc. | Analyte monitoring and management device and method to analyze the frequency of user interaction with the device |
US9913599B2 (en) | 2011-02-11 | 2018-03-13 | Abbott Diabetes Care Inc. | Software applications residing on handheld analyte determining devices |
WO2018057236A1 (en) * | 2016-09-21 | 2018-03-29 | Verily Life Sciences Llc | Systems and methods for activating a circuit of an implant device |
US9931075B2 (en) | 2008-05-30 | 2018-04-03 | Abbott Diabetes Care Inc. | Method and apparatus for providing glycemic control |
US10004439B2 (en) | 2012-09-21 | 2018-06-26 | Abbott Diabetes Care Inc. | In vivo sensors having ceria nanoparticle electrodes |
US10010273B2 (en) | 2011-03-10 | 2018-07-03 | Abbott Diabetes Care, Inc. | Multi-function analyte monitor device and methods of use |
US10022499B2 (en) | 2007-02-15 | 2018-07-17 | Abbott Diabetes Care Inc. | Device and method for automatic data acquisition and/or detection |
US10076285B2 (en) | 2013-03-15 | 2018-09-18 | Abbott Diabetes Care Inc. | Sensor fault detection using analyte sensor data pattern comparison |
EP3381360A1 (en) | 2011-09-28 | 2018-10-03 | Abbott Diabetes Care, Inc. | Methods, devices and systems for analyte monitoring management |
US10092229B2 (en) | 2010-06-29 | 2018-10-09 | Abbott Diabetes Care Inc. | Calibration of analyte measurement system |
US20180296139A1 (en) * | 2009-02-26 | 2018-10-18 | Abbott Diabetes Care Inc. | Self-powered analyte sensor |
US10117606B2 (en) | 2009-10-30 | 2018-11-06 | Abbott Diabetes Care Inc. | Method and apparatus for detecting false hypoglycemic conditions |
US10136816B2 (en) | 2009-08-31 | 2018-11-27 | Abbott Diabetes Care Inc. | Medical devices and methods |
US10213141B2 (en) | 2013-04-30 | 2019-02-26 | Abbott Diabetes Care Inc. | Systems, devices, and methods for energy efficient electrical device activation |
US10226207B2 (en) | 2004-12-29 | 2019-03-12 | Abbott Diabetes Care Inc. | Sensor inserter having introducer |
US10307091B2 (en) | 2005-12-28 | 2019-06-04 | Abbott Diabetes Care Inc. | Method and apparatus for providing analyte sensor insertion |
WO2019118231A1 (en) * | 2017-12-11 | 2019-06-20 | Microoptx Inc. | Implantable ocular glucose sensor devices and methods |
US10371617B2 (en) | 2015-04-30 | 2019-08-06 | Inside Biometrics International Limited | Electrochemical test device |
EP3540419A1 (en) * | 2018-03-12 | 2019-09-18 | Consejo Superior De Investigaciones Científicas (CSIC) | A device and a method for sensing the conductivity of a fluid |
US10433773B1 (en) | 2013-03-15 | 2019-10-08 | Abbott Diabetes Care Inc. | Noise rejection methods and apparatus for sparsely sampled analyte sensor data |
US10555695B2 (en) | 2011-04-15 | 2020-02-11 | Dexcom, Inc. | Advanced analyte sensor calibration and error detection |
US10598624B2 (en) | 2014-10-23 | 2020-03-24 | Abbott Diabetes Care Inc. | Electrodes having at least one sensing structure and methods for making and using the same |
WO2020159927A1 (en) * | 2019-01-28 | 2020-08-06 | Abbott Diabetes Care Inc. | Analyte sensors employing multiple enzymes and methods associated therewith |
ES2786450A1 (en) * | 2019-04-09 | 2020-10-09 | Consejo Superior Investigacion | PROCEDURE FOR THE QUANTIFICATION OF THE CONCENTRATION OF ANALYTS IN AN ELECTROCHEMICAL CELL (Machine-translation by Google Translate, not legally binding) |
US10872696B2 (en) | 2011-02-11 | 2020-12-22 | Abbott Diabetes Care Inc. | Method of hypoglycemia risk determination |
US10874338B2 (en) | 2010-06-29 | 2020-12-29 | Abbott Diabetes Care Inc. | Devices, systems and methods for on-skin or on-body mounting of medical devices |
US10888272B2 (en) | 2015-07-10 | 2021-01-12 | Abbott Diabetes Care Inc. | Systems, devices, and methods for meal information collection, meal assessment, and analyte data correlation |
US11000215B1 (en) | 2003-12-05 | 2021-05-11 | Dexcom, Inc. | Analyte sensor |
US11202586B2 (en) | 2009-08-31 | 2021-12-21 | Abbott Diabetes Care Inc. | Displays for a medical device |
EP3964828A1 (en) * | 2020-09-03 | 2022-03-09 | Université de Genève | Potentiometric sensor device |
US11298058B2 (en) | 2005-12-28 | 2022-04-12 | Abbott Diabetes Care Inc. | Method and apparatus for providing analyte sensor insertion |
CN114354696A (en) * | 2021-11-25 | 2022-04-15 | 中国科学院海洋研究所 | DNA biosensor driven by friction nano generator and application thereof |
US11331022B2 (en) | 2017-10-24 | 2022-05-17 | Dexcom, Inc. | Pre-connected analyte sensors |
US11350862B2 (en) | 2017-10-24 | 2022-06-07 | Dexcom, Inc. | Pre-connected analyte sensors |
WO2022164940A1 (en) | 2021-01-26 | 2022-08-04 | Abbott Diabetes Care Inc. | Systems, devices, and methods related to ketone sensors |
EP4134004A1 (en) * | 2021-08-11 | 2023-02-15 | Roche Diabetes Care GmbH | Regulation of a two-electrode analyte sensor |
WO2023110190A1 (en) | 2021-12-13 | 2023-06-22 | Heraeus Medical Gmbh | Tests and methods for detecting bacterial infection |
US11717225B2 (en) | 2014-03-30 | 2023-08-08 | Abbott Diabetes Care Inc. | Method and apparatus for determining meal start and peak events in analyte monitoring systems |
US11744492B2 (en) | 2018-08-29 | 2023-09-05 | Medtronic, Inc. | Electrochemical sensor including multiple work electrodes and common reference electrode |
US11793936B2 (en) | 2009-05-29 | 2023-10-24 | Abbott Diabetes Care Inc. | Medical device antenna systems having external antenna configurations |
USD1015366S1 (en) | 2020-07-29 | 2024-02-20 | Abbott Diabetes Care Inc. | Display screen or portion thereof with graphical user interface |
EP4357778A1 (en) | 2022-10-20 | 2024-04-24 | Heraeus Medical GmbH | Treatment of microbial infections diagnosed using the biomarker d-lactate |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7885698B2 (en) | 2006-02-28 | 2011-02-08 | Abbott Diabetes Care Inc. | Method and system for providing continuous calibration of implantable analyte sensors |
US8631679B2 (en) * | 2009-09-04 | 2014-01-21 | Isense Corporation | Additional calibration for analyte monitor |
US20140054171A1 (en) * | 2012-02-21 | 2014-02-27 | Abbott Diabetes Care Inc. | Analyte Sensor Utilizing Oxygen as Oxidant |
US9788765B2 (en) | 2012-09-28 | 2017-10-17 | Dexcom, Inc. | Zwitterion surface modifications for continuous sensors |
US9737250B2 (en) | 2013-03-15 | 2017-08-22 | Dexcom, Inc. | Membrane for continuous analyte sensors |
GB2516932B (en) | 2013-08-07 | 2018-12-26 | Nokia Technologies Oy | An apparatus and associated methods for water detection |
DE102015005003A1 (en) | 2015-04-21 | 2016-10-27 | Simanowski Holding GmbH | Device for controlling the blood sugar content of a patient |
US10765353B2 (en) | 2015-07-02 | 2020-09-08 | Verily Life Sciences Llc | Calibration methods for a bandage-type analyte sensor |
US11457809B1 (en) * | 2015-12-08 | 2022-10-04 | Verily Life Sciences Llc | NFC beacons for bidirectional communication between an electrochemical sensor and a reader device |
EP4218566A1 (en) | 2015-12-30 | 2023-08-02 | Dexcom, Inc. | Enzyme immobilized adhesive layer for analyte sensors |
US11026609B2 (en) * | 2016-08-09 | 2021-06-08 | Verily Life Sciences Llc | Wake-up batteries for invasive biosensors |
AU2019325918B2 (en) * | 2018-08-23 | 2022-08-11 | Abbott Diabetes Care Inc. | Sensors and methods for measuring pH |
US11733195B2 (en) * | 2018-09-29 | 2023-08-22 | Boe Technology Group Co., Ltd. | Electrochemical sensor for humoral detection and detection device |
WO2020131406A1 (en) | 2018-12-19 | 2020-06-25 | Abbott Diabetes Care Inc. | Systems, devices, and methods for rf detection of analyte sensor measurements |
CN109668945B (en) * | 2019-01-09 | 2024-03-15 | 杭州亚丁湾科技有限公司 | Energy self-supply wireless alarm device based on humidity triggering |
EP4058794A4 (en) * | 2019-11-12 | 2023-12-06 | Aquasensing Incorporated | Moisture, gas and fluid-enabled sensors |
WO2022265943A2 (en) * | 2021-06-10 | 2022-12-22 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Device and methods for characterization of semiconductor films |
US11955668B2 (en) * | 2021-09-23 | 2024-04-09 | Haier Us Appliance Solutions, Inc. | Self-powered leak detection sensor |
DE102022000897A1 (en) | 2022-03-15 | 2023-09-21 | Ruhr-Universität Bochum, Körperschaft des öffentlichen Rechts | Implantable biosensor |
GB2622185A (en) * | 2022-05-25 | 2024-03-13 | John William Dilleen | Electrochemical energy diagnostics device for sample analysis |
Citations (104)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3653841A (en) * | 1969-12-19 | 1972-04-04 | Hoffmann La Roche | Methods and compositions for determining glucose in blood |
US3719564A (en) * | 1971-05-10 | 1973-03-06 | Philip Morris Inc | Method of determining a reducible gas concentration and sensor therefor |
US3837339A (en) * | 1972-02-03 | 1974-09-24 | Whittaker Corp | Blood glucose level monitoring-alarm system and method therefor |
US3861397A (en) * | 1972-01-03 | 1975-01-21 | Siemens Ag | Implantable fuel cell |
US4008717A (en) * | 1973-01-15 | 1977-02-22 | The Johns Hopkins University | System for continuous withdrawal and analysis of blood |
US4016866A (en) * | 1975-12-18 | 1977-04-12 | General Electric Company | Implantable electrochemical sensor |
US4076596A (en) * | 1976-10-07 | 1978-02-28 | Leeds & Northrup Company | Apparatus for electrolytically determining a species in a fluid and method of use |
US4247297A (en) * | 1979-02-23 | 1981-01-27 | Miles Laboratories, Inc. | Test means and method for interference resistant determination of oxidizing substances |
US4318784A (en) * | 1978-08-15 | 1982-03-09 | National Research Development Corporation | Enzymatic processes |
US4375399A (en) * | 1978-09-08 | 1983-03-01 | Radelkis Elektrokemiai Miszergyarto Szovetkezet | Molecule selective sensor for industrial use and procedure for its preparation |
US4420564A (en) * | 1980-11-21 | 1983-12-13 | Fuji Electric Company, Ltd. | Blood sugar analyzer having fixed enzyme membrane sensor |
US4427770A (en) * | 1982-06-14 | 1984-01-24 | Miles Laboratories, Inc. | High glucose-determining analytical element |
US4431004A (en) * | 1981-10-27 | 1984-02-14 | Bessman Samuel P | Implantable glucose sensor |
US4436812A (en) * | 1980-10-29 | 1984-03-13 | Fuji Electric Co., Ltd. | Process of calibrating a blood sugar analyzing apparatus |
US4436094A (en) * | 1981-03-09 | 1984-03-13 | Evreka, Inc. | Monitor for continuous in vivo measurement of glucose concentration |
US4440175A (en) * | 1981-08-10 | 1984-04-03 | University Patents, Inc. | Membrane electrode for non-ionic species |
US4444892A (en) * | 1980-10-20 | 1984-04-24 | Malmros Mark K | Analytical device having semiconductive organic polymeric element associated with analyte-binding substance |
US4571292A (en) * | 1982-08-12 | 1986-02-18 | Case Western Reserve University | Apparatus for electrochemical measurements |
US4573994A (en) * | 1979-04-27 | 1986-03-04 | The Johns Hopkins University | Refillable medication infusion apparatus |
US4581336A (en) * | 1982-04-26 | 1986-04-08 | Uop Inc. | Surface-modified electrodes |
US4633878A (en) * | 1983-04-18 | 1987-01-06 | Guiseppe Bombardieri | Device for the automatic insulin or glucose infusion in diabetic subjects, based on the continuous monitoring of the patient's glucose, obtained without blood withdrawal |
US4637403A (en) * | 1985-04-08 | 1987-01-20 | Garid, Inc. | Glucose medical monitoring system |
US4650547A (en) * | 1983-05-19 | 1987-03-17 | The Regents Of The University Of California | Method and membrane applicable to implantable sensor |
US4654197A (en) * | 1983-10-18 | 1987-03-31 | Aktiebolaget Leo | Cuvette for sampling and analysis |
US4655880A (en) * | 1983-08-01 | 1987-04-07 | Case Western Reserve University | Apparatus and method for sensing species, substances and substrates using oxidase |
US4655885A (en) * | 1985-01-11 | 1987-04-07 | National Research Development Corporation | Surface-modified electrode and its use in a bioelectrochemical process |
US4717673A (en) * | 1984-11-23 | 1988-01-05 | Massachusetts Institute Of Technology | Microelectrochemical devices |
US4721601A (en) * | 1984-11-23 | 1988-01-26 | Massachusetts Institute Of Technology | Molecule-based microelectronic devices |
US4726378A (en) * | 1986-04-11 | 1988-02-23 | Minnesota Mining And Manufacturing Company | Adjustable magnetic supercutaneous device and transcutaneous coupling apparatus |
US4795707A (en) * | 1984-11-27 | 1989-01-03 | Hitachi, Ltd. | Electrochemical sensor having three layer membrane containing immobilized enzymes |
US4806468A (en) * | 1987-02-05 | 1989-02-21 | Becton, Dickinson And Company | Measurement of glycosylated hemoglobin by immunoassay |
US4805624A (en) * | 1985-09-09 | 1989-02-21 | The Montefiore Hospital Association Of Western Pa | Low-potential electrochemical redox sensors |
US4813424A (en) * | 1987-12-23 | 1989-03-21 | University Of New Mexico | Long-life membrane electrode for non-ionic species |
US4815469A (en) * | 1987-10-08 | 1989-03-28 | Siemens-Pacesetter, Inc. | Implantable blood oxygen sensor and method of use |
US4820399A (en) * | 1984-08-31 | 1989-04-11 | Shimadzu Corporation | Enzyme electrodes |
US4820636A (en) * | 1985-02-21 | 1989-04-11 | Medisense, Inc. | Electrochemical assay for cis-diols |
US4822337A (en) * | 1987-06-22 | 1989-04-18 | Stanley Newhouse | Insulin delivery method and apparatus |
US4890620A (en) * | 1985-09-20 | 1990-01-02 | The Regents Of The University Of California | Two-dimensional diffusion glucose substrate sensing electrode |
US4894253A (en) * | 1986-08-12 | 1990-01-16 | University Of Cincinnati | Method for production of coated electrode |
US4894137A (en) * | 1986-09-12 | 1990-01-16 | Omron Tateisi Electronics Co. | Enzyme electrode |
US4897162A (en) * | 1986-11-14 | 1990-01-30 | The Cleveland Clinic Foundation | Pulse voltammetry |
US4897173A (en) * | 1985-06-21 | 1990-01-30 | Matsushita Electric Industrial Co., Ltd. | Biosensor and method for making the same |
US4909908A (en) * | 1986-04-24 | 1990-03-20 | Pepi Ross | Electrochemical cncentration detector method |
US4911794A (en) * | 1986-06-20 | 1990-03-27 | Molecular Devices Corporation | Measuring with zero volume cell |
US4986271A (en) * | 1989-07-19 | 1991-01-22 | The University Of New Mexico | Vivo refillable glucose sensor |
US4994167A (en) * | 1986-04-15 | 1991-02-19 | Markwell Medical Institute, Inc. | Biological fluid measuring device |
US5078854A (en) * | 1990-01-22 | 1992-01-07 | Mallinckrodt Sensor Systems, Inc. | Polarographic chemical sensor with external reference electrode |
US5082550A (en) * | 1989-12-11 | 1992-01-21 | The United States Of America As Represented By The Department Of Energy | Enzyme electrochemical sensor electrode and method of making it |
US5082786A (en) * | 1987-11-26 | 1992-01-21 | Nec Corporation | Glucose sensor with gel-immobilized glucose oxidase and gluconolactonase |
US5089112A (en) * | 1989-03-20 | 1992-02-18 | Associated Universities, Inc. | Electrochemical biosensor based on immobilized enzymes and redox polymers |
US5094951A (en) * | 1988-06-21 | 1992-03-10 | Chiron Corporation | Production of glucose oxidase in recombinant systems |
US5096836A (en) * | 1987-06-27 | 1992-03-17 | Boehringer Mannheim Gmbh | Diagnostic test carrier |
US5096560A (en) * | 1989-05-30 | 1992-03-17 | Mitsubishi Petrochemical Co., Ltd. | Electrode for electrochemical detectors |
US5185256A (en) * | 1985-06-21 | 1993-02-09 | Matsushita Electric Industrial Co., Ltd. | Method for making a biosensor |
US5192415A (en) * | 1991-03-04 | 1993-03-09 | Matsushita Electric Industrial Co., Ltd. | Biosensor utilizing enzyme and a method for producing the same |
US5192416A (en) * | 1991-04-09 | 1993-03-09 | New Mexico State University Technology Transfer Corporation | Method and apparatus for batch injection analysis |
US5198367A (en) * | 1989-06-09 | 1993-03-30 | Masuo Aizawa | Homogeneous amperometric immunoassay |
US5278079A (en) * | 1992-09-02 | 1994-01-11 | Enzymatics, Inc. | Sealing device and method for inhibition of flow in capillary measuring devices |
US5286362A (en) * | 1990-02-03 | 1994-02-15 | Boehringer Mannheim Gmbh | Method and sensor electrode system for the electrochemical determination of an analyte or an oxidoreductase as well as the use of suitable compounds therefor |
US5286364A (en) * | 1987-06-08 | 1994-02-15 | Rutgers University | Surface-modified electochemical biosensor |
US5288636A (en) * | 1989-12-15 | 1994-02-22 | Boehringer Mannheim Corporation | Enzyme electrode system |
US5293546A (en) * | 1991-04-17 | 1994-03-08 | Martin Marietta Corporation | Oxide coated metal grid electrode structure in display devices |
US5378628A (en) * | 1991-02-21 | 1995-01-03 | Asulab, S.A. | Sensor for measuring the amount of a component in solution |
US5380422A (en) * | 1991-07-18 | 1995-01-10 | Agency Of Industrial Science And Technology | Micro-electrode and method for preparing it |
US5382346A (en) * | 1991-05-17 | 1995-01-17 | Kyoto Daiichi Kagaku Co., Ltd. | Biosensor and method of quantitative analysis using the same |
US5387327A (en) * | 1992-10-19 | 1995-02-07 | Duquesne University Of The Holy Ghost | Implantable non-enzymatic electrochemical glucose sensor |
US5390671A (en) * | 1994-03-15 | 1995-02-21 | Minimed Inc. | Transcutaneous sensor insertion set |
US5391250A (en) * | 1994-03-15 | 1995-02-21 | Minimed Inc. | Method of fabricating thin film sensors |
US5393903A (en) * | 1991-02-21 | 1995-02-28 | Asulab S.A. | Mono, bis or tris(substituted 2,2'-bipyridine) iron, ruthenium, osmium or vanadium complexes and their methods of preparation |
US5395504A (en) * | 1993-02-04 | 1995-03-07 | Asulab S.A. | Electrochemical measuring system with multizone sensors |
US5494562A (en) * | 1994-06-27 | 1996-02-27 | Ciba Corning Diagnostics Corp. | Electrochemical sensors |
US5497772A (en) * | 1993-11-19 | 1996-03-12 | Alfred E. Mann Foundation For Scientific Research | Glucose monitoring system |
US5501956A (en) * | 1990-03-23 | 1996-03-26 | Molecular Devices Corporation | Polyredox couples in analyte determinations |
US5593852A (en) * | 1993-12-02 | 1997-01-14 | Heller; Adam | Subcutaneous glucose electrode |
US5595479A (en) * | 1993-04-05 | 1997-01-21 | Danfoss A/S | Hydraulic machine having teeth formed by rollers |
US5596150A (en) * | 1995-03-08 | 1997-01-21 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Capacitance probe for fluid flow and volume measurements |
US5609749A (en) * | 1993-12-29 | 1997-03-11 | Mochida Pharmaceutical Co., Ltd. | Electrochemical assay method with novel p-phenylenediamine compound |
US5667653A (en) * | 1996-03-15 | 1997-09-16 | Mine Safety Appliances Company | Electrochemical sensor |
US5708247A (en) * | 1996-02-14 | 1998-01-13 | Selfcare, Inc. | Disposable glucose test strips, and methods and compositions for making same |
US5711862A (en) * | 1995-03-15 | 1998-01-27 | Omron Corporation | Portable biochemical measurement device using an enzyme sensor |
US5711861A (en) * | 1995-11-22 | 1998-01-27 | Ward; W. Kenneth | Device for monitoring changes in analyte concentration |
US5720862A (en) * | 1995-04-07 | 1998-02-24 | Kyoto Daiichi Kagaku Co., Ltd. | Sensor and production method of and measurement method using the same |
US5727548A (en) * | 1983-05-05 | 1998-03-17 | Medisense, Inc. | Strip electrode with screen printing |
US5857983A (en) * | 1996-05-17 | 1999-01-12 | Mercury Diagnostics, Inc. | Methods and apparatus for sampling body fluid |
US5879311A (en) * | 1996-05-17 | 1999-03-09 | Mercury Diagnostics, Inc. | Body fluid sampling device and methods of use |
US5888787A (en) * | 1996-07-02 | 1999-03-30 | North Carolina State University | Selective enzymatic oxidation of aromatic methyl groups to aldehydes by oxygen in the presence of a laccase-mediator catalyst |
US6033866A (en) * | 1997-12-08 | 2000-03-07 | Biomedix, Inc. | Highly sensitive amperometric bi-mediator-based glucose biosensor |
US6174734B1 (en) * | 1997-10-24 | 2001-01-16 | Abbott Laboratories | Measurement of glycated hemoglobin |
US6175752B1 (en) * | 1998-04-30 | 2001-01-16 | Therasense, Inc. | Analyte monitoring device and methods of use |
US6206835B1 (en) * | 1999-03-24 | 2001-03-27 | The B. F. Goodrich Company | Remotely interrogated diagnostic implant device with electrically passive sensor |
US6338790B1 (en) * | 1998-10-08 | 2002-01-15 | Therasense, Inc. | Small volume in vitro analyte sensor with diffusible or non-leachable redox mediator |
US6352824B1 (en) * | 1998-06-01 | 2002-03-05 | Roche Diagnostics Corporation | Redox reversible bipyridyl-osmium complex conjugates |
US20030042137A1 (en) * | 2001-05-15 | 2003-03-06 | Therasense, Inc. | Biosensor membranes composed of polymers containing heterocyclic nitrogens |
US6531239B2 (en) * | 1998-06-17 | 2003-03-11 | Therasense, Inc. | Biological fuel cell and methods |
US20030148169A1 (en) * | 2002-02-04 | 2003-08-07 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Biosensor carrying redox enzymes |
US20040122489A1 (en) * | 2002-12-23 | 2004-06-24 | Cardiac Pacemakers, Inc. | Implantable medical device having long-term wireless capabilities |
US20040245101A1 (en) * | 2001-08-29 | 2004-12-09 | Itamar Willner | Self-powered biosensor |
US20050261562A1 (en) * | 2004-05-20 | 2005-11-24 | Peter Zhou | Embedded bio-sensor system |
US7018755B2 (en) * | 2002-09-24 | 2006-03-28 | Ricoh Company, Ltd. | Electrophotographic photoconductor, electrophotography method using the same, electrophotographic apparatus, electrographic apparatus process cartridge and electrophotographic photoconductor outermost surface layer coating solution |
US7171252B1 (en) * | 1998-09-30 | 2007-01-30 | Sicel Technologies, Inc. | Methods, computer program products, and devices for calibrating chronically tissue implanted sensors using chronically tissue |
US20080044721A1 (en) * | 2002-05-02 | 2008-02-21 | Adam Heller | Miniature biological fuel cell that is operational under physiological conditions, and associated devices and methods |
US7410709B2 (en) * | 2004-06-24 | 2008-08-12 | Purdue Research Foundation | Bio-battery |
US20090000961A1 (en) * | 1997-02-06 | 2009-01-01 | Adam Heller | Small Volume in Vitro Analyte Sensor |
US20090018425A1 (en) * | 2005-12-28 | 2009-01-15 | Tianmei Ouyang | Analyte monitoring: stabilizer for subcutaneous glucose sensor with incorporated antiglycolytic agent |
Family Cites Families (295)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE227029C (en) | ||||
DE301808C (en) | ||||
US3260656A (en) | 1962-09-27 | 1966-07-12 | Corning Glass Works | Method and apparatus for electrolytically determining a species in a fluid |
US3776832A (en) | 1970-11-10 | 1973-12-04 | Energetics Science | Electrochemical detection cell |
US3774243A (en) | 1971-10-20 | 1973-11-27 | D Ng | Implantable power system for an artificial heart |
US3811950A (en) | 1972-01-26 | 1974-05-21 | R Dibella | Biochemical fuel cell and method of operating same |
GB1394171A (en) | 1973-05-16 | 1975-05-14 | Whittaker Corp | Blood glucose level monitoring-alarm system and method therefor |
US4100048A (en) | 1973-09-20 | 1978-07-11 | U.S. Philips Corporation | Polarographic cell |
US3972320A (en) | 1974-08-12 | 1976-08-03 | Gabor Ujhelyi Kalman | Patient monitoring system |
US3979274A (en) | 1975-09-24 | 1976-09-07 | The Yellow Springs Instrument Company, Inc. | Membrane for enzyme electrodes |
US4055175A (en) | 1976-05-07 | 1977-10-25 | Miles Laboratories, Inc. | Blood glucose control apparatus |
DE2625834B2 (en) | 1976-06-09 | 1978-10-12 | Boehringer Mannheim Gmbh, 6800 Mannheim | Method for the determination of substrates or enzyme activities |
US4059406A (en) | 1976-07-12 | 1977-11-22 | E D T Supplies Limited | Electrochemical detector system |
US4117202A (en) | 1976-11-12 | 1978-09-26 | Beck Timothy A | Solar powered biological fuel cell |
FR2387659A1 (en) | 1977-04-21 | 1978-11-17 | Armines | GLYCEMIA CONTROL AND REGULATION DEVICE |
US4098574A (en) | 1977-08-01 | 1978-07-04 | Eastman Kodak Company | Glucose detection system free from fluoride-ion interference |
JPS5441191A (en) | 1977-09-08 | 1979-04-02 | Omron Tateisi Electronics Co | Glucose-oxygen sensitive electrode |
US4178916A (en) | 1977-09-26 | 1979-12-18 | Mcnamara Elger W | Diabetic insulin alarm system |
JPS5912135B2 (en) | 1977-09-28 | 1984-03-21 | 松下電器産業株式会社 | enzyme electrode |
US4151845A (en) | 1977-11-25 | 1979-05-01 | Miles Laboratories, Inc. | Blood glucose control apparatus |
JPS5921500B2 (en) | 1978-01-28 | 1984-05-21 | 東洋紡績株式会社 | Enzyme membrane for oxygen electrode |
DK151000C (en) | 1978-02-17 | 1988-06-13 | Radiometer As | PROCEDURE AND APPARATUS FOR DETERMINING A PATIENT'S IN VIVO PLASMA-PH VALUE |
US4172770A (en) | 1978-03-27 | 1979-10-30 | Technicon Instruments Corporation | Flow-through electrochemical system analytical method |
DE2817363C2 (en) | 1978-04-20 | 1984-01-26 | Siemens AG, 1000 Berlin und 8000 München | Method for determining the concentration of sugar and a suitable electrocatalytic sugar sensor |
JPS5816698B2 (en) | 1978-07-10 | 1983-04-01 | 松下電器産業株式会社 | Enzyme electrode and its manufacturing method |
JPS5816696B2 (en) | 1978-07-10 | 1983-04-01 | 松下電器産業株式会社 | enzyme electrode |
JPS5816697B2 (en) | 1978-07-10 | 1983-04-01 | 松下電器産業株式会社 | Enzyme electrode and its manufacturing method |
JPS5512406A (en) | 1978-07-12 | 1980-01-29 | Nippon Seiko Kk | Method of compensating error in measuring circle or arc and meter with compensator |
US4240438A (en) | 1978-10-02 | 1980-12-23 | Wisconsin Alumni Research Foundation | Method for monitoring blood glucose levels and elements |
JPS584982B2 (en) | 1978-10-31 | 1983-01-28 | 松下電器産業株式会社 | enzyme electrode |
JPS5817427B2 (en) | 1978-12-11 | 1983-04-07 | 松下電器産業株式会社 | enzyme electrode |
US4365637A (en) | 1979-07-05 | 1982-12-28 | Dia-Med, Inc. | Perspiration indicating alarm for diabetics |
US4271119A (en) | 1979-07-23 | 1981-06-02 | Eastman Kodak Company | Capillary transport device having connected transport zones |
US4401122A (en) | 1979-08-02 | 1983-08-30 | Children's Hospital Medical Center | Cutaneous methods of measuring body substances |
DE3114441A1 (en) | 1980-04-11 | 1982-03-04 | Radiometer A/S, 2400 Koebenhavn | ELECTROCHEMICAL MEASURING ELECTRODE DEVICE |
US4450842A (en) | 1980-04-25 | 1984-05-29 | Cordis Corporation | Solid state reference electrode |
JPS56163447A (en) | 1980-05-22 | 1981-12-16 | Matsushita Electric Ind Co Ltd | Enzyme electrode |
US4340458A (en) | 1980-06-02 | 1982-07-20 | Joslin Diabetes Center, Inc. | Glucose sensor |
JPS5712359A (en) | 1980-06-26 | 1982-01-22 | Matsushita Electric Ind Co Ltd | Enzyme electrode |
US4404066A (en) | 1980-08-25 | 1983-09-13 | The Yellow Springs Instrument Company | Method for quantitatively determining a particular substrate catalyzed by a multisubstrate enzyme |
US4356074A (en) | 1980-08-25 | 1982-10-26 | The Yellow Springs Instrument Company, Inc. | Substrate specific galactose oxidase enzyme electrodes |
JPS5770448A (en) | 1980-10-20 | 1982-04-30 | Matsushita Electric Ind Co Ltd | Enzyme electrode |
US4407959A (en) | 1980-10-29 | 1983-10-04 | Fuji Electric Co., Ltd. | Blood sugar analyzing apparatus |
US4483924A (en) | 1980-12-09 | 1984-11-20 | Fuji Electric Company, Ltd. | System for controlling a printer in a blood sugar analyzer |
EP0076266B1 (en) | 1981-04-08 | 1988-11-09 | GORTON, Lo | Electrode for the electrochemical regeneration of co-enzyme, a method of making said electrode, and the use thereof |
AT369254B (en) | 1981-05-07 | 1982-12-27 | Otto Dipl Ing Dr Tech Prohaska | MEDICAL PROBE |
FR2508305B1 (en) | 1981-06-25 | 1986-04-11 | Slama Gerard | DEVICE FOR CAUSING A LITTLE BITE TO COLLECT A BLOOD DROP |
DE3278334D1 (en) | 1981-10-23 | 1988-05-19 | Genetics Int Inc | Sensor for components of a liquid mixture |
US4418148A (en) | 1981-11-05 | 1983-11-29 | Miles Laboratories, Inc. | Multilayer enzyme electrode membrane |
JPS5886083A (en) | 1981-11-12 | 1983-05-23 | Wako Pure Chem Ind Ltd | Stabilizing agent for glycerol-3-phosphoric acid oxidase |
JPS58153154A (en) | 1982-03-09 | 1983-09-12 | Ajinomoto Co Inc | Qualified electrode |
DD227029A3 (en) | 1982-05-13 | 1985-09-04 | Zentralinst F Diabetiker G Kat | ENZYME ELECTRODE FOR GLUCOSE MEASUREMENT |
DE3221339A1 (en) | 1982-06-05 | 1983-12-08 | Basf Ag, 6700 Ludwigshafen | METHOD FOR THE ELECTROCHEMICAL HYDRATION OF NICOTINAMIDADENINE-DINUCLEOTIDE |
US4534356A (en) | 1982-07-30 | 1985-08-13 | Diamond Shamrock Chemicals Company | Solid state transcutaneous blood gas sensors |
DE3228551A1 (en) | 1982-07-30 | 1984-02-02 | Siemens AG, 1000 Berlin und 8000 München | METHOD FOR DETERMINING SUGAR CONCENTRATION |
US4595479A (en) | 1982-11-09 | 1986-06-17 | Ajinomoto Co., Inc. | Modified electrode |
US4552840A (en) | 1982-12-02 | 1985-11-12 | California And Hawaiian Sugar Company | Enzyme electrode and method for dextran analysis |
US4461691A (en) | 1983-02-10 | 1984-07-24 | The United States Of America As Represented By The United States Department Of Energy | Organic conductive films for semiconductor electrodes |
US4679562A (en) | 1983-02-16 | 1987-07-14 | Cardiac Pacemakers, Inc. | Glucose sensor |
EP0136362B1 (en) | 1983-03-11 | 1990-12-19 | Matsushita Electric Industrial Co., Ltd. | Biosensor |
CA1220818A (en) | 1983-05-05 | 1987-04-21 | Hugh A.O. Hill | Assay techniques utilising specific binding agents |
CA1219040A (en) | 1983-05-05 | 1987-03-10 | Elliot V. Plotkin | Measurement of enzyme-catalysed reactions |
CA1226036A (en) | 1983-05-05 | 1987-08-25 | Irving J. Higgins | Analytical equipment and sensor electrodes therefor |
GB2154003B (en) | 1983-12-16 | 1988-02-17 | Genetics Int Inc | Diagnostic aid |
CA1218704A (en) | 1983-05-05 | 1987-03-03 | Graham Davis | Assay systems using more than one enzyme |
US4484987A (en) | 1983-05-19 | 1984-11-27 | The Regents Of The University Of California | Method and membrane applicable to implantable sensor |
US4524114A (en) | 1983-07-05 | 1985-06-18 | Allied Corporation | Bifunctional air electrode |
US4538616A (en) | 1983-07-25 | 1985-09-03 | Robert Rogoff | Blood sugar level sensing and monitoring transducer |
US4543955A (en) | 1983-08-01 | 1985-10-01 | Cordis Corporation | System for controlling body implantable action device |
US4560534A (en) | 1983-11-02 | 1985-12-24 | Miles Laboratories, Inc. | Polymer catalyst transducers |
US4522690A (en) | 1983-12-01 | 1985-06-11 | Honeywell Inc. | Electrochemical sensing of carbon monoxide |
WO1985002627A1 (en) | 1983-12-16 | 1985-06-20 | Genetics International, Inc. | Assay for nucleic acids |
JPS60173457A (en) | 1984-02-20 | 1985-09-06 | Matsushita Electric Ind Co Ltd | Biosensor |
JPS60173458A (en) | 1984-02-20 | 1985-09-06 | Matsushita Electric Ind Co Ltd | Biosensor |
JPH0640086B2 (en) | 1984-02-20 | 1994-05-25 | 松下電器産業株式会社 | Biosensor |
SU1281988A1 (en) | 1984-03-15 | 1987-01-07 | Институт биохимии АН ЛитССР | Electrochemical transducer for measuring glucose concentration |
JPS61502402A (en) | 1984-04-30 | 1986-10-23 | エル エ− シユテイツフツング | Sensitization method for oxidation/reduction photoreaction catalyst and photoreaction catalyst |
EP0171148B1 (en) | 1984-06-13 | 1991-04-17 | ARES-SERONO RESEARCH & DEVELOPMENT LIMITED PARTNERSHIP | Devices for use in chemical test procedures |
US5141868A (en) | 1984-06-13 | 1992-08-25 | Internationale Octrooi Maatschappij "Octropa" Bv | Device for use in chemical test procedures |
GB8417301D0 (en) | 1984-07-06 | 1984-08-08 | Serono Diagnostics Ltd | Assay |
DK8601218A (en) | 1984-07-18 | 1986-03-17 | ||
JPS6151008A (en) | 1984-08-21 | 1986-03-13 | Japan Styrene Paper Co Ltd | Pre-expanded polyethylene resin particle |
CA1254091A (en) | 1984-09-28 | 1989-05-16 | Vladimir Feingold | Implantable medication infusion system |
JPS6190050A (en) | 1984-10-09 | 1986-05-08 | Matsushita Electric Ind Co Ltd | Production of chip for biosensor |
GB2168815A (en) | 1984-11-13 | 1986-06-25 | Genetics Int Inc | Bioelectrochemical assay electrode |
US5034192A (en) | 1984-11-23 | 1991-07-23 | Massachusetts Institute Of Technology | Molecule-based microelectronic devices |
US4936956A (en) | 1984-11-23 | 1990-06-26 | Massachusetts Institute Of Technology | Microelectrochemical devices based on inorganic redox active material and method for sensing |
DE3585915T2 (en) | 1984-12-28 | 1993-04-15 | Terumo Corp | ION SENSOR. |
EP0200321A3 (en) | 1985-03-20 | 1987-03-11 | Ingeborg J. Hochmair | Transcutaneous signal transmission system |
US4781798A (en) | 1985-04-19 | 1988-11-01 | The Regents Of The University Of California | Transparent multi-oxygen sensor array and method of using same |
US4671288A (en) | 1985-06-13 | 1987-06-09 | The Regents Of The University Of California | Electrochemical cell sensor for continuous short-term use in tissues and blood |
US4938860A (en) | 1985-06-28 | 1990-07-03 | Miles Inc. | Electrode for electrochemical sensors |
GB8522834D0 (en) | 1985-09-16 | 1985-10-23 | Ici Plc | Sensor |
US4680268A (en) | 1985-09-18 | 1987-07-14 | Children's Hospital Medical Center | Implantable gas-containing biosensor and method for measuring an analyte such as glucose |
US5140393A (en) | 1985-10-08 | 1992-08-18 | Sharp Kabushiki Kaisha | Sensor device |
JPS6285855A (en) | 1985-10-11 | 1987-04-20 | Nok Corp | Formation of very small gold electrode |
CA1254616A (en) | 1985-11-11 | 1989-05-23 | Calum J. Mcneil | Electrochemical enzymic assay procedures |
JPS62114747A (en) | 1985-11-15 | 1987-05-26 | O C C:Kk | Continuous casting method for metallic bar |
GB8529300D0 (en) | 1985-11-28 | 1986-01-02 | Ici Plc | Membrane |
US4776944A (en) | 1986-03-20 | 1988-10-11 | Jiri Janata | Chemical selective sensors utilizing admittance modulated membranes |
US4685463A (en) | 1986-04-03 | 1987-08-11 | Williams R Bruce | Device for continuous in vivo measurement of blood glucose concentrations |
GB8608700D0 (en) | 1986-04-10 | 1986-05-14 | Genetics Int Inc | Measurement of electroactive species in solution |
US4757022A (en) | 1986-04-15 | 1988-07-12 | Markwell Medical Institute, Inc. | Biological fluid measuring device |
DE3614821A1 (en) | 1986-05-02 | 1987-11-05 | Siemens Ag | IMPLANTABLE, CALIBRABLE MEASURING DEVICE FOR A BODY SUBSTANCE AND CALIBRATION METHOD |
US4703756A (en) | 1986-05-06 | 1987-11-03 | The Regents Of The University Of California | Complete glucose monitoring system with an implantable, telemetered sensor module |
GB8612861D0 (en) | 1986-05-27 | 1986-07-02 | Cambridge Life Sciences | Immobilised enzyme biosensors |
US4750496A (en) | 1987-01-28 | 1988-06-14 | Xienta, Inc. | Method and apparatus for measuring blood glucose concentration |
JPS636451A (en) | 1986-06-27 | 1988-01-12 | Terumo Corp | Enzyme sensor |
US4764416A (en) | 1986-07-01 | 1988-08-16 | Mitsubishi Denki Kabushiki Kaisha | Electric element circuit using oxidation-reduction substances |
US4784736A (en) | 1986-07-07 | 1988-11-15 | Bend Research, Inc. | Functional, photochemically active, and chemically asymmetric membranes by interfacial polymerization of derivatized multifunctional prepolymers |
GB8618022D0 (en) | 1986-07-23 | 1986-08-28 | Unilever Plc | Electrochemical measurements |
JPH0654304B2 (en) | 1986-08-28 | 1994-07-20 | 松下電器産業株式会社 | Biosensor |
JPS63128252A (en) | 1986-11-18 | 1988-05-31 | Matsushita Electric Ind Co Ltd | Biosensor |
JPS63131057A (en) | 1986-11-20 | 1988-06-03 | Terumo Corp | Enzyme sensor |
JPS63139246A (en) | 1986-12-01 | 1988-06-11 | Matsushita Electric Ind Co Ltd | Biosensor |
DE3700119A1 (en) * | 1987-01-03 | 1988-07-14 | Inst Diabetestechnologie Gemei | IMPLANTABLE ELECTROCHEMICAL SENSOR |
EP0278647A3 (en) | 1987-02-09 | 1989-09-20 | AT&T Corp. | Electronchemical processes involving enzymes |
GB2201248B (en) | 1987-02-24 | 1991-04-17 | Ici Plc | Enzyme electrode sensors |
US4848351A (en) | 1987-03-04 | 1989-07-18 | Sentry Medical Products, Inc. | Medical electrode assembly |
GB2204408A (en) | 1987-03-04 | 1988-11-09 | Plessey Co Plc | Biosensor device |
US4923586A (en) | 1987-03-31 | 1990-05-08 | Daikin Industries, Ltd. | Enzyme electrode unit |
US4935345A (en) | 1987-04-07 | 1990-06-19 | Arizona Board Of Regents | Implantable microelectronic biochemical sensor incorporating thin film thermopile |
IL82131A0 (en) | 1987-04-07 | 1987-10-30 | Univ Ramot | Coulometric assay system |
US5352348A (en) | 1987-04-09 | 1994-10-04 | Nova Biomedical Corporation | Method of using enzyme electrode |
US4759828A (en) | 1987-04-09 | 1988-07-26 | Nova Biomedical Corporation | Glucose electrode and method of determining glucose |
JPH0761280B2 (en) | 1987-05-27 | 1995-07-05 | 日本化薬株式会社 | Simultaneous measurement of glucose and 1,5-anhydroglucitol |
JPS63317758A (en) | 1987-06-19 | 1988-12-26 | Matsushita Electric Ind Co Ltd | Manufacture of biosensor |
JPH07122624B2 (en) | 1987-07-06 | 1995-12-25 | ダイキン工業株式会社 | Biosensor |
GB8718430D0 (en) * | 1987-08-04 | 1987-09-09 | Ici Plc | Sensor |
JPS6423155A (en) | 1987-07-17 | 1989-01-25 | Daikin Ind Ltd | Electrode refreshing device for biosensor |
US5037527A (en) | 1987-08-28 | 1991-08-06 | Kanzaki Paper Mfg. Co., Ltd. | Reference electrode and a measuring apparatus using the same |
US4974929A (en) | 1987-09-22 | 1990-12-04 | Baxter International, Inc. | Fiber optical probe connector for physiologic measurement devices |
NL8702370A (en) | 1987-10-05 | 1989-05-01 | Groningen Science Park | METHOD AND SYSTEM FOR GLUCOSE DETERMINATION AND USEABLE MEASURING CELL ASSEMBLY. |
JPH01114746A (en) | 1987-10-29 | 1989-05-08 | Matsushita Electric Ind Co Ltd | Biosensor |
JPH0795056B2 (en) | 1987-10-29 | 1995-10-11 | 松下電器産業株式会社 | Biosensor |
JP2502635B2 (en) | 1987-11-19 | 1996-05-29 | 松下電器産業株式会社 | Biosensor |
JP2574347B2 (en) | 1987-12-15 | 1997-01-22 | 松下電器産業株式会社 | Biosensor |
GB8801199D0 (en) | 1988-01-20 | 1988-02-17 | Iq Bio Ltd | Dual enzyme assay |
US5126247A (en) | 1988-02-26 | 1992-06-30 | Enzymatics, Inc. | Method, system and devices for the assay and detection of biochemical molecules |
US5128015A (en) | 1988-03-15 | 1992-07-07 | Tall Oak Ventures | Method and apparatus for amperometric diagnostic analysis |
US5108564A (en) * | 1988-03-15 | 1992-04-28 | Tall Oak Ventures | Method and apparatus for amperometric diagnostic analysis |
WO1989009397A1 (en) | 1988-03-31 | 1989-10-05 | Matsushita Electric Industrial Co., Ltd. | Biosensor and process for its production |
US4942127A (en) | 1988-05-06 | 1990-07-17 | Molecular Devices Corporation | Polyredox couples in analyte determinations |
US5206145A (en) | 1988-05-19 | 1993-04-27 | Thorn Emi Plc | Method of measuring the concentration of a substance in a sample solution |
GB8817421D0 (en) | 1988-07-21 | 1988-08-24 | Medisense Inc | Bioelectrochemical electrodes |
JPH0262958A (en) | 1988-08-30 | 1990-03-02 | Kanzaki Paper Mfg Co Ltd | Method of measuring concentration of phosphoric acid |
US5264106A (en) | 1988-10-07 | 1993-11-23 | Medisense, Inc. | Enhanced amperometric sensor |
JP2689531B2 (en) | 1988-10-31 | 1997-12-10 | エヌオーケー株式会社 | Glucose sensor |
JPH02128152A (en) | 1988-11-08 | 1990-05-16 | Nec Corp | Immobilization of enzyme and biosensor |
AU4647589A (en) | 1988-11-10 | 1990-05-28 | Midwest Research Technologies, Inc. | Method for electrical detection of a binding reaction |
US5200051A (en) | 1988-11-14 | 1993-04-06 | I-Stat Corporation | Wholly microfabricated biosensors and process for the manufacture and use thereof |
DE3842700A1 (en) | 1988-12-19 | 1990-06-21 | Boehringer Mannheim Gmbh | METHOD FOR PROTEIN IMMOBILIZATION ON A SOLID PHASE, PROTEIN-CARRYING SOLID PHASE PRODUCED THEREOF AND THE USE THEREOF |
AT392847B (en) | 1989-01-27 | 1991-06-25 | Avl Verbrennungskraft Messtech | SENSOR ELECTRODE ARRANGEMENT |
US5205920A (en) | 1989-03-03 | 1993-04-27 | Noboru Oyama | Enzyme sensor and method of manufacturing the same |
JPH02298855A (en) | 1989-03-20 | 1990-12-11 | Assoc Univ Inc | Electrochemical biosensor using immobilized enzyme and redox polymer |
US4953552A (en) | 1989-04-21 | 1990-09-04 | Demarzo Arthur P | Blood glucose monitoring system |
JP2752429B2 (en) | 1989-04-27 | 1998-05-18 | 株式会社クラレ | Small-diameter tube to which receptor is fixed and method of fixing receptor |
JPH02310457A (en) | 1989-05-26 | 1990-12-26 | Matsushita Electric Ind Co Ltd | Biosensor |
US5236567A (en) | 1989-05-31 | 1993-08-17 | Nakano Vinegar Co., Ltd. | Enzyme sensor |
US5807747A (en) | 1989-06-13 | 1998-09-15 | Clinical Innovations Limited | Method and apparatus for determination of glycosylated protein |
JPH0326956A (en) | 1989-06-24 | 1991-02-05 | Matsushita Electric Works Ltd | Electrochemical sensor and preparation thereof |
JPH0750058B2 (en) | 1989-06-27 | 1995-05-31 | 松下電工株式会社 | Enzyme-immobilized electrode and method for producing the same |
CH677149A5 (en) | 1989-07-07 | 1991-04-15 | Disetronic Ag | |
JPH0737991B2 (en) | 1989-07-13 | 1995-04-26 | 株式会社京都第一科学 | Method for measuring glucose concentration |
US5272060A (en) | 1989-07-13 | 1993-12-21 | Kyoto Daiichi Kagaku Co., Ltd. | Method for determination of glucose concentration in whole blood |
US5262035A (en) | 1989-08-02 | 1993-11-16 | E. Heller And Company | Enzyme electrodes |
US5264104A (en) | 1989-08-02 | 1993-11-23 | Gregg Brian A | Enzyme electrodes |
US5264105A (en) | 1989-08-02 | 1993-11-23 | Gregg Brian A | Enzyme electrodes |
US5320725A (en) | 1989-08-02 | 1994-06-14 | E. Heller & Company | Electrode and method for the detection of hydrogen peroxide |
US5101814A (en) * | 1989-08-11 | 1992-04-07 | Palti Yoram Prof | System for monitoring and controlling blood glucose |
JP2517153B2 (en) | 1989-09-21 | 1996-07-24 | 松下電器産業株式会社 | Biosensor and manufacturing method thereof |
FR2652736A1 (en) | 1989-10-06 | 1991-04-12 | Neftel Frederic | IMPLANTABLE DEVICE FOR EVALUATING THE RATE OF GLUCOSE. |
DE69025134T2 (en) | 1989-11-24 | 1996-08-14 | Matsushita Electric Ind Co Ltd | Method of manufacturing a biosensor |
US5508171A (en) | 1989-12-15 | 1996-04-16 | Boehringer Mannheim Corporation | Assay method with enzyme electrode system |
US5109850A (en) | 1990-02-09 | 1992-05-05 | Massachusetts Institute Of Technology | Automatic blood monitoring for medication delivery method and apparatus |
US5161532A (en) | 1990-04-19 | 1992-11-10 | Teknekron Sensor Development Corporation | Integral interstitial fluid sensor |
US5165407A (en) | 1990-04-19 | 1992-11-24 | The University Of Kansas | Implantable glucose sensor |
DE4014109A1 (en) | 1990-05-02 | 1991-11-07 | Siemens Ag | ELECROCHEMICAL DETERMINATION OF THE OXYGEN CONCENTRATION |
US5250439A (en) | 1990-07-19 | 1993-10-05 | Miles Inc. | Use of conductive sensors in diagnostic assays |
US5202261A (en) | 1990-07-19 | 1993-04-13 | Miles Inc. | Conductive sensors and their use in diagnostic assays |
US5120421A (en) | 1990-08-31 | 1992-06-09 | The United States Of America As Represented By The United States Department Of Energy | Electrochemical sensor/detector system and method |
GB9019126D0 (en) | 1990-09-01 | 1990-10-17 | Cranfield Biotech Ltd | Electrochemical biosensor stability |
GB9024771D0 (en) | 1990-11-14 | 1991-01-02 | Axis Research | Assay |
NL9002764A (en) | 1990-12-14 | 1992-07-01 | Tno | ELECTRODE, FITTED WITH A POLYMER COATING WITH A REDOX ENZYM BOND TO IT. |
AU1356792A (en) | 1991-01-25 | 1992-08-27 | Markwell Medical Institute, Inc. | Implantable biological fluid measuring device |
US5262305A (en) | 1991-03-04 | 1993-11-16 | E. Heller & Company | Interferant eliminating biosensors |
JPH04278450A (en) | 1991-03-04 | 1992-10-05 | Adam Heller | Biosensor and method for analyzing subject |
US5208154A (en) | 1991-04-08 | 1993-05-04 | The United States Of America As Represented By The Department Of Energy | Reversibly immobilized biological materials in monolayer films on electrodes |
DE4126692C2 (en) | 1991-08-13 | 1995-05-11 | Bst Bio Sensor Tech Gmbh | Immunosensor device and method for determining antigens <2,000 daltons |
JPH0572171A (en) | 1991-09-12 | 1993-03-23 | Omron Corp | Enzyme electrode |
US5264103A (en) | 1991-10-18 | 1993-11-23 | Matsushita Electric Industrial Co., Ltd. | Biosensor and a method for measuring a concentration of a substrate in a sample |
US5217595A (en) | 1991-10-25 | 1993-06-08 | The Yellow Springs Instrument Company, Inc. | Electrochemical gas sensor |
US5271815A (en) | 1991-12-26 | 1993-12-21 | Via Medical Corporation | Method for measuring glucose |
WO1993013408A1 (en) | 1991-12-31 | 1993-07-08 | Abbott Laboratories | Composite membrane |
JP3084877B2 (en) | 1992-01-21 | 2000-09-04 | 松下電器産業株式会社 | Manufacturing method of glucose sensor |
NL9200207A (en) | 1992-02-05 | 1993-09-01 | Nedap Nv | IMPLANTABLE BIOMEDICAL SENSOR DEVICE, IN PARTICULAR FOR MEASUREMENT OF THE GLUCOSE CONCENTRATION. |
CA2591834C (en) | 1992-03-04 | 2009-04-28 | Abbott Laboratories | Determination of glycated hemoglobin by fluorescence quenching |
US5227042A (en) | 1992-05-15 | 1993-07-13 | The United States Of America As Represented By The United States Department Of Energy | Catalyzed enzyme electrodes |
US5580527A (en) | 1992-05-18 | 1996-12-03 | Moltech Corporation | Polymeric luminophores for sensing of oxygen |
GB9211402D0 (en) | 1992-05-29 | 1992-07-15 | Univ Manchester | Sensor devices |
IL102930A (en) * | 1992-08-25 | 1997-03-18 | Yissum Res Dev Co | Electrobiochemical analytical method and electrodes |
US5421816A (en) | 1992-10-14 | 1995-06-06 | Endodermic Medical Technologies Company | Ultrasonic transdermal drug delivery system |
ZA938555B (en) | 1992-11-23 | 1994-08-02 | Lilly Co Eli | Technique to improve the performance of electrochemical sensors |
DK148592D0 (en) | 1992-12-10 | 1992-12-10 | Novo Nordisk As | APPARATUS |
GB9304306D0 (en) | 1993-03-03 | 1993-04-21 | Univ Alberta | Glucose sensor |
DE4314417A1 (en) | 1993-05-03 | 1994-11-10 | Byk Gulden Italia Spa | Biosensor |
GB9309797D0 (en) | 1993-05-12 | 1993-06-23 | Medisense Inc | Electrochemical sensors |
US5364797A (en) | 1993-05-20 | 1994-11-15 | Mobil Oil Corp. | Sensor device containing mesoporous crystalline material |
DK0700520T3 (en) | 1993-05-29 | 1998-03-02 | Cambridge Life Sciences | Sensors based on polymer conversion |
DE4318519C2 (en) | 1993-06-03 | 1996-11-28 | Fraunhofer Ges Forschung | Electrochemical sensor |
DK0712492T3 (en) | 1993-07-14 | 1999-07-05 | Lion Lab Plc | fuel cells |
US5413690A (en) | 1993-07-23 | 1995-05-09 | Boehringer Mannheim Corporation | Potentiometric biosensor and the method of its use |
US5837546A (en) | 1993-08-24 | 1998-11-17 | Metrika, Inc. | Electronic assay device and method |
EP0644266A1 (en) | 1993-09-22 | 1995-03-22 | Siemens Aktiengesellschaft | Working electrode for electrochemical-enzymatical sensor systems |
US5582184A (en) | 1993-10-13 | 1996-12-10 | Integ Incorporated | Interstitial fluid collection and constituent measurement |
US5791344A (en) | 1993-11-19 | 1998-08-11 | Alfred E. Mann Foundation For Scientific Research | Patient monitoring system |
DE4344646A1 (en) | 1993-12-24 | 1995-06-29 | Frieder Prof Dr Scheller | Device for a competitive immuno-assay for the detection of hapten(s) |
US5478751A (en) | 1993-12-29 | 1995-12-26 | Abbott Laboratories | Self-venting immunodiagnositic devices and methods of performing assays |
US5589326A (en) | 1993-12-30 | 1996-12-31 | Boehringer Mannheim Corporation | Osmium-containing redox mediator |
US5320715A (en) | 1994-01-14 | 1994-06-14 | Lloyd Berg | Separation of 1-pentanol from cyclopentanol by extractive distillation |
CA2179309A1 (en) | 1994-02-09 | 1995-08-17 | Ted J. Hanagan | Diagnostic flow cell device |
FI95574C (en) | 1994-02-16 | 1996-02-26 | Valtion Teknillinen | Electron-conducting molecular preparations |
US5437999A (en) * | 1994-02-22 | 1995-08-01 | Boehringer Mannheim Corporation | Electrochemical sensor |
JP3061351B2 (en) | 1994-04-25 | 2000-07-10 | 松下電器産業株式会社 | Method and apparatus for quantifying specific compounds |
US5569186A (en) | 1994-04-25 | 1996-10-29 | Minimed Inc. | Closed loop infusion pump system with removable glucose sensor |
US5741688A (en) | 1994-05-03 | 1998-04-21 | Novo Nordisk A/S | Alkaline glucose oxidase obtained from cladosporium oxysporum |
DE4415896A1 (en) | 1994-05-05 | 1995-11-09 | Boehringer Mannheim Gmbh | Analysis system for monitoring the concentration of an analyte in the blood of a patient |
JP3027306B2 (en) | 1994-06-02 | 2000-04-04 | 松下電器産業株式会社 | Biosensor and manufacturing method thereof |
US5514253A (en) | 1994-07-13 | 1996-05-07 | I-Stat Corporation | Method of measuring gas concentrations and microfabricated sensing device for practicing same |
DE4430023A1 (en) | 1994-08-24 | 1996-02-29 | Boehringer Mannheim Gmbh | Electrochemical sensor |
US5526120A (en) | 1994-09-08 | 1996-06-11 | Lifescan, Inc. | Test strip with an asymmetrical end insuring correct insertion for measuring |
IE72524B1 (en) * | 1994-11-04 | 1997-04-23 | Elan Med Tech | Analyte-controlled liquid delivery device and analyte monitor |
US5804401A (en) | 1995-01-09 | 1998-09-08 | Board Of Trustees Operating Michigan State University | Device for detecting oxygen with oxidase |
US5568806A (en) | 1995-02-16 | 1996-10-29 | Minimed Inc. | Transcutaneous sensor insertion set |
US5586553A (en) | 1995-02-16 | 1996-12-24 | Minimed Inc. | Transcutaneous sensor insertion set |
US5651869A (en) | 1995-02-28 | 1997-07-29 | Matsushita Electric Industrial Co., Ltd. | Biosensor |
US5650062A (en) | 1995-03-17 | 1997-07-22 | Matsushita Electric Industrial Co., Ltd. | Biosensor, and a method and a device for quantifying a substrate in a sample liquid using the same |
US5582697A (en) | 1995-03-17 | 1996-12-10 | Matsushita Electric Industrial Co., Ltd. | Biosensor, and a method and a device for quantifying a substrate in a sample liquid using the same |
KR0156176B1 (en) | 1995-06-01 | 1998-12-01 | 구자홍 | Electrochemical immune biosensor |
US5695947A (en) | 1995-06-06 | 1997-12-09 | Biomedix, Inc. | Amperometric cholesterol biosensor |
US5567302A (en) | 1995-06-07 | 1996-10-22 | Molecular Devices Corporation | Electrochemical system for rapid detection of biochemical agents that catalyze a redox potential change |
AUPN363995A0 (en) | 1995-06-19 | 1995-07-13 | Memtec Limited | Electrochemical cell |
DE19530376C2 (en) | 1995-08-18 | 1999-09-02 | Fresenius Ag | Biosensor |
US5682233A (en) | 1995-09-08 | 1997-10-28 | Integ, Inc. | Interstitial fluid sampler |
US5628890A (en) | 1995-09-27 | 1997-05-13 | Medisense, Inc. | Electrochemical sensor |
US5665222A (en) | 1995-10-11 | 1997-09-09 | E. Heller & Company | Soybean peroxidase electrochemical sensor |
US5972199A (en) | 1995-10-11 | 1999-10-26 | E. Heller & Company | Electrochemical analyte sensors using thermostable peroxidase |
US5639672A (en) | 1995-10-16 | 1997-06-17 | Lxn Corporation | Electrochemical determination of fructosamine |
US5741211A (en) | 1995-10-26 | 1998-04-21 | Medtronic, Inc. | System and method for continuous monitoring of diabetes-related blood constituents |
AUPN661995A0 (en) | 1995-11-16 | 1995-12-07 | Memtec America Corporation | Electrochemical cell 2 |
JP3365184B2 (en) | 1996-01-10 | 2003-01-08 | 松下電器産業株式会社 | Biosensor |
US5830341A (en) | 1996-01-23 | 1998-11-03 | Gilmartin; Markas A. T. | Electrodes and metallo isoindole ringed compounds |
US5951492A (en) | 1996-05-17 | 1999-09-14 | Mercury Diagnostics, Inc. | Methods and apparatus for sampling and analyzing body fluid |
US5951493A (en) | 1997-05-16 | 1999-09-14 | Mercury Diagnostics, Inc. | Methods and apparatus for expressing body fluid from an incision |
DE69739783D1 (en) | 1996-05-17 | 2010-04-08 | Roche Diagnostics Operations | DEVICE FOR SAMPLING BODY FLUIDS |
AU3070397A (en) | 1996-05-17 | 1997-12-05 | Mercury Diagnostics Inc. | Methods and apparatus for sampling body fluid |
ES2297858T3 (en) | 1996-05-17 | 2008-05-01 | Roche Diagnostics Operations, Inc. | DISPOSABLE ELEMENT THAT IS USED IN A BODY LIQUID SAMPLING DEVICE. |
US5804048A (en) | 1996-08-15 | 1998-09-08 | Via Medical Corporation | Electrode assembly for assaying glucose |
US6063039A (en) | 1996-12-06 | 2000-05-16 | Abbott Laboratories | Method and apparatus for obtaining blood for diagnostic tests |
IT1294642B1 (en) | 1997-08-08 | 1999-04-12 | Nika Srl | METHOD FOR DETERMINING THE CONCENTRATION OF AN ANALYTE BY USING A BIO-ELEMENT AND OPERATING DEVICE ACCORDING TO |
US6054039A (en) | 1997-08-18 | 2000-04-25 | Shieh; Paul | Determination of glycoprotein and glycosylated hemoglobin in blood |
US6071391A (en) | 1997-09-12 | 2000-06-06 | Nok Corporation | Enzyme electrode structure |
US5906921A (en) | 1997-09-29 | 1999-05-25 | Matsushita Electric Industrial Co., Ltd. | Biosensor and method for quantitative measurement of a substrate using the same |
US6736957B1 (en) | 1997-10-16 | 2004-05-18 | Abbott Laboratories | Biosensor electrode mediators for regeneration of cofactors and process for using |
US5997817A (en) | 1997-12-05 | 1999-12-07 | Roche Diagnostics Corporation | Electrochemical biosensor test strip |
US6103033A (en) | 1998-03-04 | 2000-08-15 | Therasense, Inc. | Process for producing an electrochemical biosensor |
US6134461A (en) | 1998-03-04 | 2000-10-17 | E. Heller & Company | Electrochemical analyte |
US6500571B2 (en) | 1998-08-19 | 2002-12-31 | Powerzyme, Inc. | Enzymatic fuel cell |
DE19843094A1 (en) | 1998-09-21 | 2000-03-23 | Roche Diagnostics Gmbh | Method for the determination of glycated hemoglobin |
US6740215B1 (en) | 1999-11-16 | 2004-05-25 | Matsushita Electric Industrial Co., Ltd. | Biosensor |
ES2238254T3 (en) | 1999-12-27 | 2005-09-01 | Matsushita Electric Industrial Co., Ltd. | BIOSENSOR |
JP2001201479A (en) | 2000-01-21 | 2001-07-27 | Matsushita Electric Ind Co Ltd | Biosensor |
WO2001088524A1 (en) * | 2000-05-12 | 2001-11-22 | Therasense, Inc. | Electrodes with multilayer membranes and methods of using and making the electrodes |
US6442413B1 (en) * | 2000-05-15 | 2002-08-27 | James H. Silver | Implantable sensor |
PL359335A1 (en) | 2000-07-14 | 2004-08-23 | Lifescan Inc | Electrochemical method for measuring chemical reaction rates |
ES2331689T3 (en) | 2000-07-24 | 2010-01-13 | Panasonic Corporation | BIOSENSOR |
US7005273B2 (en) | 2001-05-16 | 2006-02-28 | Therasense, Inc. | Method for the determination of glycated hemoglobin |
US6766817B2 (en) | 2001-07-25 | 2004-07-27 | Tubarc Technologies, Llc | Fluid conduction utilizing a reversible unsaturated siphon with tubarc porosity action |
JP2003084101A (en) | 2001-09-17 | 2003-03-19 | Dainippon Printing Co Ltd | Resin composition for optical device, optical device and projection screen |
US7828728B2 (en) | 2003-07-25 | 2010-11-09 | Dexcom, Inc. | Analyte sensor |
US6908535B2 (en) * | 2002-03-06 | 2005-06-21 | Medtronic, Inc. | Current-to-voltage-converter for a biosensor |
US7736309B2 (en) | 2002-09-27 | 2010-06-15 | Medtronic Minimed, Inc. | Implantable sensor method and system |
US7501053B2 (en) | 2002-10-23 | 2009-03-10 | Abbott Laboratories | Biosensor having improved hematocrit and oxygen biases |
US20060269826A1 (en) * | 2003-03-03 | 2006-11-30 | Eugenii Katz | Novel electrode with switchable and tunable power output and fuel cell using such electrode |
US20050027175A1 (en) * | 2003-07-31 | 2005-02-03 | Zhongping Yang | Implantable biosensor |
AU2004284368B2 (en) * | 2003-10-29 | 2008-11-20 | Agency For Science, Technology And Research | Biosensor |
US20070045902A1 (en) | 2004-07-13 | 2007-03-01 | Brauker James H | Analyte sensor |
US7191013B1 (en) * | 2004-11-08 | 2007-03-13 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Hand held device for wireless powering and interrogation of biomems sensors and actuators |
US7826879B2 (en) * | 2006-02-28 | 2010-11-02 | Abbott Diabetes Care Inc. | Analyte sensors and methods of use |
US7620438B2 (en) * | 2006-03-31 | 2009-11-17 | Abbott Diabetes Care Inc. | Method and system for powering an electronic device |
WO2008049075A2 (en) * | 2006-10-18 | 2008-04-24 | Agamatrix, Inc. | Electrochemical determination of analytes |
US7752002B2 (en) * | 2008-05-30 | 2010-07-06 | Pacesetter, Inc. | Methods and apparatus for non-invasive implantable pressure sensor calibration |
US20100213057A1 (en) * | 2009-02-26 | 2010-08-26 | Benjamin Feldman | Self-Powered Analyte Sensor |
US20100331643A1 (en) | 2009-06-30 | 2010-12-30 | Abbott Diabetes Care Inc. | Extruded Analyte Sensors and Methods of Using Same |
CA2957676A1 (en) * | 2014-08-15 | 2016-02-18 | Abbott Diabetes Care Inc. | Temperature insensitive in vivo analyte devices, methods and systems |
-
2009
- 2009-02-26 US US12/393,921 patent/US20100213057A1/en not_active Abandoned
-
2010
- 2010-02-25 WO PCT/US2010/025436 patent/WO2010099335A1/en active Application Filing
- 2010-02-25 EP EP17183254.6A patent/EP3255154B1/en active Active
- 2010-02-25 EP EP22208507.8A patent/EP4219733A1/en active Pending
- 2010-02-25 EP EP10746844.9A patent/EP2401390B1/en active Active
- 2010-03-04 US US12/717,634 patent/US9668684B2/en active Active
-
2016
- 2016-11-14 US US15/351,162 patent/US10004441B2/en active Active
-
2018
- 2018-06-22 US US16/015,882 patent/US10631768B2/en active Active
Patent Citations (108)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3653841A (en) * | 1969-12-19 | 1972-04-04 | Hoffmann La Roche | Methods and compositions for determining glucose in blood |
US3719564A (en) * | 1971-05-10 | 1973-03-06 | Philip Morris Inc | Method of determining a reducible gas concentration and sensor therefor |
US3861397A (en) * | 1972-01-03 | 1975-01-21 | Siemens Ag | Implantable fuel cell |
US3837339A (en) * | 1972-02-03 | 1974-09-24 | Whittaker Corp | Blood glucose level monitoring-alarm system and method therefor |
US4008717A (en) * | 1973-01-15 | 1977-02-22 | The Johns Hopkins University | System for continuous withdrawal and analysis of blood |
US4016866A (en) * | 1975-12-18 | 1977-04-12 | General Electric Company | Implantable electrochemical sensor |
US4076596A (en) * | 1976-10-07 | 1978-02-28 | Leeds & Northrup Company | Apparatus for electrolytically determining a species in a fluid and method of use |
US4318784A (en) * | 1978-08-15 | 1982-03-09 | National Research Development Corporation | Enzymatic processes |
US4375399A (en) * | 1978-09-08 | 1983-03-01 | Radelkis Elektrokemiai Miszergyarto Szovetkezet | Molecule selective sensor for industrial use and procedure for its preparation |
US4247297A (en) * | 1979-02-23 | 1981-01-27 | Miles Laboratories, Inc. | Test means and method for interference resistant determination of oxidizing substances |
US4573994A (en) * | 1979-04-27 | 1986-03-04 | The Johns Hopkins University | Refillable medication infusion apparatus |
US4444892A (en) * | 1980-10-20 | 1984-04-24 | Malmros Mark K | Analytical device having semiconductive organic polymeric element associated with analyte-binding substance |
US4436812A (en) * | 1980-10-29 | 1984-03-13 | Fuji Electric Co., Ltd. | Process of calibrating a blood sugar analyzing apparatus |
US4420564A (en) * | 1980-11-21 | 1983-12-13 | Fuji Electric Company, Ltd. | Blood sugar analyzer having fixed enzyme membrane sensor |
US4436094A (en) * | 1981-03-09 | 1984-03-13 | Evreka, Inc. | Monitor for continuous in vivo measurement of glucose concentration |
US4440175A (en) * | 1981-08-10 | 1984-04-03 | University Patents, Inc. | Membrane electrode for non-ionic species |
US4431004A (en) * | 1981-10-27 | 1984-02-14 | Bessman Samuel P | Implantable glucose sensor |
US4581336A (en) * | 1982-04-26 | 1986-04-08 | Uop Inc. | Surface-modified electrodes |
US4427770A (en) * | 1982-06-14 | 1984-01-24 | Miles Laboratories, Inc. | High glucose-determining analytical element |
US4571292A (en) * | 1982-08-12 | 1986-02-18 | Case Western Reserve University | Apparatus for electrochemical measurements |
US4633878A (en) * | 1983-04-18 | 1987-01-06 | Guiseppe Bombardieri | Device for the automatic insulin or glucose infusion in diabetic subjects, based on the continuous monitoring of the patient's glucose, obtained without blood withdrawal |
US5727548A (en) * | 1983-05-05 | 1998-03-17 | Medisense, Inc. | Strip electrode with screen printing |
US4650547A (en) * | 1983-05-19 | 1987-03-17 | The Regents Of The University Of California | Method and membrane applicable to implantable sensor |
US4655880A (en) * | 1983-08-01 | 1987-04-07 | Case Western Reserve University | Apparatus and method for sensing species, substances and substrates using oxidase |
US4654197A (en) * | 1983-10-18 | 1987-03-31 | Aktiebolaget Leo | Cuvette for sampling and analysis |
US4820399A (en) * | 1984-08-31 | 1989-04-11 | Shimadzu Corporation | Enzyme electrodes |
US4717673A (en) * | 1984-11-23 | 1988-01-05 | Massachusetts Institute Of Technology | Microelectrochemical devices |
US4721601A (en) * | 1984-11-23 | 1988-01-26 | Massachusetts Institute Of Technology | Molecule-based microelectronic devices |
US4795707A (en) * | 1984-11-27 | 1989-01-03 | Hitachi, Ltd. | Electrochemical sensor having three layer membrane containing immobilized enzymes |
US4655885A (en) * | 1985-01-11 | 1987-04-07 | National Research Development Corporation | Surface-modified electrode and its use in a bioelectrochemical process |
US4820636A (en) * | 1985-02-21 | 1989-04-11 | Medisense, Inc. | Electrochemical assay for cis-diols |
US4637403A (en) * | 1985-04-08 | 1987-01-20 | Garid, Inc. | Glucose medical monitoring system |
US5185256A (en) * | 1985-06-21 | 1993-02-09 | Matsushita Electric Industrial Co., Ltd. | Method for making a biosensor |
US4897173A (en) * | 1985-06-21 | 1990-01-30 | Matsushita Electric Industrial Co., Ltd. | Biosensor and method for making the same |
US4805624A (en) * | 1985-09-09 | 1989-02-21 | The Montefiore Hospital Association Of Western Pa | Low-potential electrochemical redox sensors |
US4890620A (en) * | 1985-09-20 | 1990-01-02 | The Regents Of The University Of California | Two-dimensional diffusion glucose substrate sensing electrode |
US4726378A (en) * | 1986-04-11 | 1988-02-23 | Minnesota Mining And Manufacturing Company | Adjustable magnetic supercutaneous device and transcutaneous coupling apparatus |
US4994167A (en) * | 1986-04-15 | 1991-02-19 | Markwell Medical Institute, Inc. | Biological fluid measuring device |
US4909908A (en) * | 1986-04-24 | 1990-03-20 | Pepi Ross | Electrochemical cncentration detector method |
US4911794A (en) * | 1986-06-20 | 1990-03-27 | Molecular Devices Corporation | Measuring with zero volume cell |
US4894253A (en) * | 1986-08-12 | 1990-01-16 | University Of Cincinnati | Method for production of coated electrode |
US4894137A (en) * | 1986-09-12 | 1990-01-16 | Omron Tateisi Electronics Co. | Enzyme electrode |
US4897162A (en) * | 1986-11-14 | 1990-01-30 | The Cleveland Clinic Foundation | Pulse voltammetry |
US4806468A (en) * | 1987-02-05 | 1989-02-21 | Becton, Dickinson And Company | Measurement of glycosylated hemoglobin by immunoassay |
US5286364A (en) * | 1987-06-08 | 1994-02-15 | Rutgers University | Surface-modified electochemical biosensor |
US4822337A (en) * | 1987-06-22 | 1989-04-18 | Stanley Newhouse | Insulin delivery method and apparatus |
US5096836A (en) * | 1987-06-27 | 1992-03-17 | Boehringer Mannheim Gmbh | Diagnostic test carrier |
US4815469A (en) * | 1987-10-08 | 1989-03-28 | Siemens-Pacesetter, Inc. | Implantable blood oxygen sensor and method of use |
US5082786A (en) * | 1987-11-26 | 1992-01-21 | Nec Corporation | Glucose sensor with gel-immobilized glucose oxidase and gluconolactonase |
US4813424A (en) * | 1987-12-23 | 1989-03-21 | University Of New Mexico | Long-life membrane electrode for non-ionic species |
US5094951A (en) * | 1988-06-21 | 1992-03-10 | Chiron Corporation | Production of glucose oxidase in recombinant systems |
US5089112A (en) * | 1989-03-20 | 1992-02-18 | Associated Universities, Inc. | Electrochemical biosensor based on immobilized enzymes and redox polymers |
US5096560A (en) * | 1989-05-30 | 1992-03-17 | Mitsubishi Petrochemical Co., Ltd. | Electrode for electrochemical detectors |
US5198367A (en) * | 1989-06-09 | 1993-03-30 | Masuo Aizawa | Homogeneous amperometric immunoassay |
US4986271A (en) * | 1989-07-19 | 1991-01-22 | The University Of New Mexico | Vivo refillable glucose sensor |
US5082550A (en) * | 1989-12-11 | 1992-01-21 | The United States Of America As Represented By The Department Of Energy | Enzyme electrochemical sensor electrode and method of making it |
US5288636A (en) * | 1989-12-15 | 1994-02-22 | Boehringer Mannheim Corporation | Enzyme electrode system |
US5078854A (en) * | 1990-01-22 | 1992-01-07 | Mallinckrodt Sensor Systems, Inc. | Polarographic chemical sensor with external reference electrode |
US5286362A (en) * | 1990-02-03 | 1994-02-15 | Boehringer Mannheim Gmbh | Method and sensor electrode system for the electrochemical determination of an analyte or an oxidoreductase as well as the use of suitable compounds therefor |
US5501956A (en) * | 1990-03-23 | 1996-03-26 | Molecular Devices Corporation | Polyredox couples in analyte determinations |
US5378628A (en) * | 1991-02-21 | 1995-01-03 | Asulab, S.A. | Sensor for measuring the amount of a component in solution |
US5393903A (en) * | 1991-02-21 | 1995-02-28 | Asulab S.A. | Mono, bis or tris(substituted 2,2'-bipyridine) iron, ruthenium, osmium or vanadium complexes and their methods of preparation |
US5192415A (en) * | 1991-03-04 | 1993-03-09 | Matsushita Electric Industrial Co., Ltd. | Biosensor utilizing enzyme and a method for producing the same |
US5192416A (en) * | 1991-04-09 | 1993-03-09 | New Mexico State University Technology Transfer Corporation | Method and apparatus for batch injection analysis |
US5293546A (en) * | 1991-04-17 | 1994-03-08 | Martin Marietta Corporation | Oxide coated metal grid electrode structure in display devices |
US5382346A (en) * | 1991-05-17 | 1995-01-17 | Kyoto Daiichi Kagaku Co., Ltd. | Biosensor and method of quantitative analysis using the same |
US5496453A (en) * | 1991-05-17 | 1996-03-05 | Kyoto Daiichi Kagaku Co., Ltd. | Biosensor and method of quantitative analysis using the same |
US5380422A (en) * | 1991-07-18 | 1995-01-10 | Agency Of Industrial Science And Technology | Micro-electrode and method for preparing it |
US5278079A (en) * | 1992-09-02 | 1994-01-11 | Enzymatics, Inc. | Sealing device and method for inhibition of flow in capillary measuring devices |
US5387327A (en) * | 1992-10-19 | 1995-02-07 | Duquesne University Of The Holy Ghost | Implantable non-enzymatic electrochemical glucose sensor |
US5395504A (en) * | 1993-02-04 | 1995-03-07 | Asulab S.A. | Electrochemical measuring system with multizone sensors |
US5595479A (en) * | 1993-04-05 | 1997-01-21 | Danfoss A/S | Hydraulic machine having teeth formed by rollers |
US5497772A (en) * | 1993-11-19 | 1996-03-12 | Alfred E. Mann Foundation For Scientific Research | Glucose monitoring system |
US5593852A (en) * | 1993-12-02 | 1997-01-14 | Heller; Adam | Subcutaneous glucose electrode |
US5609749A (en) * | 1993-12-29 | 1997-03-11 | Mochida Pharmaceutical Co., Ltd. | Electrochemical assay method with novel p-phenylenediamine compound |
US5390671A (en) * | 1994-03-15 | 1995-02-21 | Minimed Inc. | Transcutaneous sensor insertion set |
US5391250A (en) * | 1994-03-15 | 1995-02-21 | Minimed Inc. | Method of fabricating thin film sensors |
US5494562A (en) * | 1994-06-27 | 1996-02-27 | Ciba Corning Diagnostics Corp. | Electrochemical sensors |
US5596150A (en) * | 1995-03-08 | 1997-01-21 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Capacitance probe for fluid flow and volume measurements |
US5711862A (en) * | 1995-03-15 | 1998-01-27 | Omron Corporation | Portable biochemical measurement device using an enzyme sensor |
US5720862A (en) * | 1995-04-07 | 1998-02-24 | Kyoto Daiichi Kagaku Co., Ltd. | Sensor and production method of and measurement method using the same |
US5711861A (en) * | 1995-11-22 | 1998-01-27 | Ward; W. Kenneth | Device for monitoring changes in analyte concentration |
US5708247A (en) * | 1996-02-14 | 1998-01-13 | Selfcare, Inc. | Disposable glucose test strips, and methods and compositions for making same |
US5667653A (en) * | 1996-03-15 | 1997-09-16 | Mine Safety Appliances Company | Electrochemical sensor |
US5879311A (en) * | 1996-05-17 | 1999-03-09 | Mercury Diagnostics, Inc. | Body fluid sampling device and methods of use |
US5857983A (en) * | 1996-05-17 | 1999-01-12 | Mercury Diagnostics, Inc. | Methods and apparatus for sampling body fluid |
US5888787A (en) * | 1996-07-02 | 1999-03-30 | North Carolina State University | Selective enzymatic oxidation of aromatic methyl groups to aldehydes by oxygen in the presence of a laccase-mediator catalyst |
US20090000961A1 (en) * | 1997-02-06 | 2009-01-01 | Adam Heller | Small Volume in Vitro Analyte Sensor |
US6174734B1 (en) * | 1997-10-24 | 2001-01-16 | Abbott Laboratories | Measurement of glycated hemoglobin |
US6033866A (en) * | 1997-12-08 | 2000-03-07 | Biomedix, Inc. | Highly sensitive amperometric bi-mediator-based glucose biosensor |
US6175752B1 (en) * | 1998-04-30 | 2001-01-16 | Therasense, Inc. | Analyte monitoring device and methods of use |
US20040236200A1 (en) * | 1998-04-30 | 2004-11-25 | James Say | Analyte monitoring device and methods of use |
US6352824B1 (en) * | 1998-06-01 | 2002-03-05 | Roche Diagnostics Corporation | Redox reversible bipyridyl-osmium complex conjugates |
US6531239B2 (en) * | 1998-06-17 | 2003-03-11 | Therasense, Inc. | Biological fuel cell and methods |
US7171252B1 (en) * | 1998-09-30 | 2007-01-30 | Sicel Technologies, Inc. | Methods, computer program products, and devices for calibrating chronically tissue implanted sensors using chronically tissue |
US6338790B1 (en) * | 1998-10-08 | 2002-01-15 | Therasense, Inc. | Small volume in vitro analyte sensor with diffusible or non-leachable redox mediator |
US6206835B1 (en) * | 1999-03-24 | 2001-03-27 | The B. F. Goodrich Company | Remotely interrogated diagnostic implant device with electrically passive sensor |
US20030042137A1 (en) * | 2001-05-15 | 2003-03-06 | Therasense, Inc. | Biosensor membranes composed of polymers containing heterocyclic nitrogens |
US7485212B2 (en) * | 2001-08-29 | 2009-02-03 | Yissum Reseach Development Company Of The Hebrew University Of Jerusalem | Self-powered biosensor |
US20040245101A1 (en) * | 2001-08-29 | 2004-12-09 | Itamar Willner | Self-powered biosensor |
US20030148169A1 (en) * | 2002-02-04 | 2003-08-07 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Biosensor carrying redox enzymes |
US20080044721A1 (en) * | 2002-05-02 | 2008-02-21 | Adam Heller | Miniature biological fuel cell that is operational under physiological conditions, and associated devices and methods |
US7018755B2 (en) * | 2002-09-24 | 2006-03-28 | Ricoh Company, Ltd. | Electrophotographic photoconductor, electrophotography method using the same, electrophotographic apparatus, electrographic apparatus process cartridge and electrophotographic photoconductor outermost surface layer coating solution |
US20040122489A1 (en) * | 2002-12-23 | 2004-06-24 | Cardiac Pacemakers, Inc. | Implantable medical device having long-term wireless capabilities |
US20070038054A1 (en) * | 2004-05-20 | 2007-02-15 | Peter Zhou | Embedded bio-sensor system |
US20050261562A1 (en) * | 2004-05-20 | 2005-11-24 | Peter Zhou | Embedded bio-sensor system |
US7410709B2 (en) * | 2004-06-24 | 2008-08-12 | Purdue Research Foundation | Bio-battery |
US20090018425A1 (en) * | 2005-12-28 | 2009-01-15 | Tianmei Ouyang | Analyte monitoring: stabilizer for subcutaneous glucose sensor with incorporated antiglycolytic agent |
Non-Patent Citations (1)
Title |
---|
Song et al. "Electrocatalytic Oxygen Reduction Reaction." PEM Fuel Cell Electrocatalysts and Catalyst Layers Fundamentals and Applications. Zhang, Jiujun (Ed.) 1st Edition., 2008, XXII, 1137 pages. * |
Cited By (215)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11627900B2 (en) | 2003-12-05 | 2023-04-18 | Dexcom, Inc. | Analyte sensor |
US11020031B1 (en) | 2003-12-05 | 2021-06-01 | Dexcom, Inc. | Analyte sensor |
US11000215B1 (en) | 2003-12-05 | 2021-05-11 | Dexcom, Inc. | Analyte sensor |
US11160475B2 (en) | 2004-12-29 | 2021-11-02 | Abbott Diabetes Care Inc. | Sensor inserter having introducer |
US10226207B2 (en) | 2004-12-29 | 2019-03-12 | Abbott Diabetes Care Inc. | Sensor inserter having introducer |
US11298058B2 (en) | 2005-12-28 | 2022-04-12 | Abbott Diabetes Care Inc. | Method and apparatus for providing analyte sensor insertion |
US10307091B2 (en) | 2005-12-28 | 2019-06-04 | Abbott Diabetes Care Inc. | Method and apparatus for providing analyte sensor insertion |
US10903914B2 (en) | 2006-10-26 | 2021-01-26 | Abbott Diabetes Care Inc. | Method, system and computer program product for real-time detection of sensitivity decline in analyte sensors |
US11722229B2 (en) | 2006-10-26 | 2023-08-08 | Abbott Diabetes Care Inc. | Method, system and computer program product for real-time detection of sensitivity decline in analyte sensors |
US9882660B2 (en) | 2006-10-26 | 2018-01-30 | Abbott Diabetes Care Inc. | Method, system and computer program product for real-time detection of sensitivity decline in analyte sensors |
US10617823B2 (en) | 2007-02-15 | 2020-04-14 | Abbott Diabetes Care Inc. | Device and method for automatic data acquisition and/or detection |
US10022499B2 (en) | 2007-02-15 | 2018-07-17 | Abbott Diabetes Care Inc. | Device and method for automatic data acquisition and/or detection |
US11678821B2 (en) | 2007-06-29 | 2023-06-20 | Abbott Diabetes Care Inc. | Analyte monitoring and management device and method to analyze the frequency of user interaction with the device |
US10856785B2 (en) | 2007-06-29 | 2020-12-08 | Abbott Diabetes Care Inc. | Analyte monitoring and management device and method to analyze the frequency of user interaction with the device |
US9913600B2 (en) | 2007-06-29 | 2018-03-13 | Abbott Diabetes Care Inc. | Analyte monitoring and management device and method to analyze the frequency of user interaction with the device |
US9541556B2 (en) | 2008-05-30 | 2017-01-10 | Abbott Diabetes Care Inc. | Method and apparatus for providing glycemic control |
US9795328B2 (en) | 2008-05-30 | 2017-10-24 | Abbott Diabetes Care Inc. | Method and apparatus for providing glycemic control |
US9931075B2 (en) | 2008-05-30 | 2018-04-03 | Abbott Diabetes Care Inc. | Method and apparatus for providing glycemic control |
US11735295B2 (en) | 2008-05-30 | 2023-08-22 | Abbott Diabetes Care Inc. | Method and apparatus for providing glycemic control |
US10327682B2 (en) | 2008-05-30 | 2019-06-25 | Abbott Diabetes Care Inc. | Method and apparatus for providing glycemic control |
US9417205B2 (en) | 2008-07-17 | 2016-08-16 | Abbott Diabetes Care Inc. | Analyte measurement devices and systems, and components and methods related thereto |
US9645105B2 (en) | 2008-07-17 | 2017-05-09 | Abbott Diabetes Care Inc. | Analyte measurement devices and systems, and components and methods related thereto |
US20100064800A1 (en) * | 2008-07-17 | 2010-03-18 | Abbott Diabetes Care Inc. | Strip connectors for measurement devices |
US10980461B2 (en) | 2008-11-07 | 2021-04-20 | Dexcom, Inc. | Advanced analyte sensor calibration and error detection |
US11272890B2 (en) | 2008-11-10 | 2022-03-15 | Abbott Diabetes Care Inc. | Alarm characterization for analyte monitoring devices and systems |
US9326707B2 (en) | 2008-11-10 | 2016-05-03 | Abbott Diabetes Care Inc. | Alarm characterization for analyte monitoring devices and systems |
US9730650B2 (en) | 2008-11-10 | 2017-08-15 | Abbott Diabetes Care Inc. | Alarm characterization for analyte monitoring devices and systems |
US11678848B2 (en) | 2008-11-10 | 2023-06-20 | Abbott Diabetes Care Inc. | Alarm characterization for analyte monitoring devices and systems |
US11006871B2 (en) | 2009-02-03 | 2021-05-18 | Abbott Diabetes Care Inc. | Analyte sensor and apparatus for insertion of the sensor |
WO2010091028A1 (en) | 2009-02-03 | 2010-08-12 | Abbott Diabetes Care Inc. | Compact on-body physiological monitoring devices and methods thereof |
US11202591B2 (en) | 2009-02-03 | 2021-12-21 | Abbott Diabetes Care Inc. | Analyte sensor and apparatus for insertion of the sensor |
US11006870B2 (en) | 2009-02-03 | 2021-05-18 | Abbott Diabetes Care Inc. | Analyte sensor and apparatus for insertion of the sensor |
US11006872B2 (en) | 2009-02-03 | 2021-05-18 | Abbott Diabetes Care Inc. | Analyte sensor and apparatus for insertion of the sensor |
US11213229B2 (en) | 2009-02-03 | 2022-01-04 | Abbott Diabetes Care Inc. | Analyte sensor and apparatus for insertion of the sensor |
US11166656B2 (en) | 2009-02-03 | 2021-11-09 | Abbott Diabetes Care Inc. | Analyte sensor and apparatus for insertion of the sensor |
US9526453B2 (en) | 2009-02-26 | 2016-12-27 | Abbott Diabetes Care Inc. | Analyte monitoring devices and methods |
US9724029B2 (en) | 2009-02-26 | 2017-08-08 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods |
US20180296139A1 (en) * | 2009-02-26 | 2018-10-18 | Abbott Diabetes Care Inc. | Self-powered analyte sensor |
US9339229B2 (en) | 2009-02-26 | 2016-05-17 | Abbott Diabetes Care Inc. | Analyte monitoring devices and methods |
US10631768B2 (en) * | 2009-02-26 | 2020-04-28 | Abbott Diabetes Inc. | Self-powered analyte sensor |
US8965477B2 (en) | 2009-02-26 | 2015-02-24 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods |
US10022077B2 (en) | 2009-02-26 | 2018-07-17 | Abbott Diabeetes Care Inc. | Analyte monitoring devices and methods |
US11872370B2 (en) | 2009-05-29 | 2024-01-16 | Abbott Diabetes Care Inc. | Medical device antenna systems having external antenna configurations |
US11793936B2 (en) | 2009-05-29 | 2023-10-24 | Abbott Diabetes Care Inc. | Medical device antenna systems having external antenna configurations |
US9795326B2 (en) | 2009-07-23 | 2017-10-24 | Abbott Diabetes Care Inc. | Continuous analyte measurement systems and systems and methods for implanting them |
US10827954B2 (en) | 2009-07-23 | 2020-11-10 | Abbott Diabetes Care Inc. | Continuous analyte measurement systems and systems and methods for implanting them |
US11730429B2 (en) | 2009-08-31 | 2023-08-22 | Abbott Diabetes Care Inc. | Displays for a medical device |
US10492685B2 (en) | 2009-08-31 | 2019-12-03 | Abbott Diabetes Care Inc. | Medical devices and methods |
US10136816B2 (en) | 2009-08-31 | 2018-11-27 | Abbott Diabetes Care Inc. | Medical devices and methods |
USD1010133S1 (en) | 2009-08-31 | 2024-01-02 | Abbott Diabetes Care Inc. | Analyte sensor assembly |
US11202586B2 (en) | 2009-08-31 | 2021-12-21 | Abbott Diabetes Care Inc. | Displays for a medical device |
US11241175B2 (en) | 2009-08-31 | 2022-02-08 | Abbott Diabetes Care Inc. | Displays for a medical device |
US10117606B2 (en) | 2009-10-30 | 2018-11-06 | Abbott Diabetes Care Inc. | Method and apparatus for detecting false hypoglycemic conditions |
US12048530B2 (en) | 2009-10-30 | 2024-07-30 | Abbott Diabetes Care Inc. | Method and apparatus for detecting false hypoglycemic conditions |
US11207005B2 (en) | 2009-10-30 | 2021-12-28 | Abbott Diabetes Care Inc. | Method and apparatus for detecting false hypoglycemic conditions |
US8828330B2 (en) | 2010-01-28 | 2014-09-09 | Abbott Diabetes Care Inc. | Universal test strip port |
US9291591B2 (en) | 2010-01-28 | 2016-03-22 | Abbott Diabetes Care Inc. | Universal test strip port |
US20110184264A1 (en) * | 2010-01-28 | 2011-07-28 | Abbott Diabetes Care Inc. | Universal Test Strip Port |
US9220451B2 (en) * | 2010-03-11 | 2015-12-29 | Roche Diabetes Care, Inc. | Method and fuel cell for electrochemical measurement of analyte concentration in vivo |
CN102781308A (en) * | 2010-03-11 | 2012-11-14 | 霍夫曼-拉罗奇有限公司 | Method for the electrochemical measurement of an analyte concentration in vivo, and fuel cell for this purpose |
US9709520B2 (en) | 2010-03-11 | 2017-07-18 | Roche Diabetes Care, Inc. | Method and fuel cell for electrochemical measurement of analyte concentration in vivo |
EP4066731A1 (en) | 2010-03-24 | 2022-10-05 | Abbott Diabetes Care, Inc. | Medical device inserters |
EP3622883A1 (en) | 2010-03-24 | 2020-03-18 | Abbott Diabetes Care, Inc. | Medical device inserters and processes of inserting and using medical devices |
EP3766408A1 (en) | 2010-03-24 | 2021-01-20 | Abbott Diabetes Care, Inc. | Medical device inserters and processes of inserting and using medical devices |
WO2011119896A1 (en) | 2010-03-24 | 2011-09-29 | Abbott Diabetes Care Inc. | Medical device inserters and processes of inserting and using medical devices |
EP4245220A2 (en) | 2010-03-24 | 2023-09-20 | Abbott Diabetes Care, Inc. | Medical device inserters |
EP4248866A2 (en) | 2010-03-24 | 2023-09-27 | Abbott Diabetes Care, Inc. | Medical device inserters |
US11992313B2 (en) | 2010-04-16 | 2024-05-28 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods |
US9320432B2 (en) | 2010-04-16 | 2016-04-26 | Abbott Diabetes Care Inc. | Analyte meter communication module |
US10285632B2 (en) | 2010-04-16 | 2019-05-14 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods |
US11169794B2 (en) | 2010-05-24 | 2021-11-09 | Abbott Diabetes Care Inc. | Systems and methods for updating a medical device |
US10255055B2 (en) | 2010-05-24 | 2019-04-09 | Abbott Diabetes Care Inc. | Systems and methods for updating a medical device |
US9501272B2 (en) | 2010-05-24 | 2016-11-22 | Abbott Diabetes Care Inc. | Systems and methods for updating a medical device |
US11748088B2 (en) | 2010-05-24 | 2023-09-05 | Abbott Diabetes Care Inc. | Systems and methods for updating a medical device |
US10966644B2 (en) | 2010-06-29 | 2021-04-06 | Abbott Diabetes Care Inc. | Devices, systems and methods for on-skin or on-body mounting of medical devices |
US9572534B2 (en) | 2010-06-29 | 2017-02-21 | Abbott Diabetes Care Inc. | Devices, systems and methods for on-skin or on-body mounting of medical devices |
US10092229B2 (en) | 2010-06-29 | 2018-10-09 | Abbott Diabetes Care Inc. | Calibration of analyte measurement system |
US11478173B2 (en) | 2010-06-29 | 2022-10-25 | Abbott Diabetes Care Inc. | Calibration of analyte measurement system |
US10874338B2 (en) | 2010-06-29 | 2020-12-29 | Abbott Diabetes Care Inc. | Devices, systems and methods for on-skin or on-body mounting of medical devices |
US10959653B2 (en) | 2010-06-29 | 2021-03-30 | Abbott Diabetes Care Inc. | Devices, systems and methods for on-skin or on-body mounting of medical devices |
US11064921B2 (en) | 2010-06-29 | 2021-07-20 | Abbott Diabetes Care Inc. | Devices, systems and methods for on-skin or on-body mounting of medical devices |
US10973449B2 (en) | 2010-06-29 | 2021-04-13 | Abbott Diabetes Care Inc. | Devices, systems and methods for on-skin or on-body mounting of medical devices |
US11175269B1 (en) | 2010-09-17 | 2021-11-16 | Hrl Laboratories, Llc | Substance detection device and method |
US9625410B1 (en) * | 2010-09-17 | 2017-04-18 | Hrl Laboratories, Llc | Substance detection device and method |
US10267779B1 (en) | 2010-09-17 | 2019-04-23 | Hrl Laboratories, Llc | Substance detection device and method |
WO2012048168A2 (en) | 2010-10-07 | 2012-04-12 | Abbott Diabetes Care Inc. | Analyte monitoring devices and methods |
US9952172B2 (en) | 2010-10-26 | 2018-04-24 | Abbott Diabetes Care Inc. | Analyte measurement devices and systems, and components and methods related thereto |
US8632731B2 (en) | 2010-10-26 | 2014-01-21 | Abbott Diabetes Care Inc. | Analyte measurement devices and systems, and components and methods related thereto |
US8475732B2 (en) | 2010-10-26 | 2013-07-02 | Abbott Diabetes Care Inc. | Analyte measurement devices and systems, and components and methods related thereto |
WO2012058237A1 (en) | 2010-10-26 | 2012-05-03 | Abbott Diabetes Care Inc. | Analyte measurement devices and systems, and components and methods related thereto |
WO2012068393A1 (en) * | 2010-11-18 | 2012-05-24 | Abbott Diabetes Care Inc. | Adaptor for on-body analyte monitoring system |
US9770202B2 (en) | 2010-11-22 | 2017-09-26 | Abbott Diabetes Care Inc. | Modular analyte measurement system with extendable strip port |
US9465034B2 (en) | 2010-11-22 | 2016-10-11 | Abbott Diabetes Care Inc. | Modular analyte measurement system with extendable strip port |
US9103777B2 (en) | 2010-11-22 | 2015-08-11 | Abbott Diabetes Care Inc. | Modular analyte measurement system with extendable strip port |
US8702928B2 (en) | 2010-11-22 | 2014-04-22 | Abbott Diabetes Care Inc. | Modular analyte measurement system with extendable strip port |
US9713440B2 (en) | 2010-12-08 | 2017-07-25 | Abbott Diabetes Care Inc. | Modular analyte measurement systems, modular components thereof and related methods |
US12042275B2 (en) | 2010-12-09 | 2024-07-23 | Abbott Diabetes Care Inc. | Analyte sensors with a sensing surface having small sensing spots |
US10327677B2 (en) | 2010-12-09 | 2019-06-25 | Abbott Diabetes Care Inc. | Analyte sensors with a sensing surface having small sensing spots |
US11457840B2 (en) | 2010-12-09 | 2022-10-04 | Abbott Diabetes Care Inc. | Analyte sensors with a sensing surface having small sensing spots |
WO2012078908A1 (en) | 2010-12-09 | 2012-06-14 | Abbott Diabetes Care Inc. | Analyte sensors with a sensing surface having small sensing spots |
US12029554B2 (en) | 2010-12-09 | 2024-07-09 | Abbott Diabetes Care Inc. | Analyte sensors with a sensing surface having small sensing spots |
EP3954781A1 (en) | 2010-12-09 | 2022-02-16 | Abbott Diabetes Care, Inc. | Analyte sensors with a sensing surface having small sensing spots |
US10923218B2 (en) | 2011-02-11 | 2021-02-16 | Abbott Diabetes Care Inc. | Data synchronization between two or more analyte detecting devices in a database |
US9760679B2 (en) | 2011-02-11 | 2017-09-12 | Abbott Diabetes Care Inc. | Data synchronization between two or more analyte detecting devices in a database |
US11017890B2 (en) | 2011-02-11 | 2021-05-25 | Abbott Diabetes Care Inc. | Systems and methods for aggregating analyte data |
US10872696B2 (en) | 2011-02-11 | 2020-12-22 | Abbott Diabetes Care Inc. | Method of hypoglycemia risk determination |
US9913599B2 (en) | 2011-02-11 | 2018-03-13 | Abbott Diabetes Care Inc. | Software applications residing on handheld analyte determining devices |
US9532737B2 (en) | 2011-02-28 | 2017-01-03 | Abbott Diabetes Care Inc. | Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same |
US10010273B2 (en) | 2011-03-10 | 2018-07-03 | Abbott Diabetes Care, Inc. | Multi-function analyte monitor device and methods of use |
US10682084B2 (en) | 2011-04-15 | 2020-06-16 | Dexcom, Inc. | Advanced analyte sensor calibration and error detection |
US10610141B2 (en) | 2011-04-15 | 2020-04-07 | Dexcom, Inc. | Advanced analyte sensor calibration and error detection |
US10555695B2 (en) | 2011-04-15 | 2020-02-11 | Dexcom, Inc. | Advanced analyte sensor calibration and error detection |
US10561354B2 (en) | 2011-04-15 | 2020-02-18 | Dexcom, Inc. | Advanced analyte sensor calibration and error detection |
US10624568B2 (en) | 2011-04-15 | 2020-04-21 | Dexcom, Inc. | Advanced analyte sensor calibration and error detection |
US10835162B2 (en) | 2011-04-15 | 2020-11-17 | Dexcom, Inc. | Advanced analyte sensor calibration and error detection |
US10722162B2 (en) | 2011-04-15 | 2020-07-28 | Dexcom, Inc. | Advanced analyte sensor calibration and error detection |
US11033211B2 (en) | 2011-04-20 | 2021-06-15 | Abbott Diabetes Care Inc. | Analyte monitoring devices and methods |
US9380965B2 (en) | 2011-05-20 | 2016-07-05 | Abbott Diabetes Care Inc. | Analyte sensors having a membrane with low temperature sensitivity |
US9775544B2 (en) | 2011-05-20 | 2017-10-03 | Abbott Diabetes Care Inc. | Analyte sensors having a membrane with low temperature sensitivity |
US9492108B2 (en) | 2011-05-20 | 2016-11-15 | Abbott Diabetes Care Inc. | Analyte sensors having a membrane with low temperature sensitivity |
WO2013039455A1 (en) * | 2011-09-13 | 2013-03-21 | Nanyang Technological University | Amperometric sensor |
WO2013040079A1 (en) * | 2011-09-13 | 2013-03-21 | Dose Medical Corporation | Intraocular physiological sensor |
US11564569B2 (en) | 2011-09-13 | 2023-01-31 | Glaukos Corporation | Intraocular physiological sensor |
US11363951B2 (en) | 2011-09-13 | 2022-06-21 | Glaukos Corporation | Intraocular physiological sensor |
EP3659495A1 (en) * | 2011-09-13 | 2020-06-03 | Dose Medical Corporation | Intraocular physiological sensor |
US11087868B2 (en) | 2011-09-28 | 2021-08-10 | Abbott Diabetes Care Inc. | Methods, devices and systems for analyte monitoring management |
EP3381360A1 (en) | 2011-09-28 | 2018-10-03 | Abbott Diabetes Care, Inc. | Methods, devices and systems for analyte monitoring management |
EP4060673A1 (en) | 2011-09-28 | 2022-09-21 | Abbott Diabetes Care, Inc. | Methods, devices and systems for analyte monitoring management |
USD680454S1 (en) | 2011-10-25 | 2013-04-23 | Abbott Diabetes Care Inc. | Analyte meter and strip port |
US9622691B2 (en) | 2011-10-31 | 2017-04-18 | Abbott Diabetes Care Inc. | Model based variable risk false glucose threshold alarm prevention mechanism |
US9465420B2 (en) | 2011-10-31 | 2016-10-11 | Abbott Diabetes Care Inc. | Electronic devices having integrated reset systems and methods thereof |
US11406331B2 (en) | 2011-10-31 | 2022-08-09 | Abbott Diabetes Care Inc. | Model based variable risk false glucose threshold alarm prevention mechanism |
US9069536B2 (en) | 2011-10-31 | 2015-06-30 | Abbott Diabetes Care Inc. | Electronic devices having integrated reset systems and methods thereof |
US9913619B2 (en) | 2011-10-31 | 2018-03-13 | Abbott Diabetes Care Inc. | Model based variable risk false glucose threshold alarm prevention mechanism |
US9462970B2 (en) | 2012-04-24 | 2016-10-11 | Abbott Diabetes Care Inc. | Methods of lag-compensation for analyte measurements, and devices related thereto |
WO2013163342A1 (en) | 2012-04-24 | 2013-10-31 | Abbott Diabetes Care Inc. | Methods of lag-compensation for analyte measurements, and devices related thereto |
EP3777664A1 (en) | 2012-04-24 | 2021-02-17 | Abbott Diabetes Care, Inc. | Methods of lag-compensation for analyte measurements, and devices related thereto thereto |
US10561372B2 (en) | 2012-04-24 | 2020-02-18 | Abbott Diabetes Care Inc. | Methods of lag-compensation for analyte measurements, and devices related thereto |
US10004439B2 (en) | 2012-09-21 | 2018-06-26 | Abbott Diabetes Care Inc. | In vivo sensors having ceria nanoparticle electrodes |
US10006880B2 (en) | 2012-09-21 | 2018-06-26 | Abbott Diabetes Care Inc. | Test strips having ceria nanoparticle electrodes |
US9907492B2 (en) | 2012-09-26 | 2018-03-06 | Abbott Diabetes Care Inc. | Method and apparatus for improving lag correction during in vivo measurement of analyte concentration with analyte concentration variability and range data |
US10842420B2 (en) | 2012-09-26 | 2020-11-24 | Abbott Diabetes Care Inc. | Method and apparatus for improving lag correction during in vivo measurement of analyte concentration with analyte concentration variability and range data |
US11896371B2 (en) | 2012-09-26 | 2024-02-13 | Abbott Diabetes Care Inc. | Method and apparatus for improving lag correction during in vivo measurement of analyte concentration with analyte concentration variability and range data |
US9675290B2 (en) | 2012-10-30 | 2017-06-13 | Abbott Diabetes Care Inc. | Sensitivity calibration of in vivo sensors used to measure analyte concentration |
US10188334B2 (en) | 2012-10-30 | 2019-01-29 | Abbott Diabetes Care Inc. | Sensitivity calibration of in vivo sensors used to measure analyte concentration |
US9801577B2 (en) | 2012-10-30 | 2017-10-31 | Abbott Diabetes Care Inc. | Sensitivity calibration of in vivo sensors used to measure analyte concentration |
US11633127B2 (en) | 2012-11-29 | 2023-04-25 | Abbott Diabetes Care Inc. | Methods, devices, and systems related to analyte monitoring |
US10806382B2 (en) | 2012-11-29 | 2020-10-20 | Abbott Diabetes Care Inc. | Methods, devices, and systems related to analyte monitoring |
US11576593B2 (en) | 2012-11-29 | 2023-02-14 | Abbott Diabetes Care Inc. | Methods, devices, and systems related to analyte monitoring |
WO2014085602A1 (en) | 2012-11-29 | 2014-06-05 | Abbott Diabetes Care Inc. | Methods, devices, and systems related to analyte monitoring |
US11633126B2 (en) | 2012-11-29 | 2023-04-25 | Abbott Diabetes Care Inc. | Methods, devices, and systems related to analyte monitoring |
EP4331659A2 (en) | 2012-11-29 | 2024-03-06 | Abbott Diabetes Care, Inc. | Methods, devices, and systems related to analyte monitoring |
US9872641B2 (en) | 2012-11-29 | 2018-01-23 | Abbott Diabetes Care Inc. | Methods, devices, and systems related to analyte monitoring |
US10849558B2 (en) | 2013-03-13 | 2020-12-01 | Glaukos Corporation | Intraocular physiological sensor |
US9730638B2 (en) | 2013-03-13 | 2017-08-15 | Glaukos Corporation | Intraocular physiological sensor |
US9474475B1 (en) | 2013-03-15 | 2016-10-25 | Abbott Diabetes Care Inc. | Multi-rate analyte sensor data collection with sample rate configurable signal processing |
US10433773B1 (en) | 2013-03-15 | 2019-10-08 | Abbott Diabetes Care Inc. | Noise rejection methods and apparatus for sparsely sampled analyte sensor data |
US10076285B2 (en) | 2013-03-15 | 2018-09-18 | Abbott Diabetes Care Inc. | Sensor fault detection using analyte sensor data pattern comparison |
US10874336B2 (en) | 2013-03-15 | 2020-12-29 | Abbott Diabetes Care Inc. | Multi-rate analyte sensor data collection with sample rate configurable signal processing |
US10213141B2 (en) | 2013-04-30 | 2019-02-26 | Abbott Diabetes Care Inc. | Systems, devices, and methods for energy efficient electrical device activation |
US11571149B1 (en) | 2013-04-30 | 2023-02-07 | Abbott Diabetes Care Inc. | Systems, devices, and methods for energy efficient electrical device activation |
US11207006B2 (en) | 2013-04-30 | 2021-12-28 | Abbott Diabetes Care Inc. | Systems, devices, and methods for energy efficient electrical device activation |
US11229382B2 (en) | 2013-12-31 | 2022-01-25 | Abbott Diabetes Care Inc. | Self-powered analyte sensor and devices using the same |
WO2015102745A1 (en) | 2013-12-31 | 2015-07-09 | Abbott Diabetes Care Inc. | Self-powered analyte sensor and devices using the same |
US11717225B2 (en) | 2014-03-30 | 2023-08-08 | Abbott Diabetes Care Inc. | Method and apparatus for determining meal start and peak events in analyte monitoring systems |
US20170188915A1 (en) * | 2014-05-30 | 2017-07-06 | I-Sens, Inc. | Measurement error correction device of bio-measurer |
US9775549B2 (en) | 2014-08-15 | 2017-10-03 | Abbott Diabetes Care Inc. | Temperature insensitive in vivo analyte devices, methods and systems |
US11300537B2 (en) | 2014-10-23 | 2022-04-12 | Abbott Diabetes Care Inc. | Electrodes having at least one sensing structure and methods for making and using the same |
US10598624B2 (en) | 2014-10-23 | 2020-03-24 | Abbott Diabetes Care Inc. | Electrodes having at least one sensing structure and methods for making and using the same |
US10371617B2 (en) | 2015-04-30 | 2019-08-06 | Inside Biometrics International Limited | Electrochemical test device |
WO2016205378A1 (en) | 2015-06-15 | 2016-12-22 | Abbott Diabetes Care Inc. | Stabilized lactate responsive enzymes, electrodes and sensors, and methods for making and using the same |
US9914952B2 (en) | 2015-06-15 | 2018-03-13 | Abbott Diabetes Care, Inc. | Stabilized lactate responsive enzymes, electrodes and sensors, and methods for making and using the same |
EP3967227A1 (en) | 2015-06-15 | 2022-03-16 | Abbott Diabetes Care Inc. | Stabilized lactate responsive enzymes, electrodes and sensors, and methods for making and using the same |
US10888272B2 (en) | 2015-07-10 | 2021-01-12 | Abbott Diabetes Care Inc. | Systems, devices, and methods for meal information collection, meal assessment, and analyte data correlation |
JP2017125914A (en) * | 2016-01-13 | 2017-07-20 | 国立研究開発法人科学技術振興機構 | Transmission circuit, biological molecule detection device, detection data collection method, and detection data collection system |
WO2017151952A1 (en) | 2016-03-04 | 2017-09-08 | Abbott Diabetes Care Inc. | Nad(p)-dependent responsive enzymes, electrodes and sensors, and methods for making and using the same |
EP4325222A2 (en) | 2016-03-04 | 2024-02-21 | Abbott Diabetes Care Inc. | Nad(p)-dependent responsive enzymes, electrodes and sensors, and methods for making and using the same |
TWI781958B (en) * | 2016-09-21 | 2022-11-01 | 美商維爾利生命科學有限公司 | Systems and methods for activating a circuit of an implant device |
US10448833B2 (en) | 2016-09-21 | 2019-10-22 | Verily Life Sciences Llc | Systems and methods for activating a circuit of an implant device |
CN109715052A (en) * | 2016-09-21 | 2019-05-03 | 威里利生命科学有限责任公司 | System and method for activating the circuit of implantation equipment |
US11596307B2 (en) | 2016-09-21 | 2023-03-07 | Verily Life Sciences Llc | Systems and methods for activating a circuit of an implant device |
WO2018057236A1 (en) * | 2016-09-21 | 2018-03-29 | Verily Life Sciences Llc | Systems and methods for activating a circuit of an implant device |
US11331022B2 (en) | 2017-10-24 | 2022-05-17 | Dexcom, Inc. | Pre-connected analyte sensors |
US11706876B2 (en) | 2017-10-24 | 2023-07-18 | Dexcom, Inc. | Pre-connected analyte sensors |
US11943876B2 (en) | 2017-10-24 | 2024-03-26 | Dexcom, Inc. | Pre-connected analyte sensors |
US11350862B2 (en) | 2017-10-24 | 2022-06-07 | Dexcom, Inc. | Pre-connected analyte sensors |
US11382540B2 (en) | 2017-10-24 | 2022-07-12 | Dexcom, Inc. | Pre-connected analyte sensors |
WO2019118231A1 (en) * | 2017-12-11 | 2019-06-20 | Microoptx Inc. | Implantable ocular glucose sensor devices and methods |
US11291391B2 (en) * | 2017-12-11 | 2022-04-05 | Microoptx Inc. | Implantable ocular glucose sensor devices and methods |
US20200400596A1 (en) * | 2018-03-12 | 2020-12-24 | Consejo Superior De Investigaciones Científicas | Device and method for sensing the conductivity of a fluid |
JP7179078B2 (en) | 2018-03-12 | 2022-11-28 | コンセホ スペリオール デ インベスティガシオンス シエンティヒカス | Apparatus and method for sensing electrolyte conductivity of fluids |
WO2019175119A1 (en) | 2018-03-12 | 2019-09-19 | Consejo Superior De Investigaciones Cientificas | A device and a method for sensing the conductivity of a fluid |
EP3540419A1 (en) * | 2018-03-12 | 2019-09-18 | Consejo Superior De Investigaciones Científicas (CSIC) | A device and a method for sensing the conductivity of a fluid |
JP2021517247A (en) * | 2018-03-12 | 2021-07-15 | コンセホ スペリオール デ インベスティガシオンス シエンティヒカス | Devices and methods for detecting electrolyte conductivity of fluids |
CN112105921A (en) * | 2018-03-12 | 2020-12-18 | 西班牙高等科研理事会 | Apparatus and method for sensing electrolytic conductivity of fluid |
US11744492B2 (en) | 2018-08-29 | 2023-09-05 | Medtronic, Inc. | Electrochemical sensor including multiple work electrodes and common reference electrode |
US12048539B2 (en) | 2019-01-28 | 2024-07-30 | Abbott Diabetes Care Inc. | Analyte sensors employing multiple enzymes and methods associated therewith |
JP2022518569A (en) * | 2019-01-28 | 2022-03-15 | アボット ダイアベティス ケア インコーポレイテッド | Analyte sensors using multiple enzymes and related methods |
US12004858B2 (en) | 2019-01-28 | 2024-06-11 | Abbott Diabetes Care Inc. | Analyte sensors employing multiple enzymes and methods associated therewith |
AU2020214230B2 (en) * | 2019-01-28 | 2023-03-02 | Abbott Diabetes Care Inc. | Analyte sensors employing multiple enzymes and methods associated therewith |
JP7410158B2 (en) | 2019-01-28 | 2024-01-09 | アボット ダイアベティス ケア インコーポレイテッド | Analyte sensor using multiple enzymes |
WO2020159927A1 (en) * | 2019-01-28 | 2020-08-06 | Abbott Diabetes Care Inc. | Analyte sensors employing multiple enzymes and methods associated therewith |
ES2786450A1 (en) * | 2019-04-09 | 2020-10-09 | Consejo Superior Investigacion | PROCEDURE FOR THE QUANTIFICATION OF THE CONCENTRATION OF ANALYTS IN AN ELECTROCHEMICAL CELL (Machine-translation by Google Translate, not legally binding) |
WO2020208286A1 (en) | 2019-04-09 | 2020-10-15 | Consejo Superior De Investigaciones Científicas | Device and procedure for the quantification of the concentration of analytes in a sample |
US20220170878A1 (en) * | 2019-04-09 | 2022-06-02 | Consejo Superior De Investigaciones Científicas | Device and procedure for the quantification of the concentration of analytes in a sample |
USD1015366S1 (en) | 2020-07-29 | 2024-02-20 | Abbott Diabetes Care Inc. | Display screen or portion thereof with graphical user interface |
EP3964828A1 (en) * | 2020-09-03 | 2022-03-09 | Université de Genève | Potentiometric sensor device |
WO2022049073A1 (en) * | 2020-09-03 | 2022-03-10 | Université De Genève | Sensor device |
WO2022164940A1 (en) | 2021-01-26 | 2022-08-04 | Abbott Diabetes Care Inc. | Systems, devices, and methods related to ketone sensors |
EP4134004A1 (en) * | 2021-08-11 | 2023-02-15 | Roche Diabetes Care GmbH | Regulation of a two-electrode analyte sensor |
WO2023017015A1 (en) * | 2021-08-11 | 2023-02-16 | F. Hoffmann-La Roche Ag | Regulation of a two-electrode analyte sensor |
CN114354696A (en) * | 2021-11-25 | 2022-04-15 | 中国科学院海洋研究所 | DNA biosensor driven by friction nano generator and application thereof |
WO2023110190A1 (en) | 2021-12-13 | 2023-06-22 | Heraeus Medical Gmbh | Tests and methods for detecting bacterial infection |
EP4357778A1 (en) | 2022-10-20 | 2024-04-24 | Heraeus Medical GmbH | Treatment of microbial infections diagnosed using the biomarker d-lactate |
WO2024083429A1 (en) | 2022-10-20 | 2024-04-25 | Heraeus Medical Gmbh | Treatment of microbial infections diagnosed using the biomarker d-lactate |
Also Published As
Publication number | Publication date |
---|---|
US20100213082A1 (en) | 2010-08-26 |
US10631768B2 (en) | 2020-04-28 |
US20170188904A1 (en) | 2017-07-06 |
EP4219733A1 (en) | 2023-08-02 |
WO2010099335A1 (en) | 2010-09-02 |
EP2401390A4 (en) | 2014-10-22 |
EP3255154B1 (en) | 2022-11-23 |
EP2401390B1 (en) | 2017-12-13 |
EP2401390A1 (en) | 2012-01-04 |
US20180296139A1 (en) | 2018-10-18 |
US10004441B2 (en) | 2018-06-26 |
US9668684B2 (en) | 2017-06-06 |
EP3255154A1 (en) | 2017-12-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10631768B2 (en) | Self-powered analyte sensor | |
US10022076B2 (en) | Analyte sensors having temperature independent membranes | |
US20180153449A1 (en) | Reference Electrodes Having an Extended Lifetime for Use in Long Term Amperometric Sensors | |
US8620398B2 (en) | Reference electrodes having an extended lifetime for use in long term amperometric sensors | |
US9717450B2 (en) | Service-detectable analyte sensors and methods of using and making same | |
US8155722B2 (en) | Reference electrodes having an extended lifetime for use in long term amperometric sensors | |
US20090294307A1 (en) | Redox polymer based reference electrodes having an extended lifetime for use in long term amperometric sensors | |
US20110046466A1 (en) | Analyte Sensors Including Nanomaterials and Methods of Using Same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ABBOTT DIABETES CARE INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FELDMAN, BENJAMIN J.;LIU, ZENGHE;OUYANG, TIANMEI;SIGNING DATES FROM 20090706 TO 20090708;REEL/FRAME:022954/0986 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |